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Abstract 
 
Hypoxia, the state of low levels of oxygen concentration in tissue, results in the up-
regulation of heterodimeric transcription factors called hypoxia inducible factors 
(HIFs) of which HIF-1, consisting of the sub-units HIF-1 and ARNT, is the most 
globally expressed. HIF up-regulation results in the transcriptional activation of 
genes whose protein products participate in the cellular adaptation to hypoxia. In 
normoxia, HIF-1α is targeted for proteasomal degradation by a ubiquitin ligase 
complex containing the tumour suppressor pVHL. VHL disease, an inherited cancer 
syndrome, results in inactivation of the gene encoding pVHL, and thus disregulation 
of HIF-α degradation. Altered HIF function has also been identified as a major 
contributory factor in several major diseases including ischaemia and 
tumourigenesis.  
 
In order to modulate HIF function in normoxia, RNA aptamers were targeted to the 
HIF-1α oxygen dependent degradation domain and their effect on the transcription of 
a hypoxia responsive target gene was assessed. RNA aptamers were successfully 
produced but appeared to have little or no effect  on a hypoxia responsive target gene 
possibly as a result of the mixed aptamer pool containing aptamers that increased 
transcriptional activity as well as those that decreased transcriptional activity which 
resulted in the observation of little or no effect on an a hypoxia responsive target 
gene . 
 
Pheochromocytoma, a tumour associated with VHL disease, also occurs as a result of 
inactivating mutations in SDH B, SDH C and SDH D, three of the four sub-units of 
mitochondrial complex II/succinate dehydrogenase (SDH). Similarities in tumour 
type suggested that inactivation of SDH B-D would have an impact on HIF-1α 
regulation. Cells were treated with an SDH inhibitor: 3-NPA, which resulted in 
increased HIF-1α protein levels, yet unexpectedly decreased ARNT and PTEN 
protein levels. Specific targeting of SDH B with siRNA resulted in the suppression of 
HIF-1α and GLUT-1 protein levels that were not due to an off target effect of the 
siRNA.  The discovery that regulation of HIF is a factor in a metabolic cancer 
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syndrome emphasises the need for research into new therapeutic strategies such as 
those that could be offered by  small molecule technologies. 
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PFKL  phosphofructokinase liver type 
PGK1  phosphoglycerate kinase 1 
PGL  hereditary paraganglioma 
pH2O  HPLC grade water 
PHD  prolyl hydroxylase domain containing protein 
PI  phosphoinosite 
PI3K  phosphatidylinositol 3-kinase 
PIC  pre-initiation complex 
PIP2   phophatidylinositol 4,5 bisphosphate 
PIP3  phosphatidylinositol 3,4,5 triphosphate 
PKC  protein kinase C delta 
PKC  protein kinase C lambda 
PKC  protein kinase C zeta 
PKM  pyruvate kinase muscle 
PRMT1 protein arginine methyltransferase 1 
Pro  proline 
PtdIns  phosphatidylinositol 
PTEN  phosphatase and tensin homologue deleted on chromosome ten 
pVHL  von Hippel Lindau tumour suppressor protein 
Q  glutamine 
 
R  arginine 
r0  starting RNA aptamer pool 
r1  1
st selected RNA aptamer pool 
r2  2
nd selected RNA aptamer pool 
r3  3
rd selected RNA aptamer pool 
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r4  4
th selected RNA aptamer pool 
Rbx  RING box protein 
RCC  renal cell carcinoma 
Ref-1  pedox-effector factor-1 
RING  really interesting new gene 
RNA pol II RNA polymerase II 
RNA  ribonucleic acid 
RNAi  RNA interference 
RNI  reactive nitrogen intermediates 
rNTP  ribonucleotide triphosphate 
ROS  reactive oxygen species 
RP  regulatory particle 
Rpb1  RNA polymerase II sub-unit 1 
Rpb6  RNA polymerase II sub-unit 6 
Rpb7  RNA polymerase II sub-unit 7 
rpm  revolutions per minute 
RT  reverse transciptase 
rt  room temperature 
RTP801 HIF-1 responsive protein 801 
RT-PCR reverse transcription PCR 
S  serine 
SCF  Skp-Cul-F box complex 
SDH  succinate dehydrogenase 
SDHA  succinate dehydrogenase sub-unit A 
SDHAF2 succinate dehydrogenase assembly factor 2 
SDHB  succinate dehydrogenase sub-unit B 
SDHC  succinate dehydrogenase sub-unit C 
SDHD  succinate dehydrogenase sub-unit D 
SDS  sodium dodecyl sulphate 
SDS-PAGE SDS polyacrylamide gel electrophoresis 
sec  second(s) 
SELEX systematic evolution of ligands by exponential enrichment procedure  
SFQ  serum free media containing glutamine 
Siah  mammalian homologue of Drospohila seven in absentia 
siRNA  small interfering RNAs 
SphK1  sphingosine kinase 1 
SQR  succinate: ubiquinone oxidoreductase 
SRC-1  steroid receptor co-activator 1 
T  threonine 
TAD  transactivation domain 
TAE  tris acetate EDTA 
TAFs  TBP associated factors 
TAK-1  transforming growth factor- activating kinase 
TBP  TATA box binding protein 
TBS  tris-buffered saline 
TBS-T  tris buffered saline containing Tween-20 
TCA  tricarboxylic acid cycle 
TCP-1  T-complex polypeptide 1 
TGF-  transforming growth factor  
TGF-3 transforming growth factor 3 
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TGF-α  transforming growth factor α 
TIF2  transcriptional intermediary factor 2 
TLR  toll like receptor 
TNF-  tumour necrosis factor  
TPI  triosephosphate isomerise 
TRiC  TCP-1 ring complex 
Tris  trizma base 
Trx-1  thioredoxin-1 
U2OS  human osteosarcoma cells 
Ub  ubiquitin 
Uba  ubiquitin activating enzyme 
UBA  ubiquitin pathway associated domain 
Ubc  ubiquitin conjugating enzyme 
UBL  ubiquitin like domain 
UIM  ubiquitin interacting motif 
UPAR  urokinase-type plasminogen activator receptor 
UV  ultraviolet  
V  valine 
V  Volts 
v/v  volume per volume 
VBC  pVHL-Elongin B-Elongin C complex 
VDU1  von Hippel Lindau protein interacting deubiquitinating enzyme-1 
VDU2  von Hippel Lindau protein-interaction deubiquitinating enzyme-2 
VEGF  Vascular endothelial growth factor 
VEGFR1 vascular endothelial growth factor receptor 1 
VEGFR2 vascular endothelial growth factor receptor 2 
VHL  von Hippel Lindau  
VHLaK pVHL associate KRAB-A domain containing protein 
VIM  vimentin 
W  tryptophan 
w/v  weight per volume 
WAF1  wild-type p53-activated fragment 1 
Wnt  wingless – type MMTV integration site  
X  unknown amino acid 
XRE  xenobiotic response element 
Y  tyrosine 
YC-1  3-(5’-hydroxymethyl-2’-furyl)-1-benzylindazole 
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1.1 Oxygen Homeostasis 
 
Oxygen (O2) homeostasis is tightly controlled in order to maintain intracellular 
oxygen levels in a steady state. This steady state represents a balance between O2 
consumption by metabolic processes and the risk of oxidative damage if too much O2 
were available (reviewed by Semenza, 2001). Normal tissue oxygen levels range 
from 14% in pulmonary alveoli to 3% in most other organs of the body (Sharp and 
Bernaudin, 2004). To maintain these optimum tissue oxygen levels, mammalian 
tissues have developed a range of responses that help to prevent metabolic demise 
due to hypoxia (low O2 concentration) or oxidative damage due to hyperoxia (high 
O2 concentration).  
 
The primary site of oxygen sensing is the carotid body (CB), an organ located at the 
bifurcation of the carotid artery, near the heart. The CB senses the level of O2 in 
arterial blood and this sensory information is then relayed to the areas of the brain 
responsible for regulating the respiratory and cardiovascular reflex systems. This is 
an almost instantaneous response (a few seconds) which in the case of intermittent 
hypoxia results in increased heart rate and hyperventilation without related protein 
synthesis. In sustained hypoxia, such as individuals experience at high altitude, the 
morphology and function of the CB is altered. Sustained hypoxia also results in 
cellular adaptation to hypoxia which is regulated by hypoxia inducible factors (HIFs, 
section 1.2 onwards). Activation of hypoxia inducible factors results in the up-
regulation of anaerobic metabolic pathways, stress proteins involved in cell death 
and survival, red blood cell production (erythropoiesis) and new blood vessel 
formation (angiogenesis). All of the mechanisms activated during hypoxia contribute 
to the recovery of a cell from mechanisms that may induce apoptosis (Semenza, 
2001; Prabhakar and Semenza, 2012). Unbalanced oxygen homeostasis leading to 
hypoxia is a feature of many diseases including ischaemia, pulmonary hypertension, 
and cancer (section 1.6). 
 
The excess levels of oxygen present in hyperoxia lead to the development of reactive 
oxygen species (ROS) such as superoxide. Mammalian tissues prevent any oxidative 
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damage to lipids, proteins and DNA, by up-regulating antioxidant enzymes, such as 
superoxide dismutase, to scavenge excess ROS (D’angio and Finkelstein, 2000).  
 
1.2 Hypoxia inducible factor (HIF) 
 
The most prominent transcription factor that regulates oxygen homeostasis and the 
founding member of the hypoxia inducible factor (HIF) family is HIF-1, a 
heterodimeric transcription factor comprised of the subunits HIF-1 and HIF-1/ 
ARNT (aryl hydrocarbon nuclear receptor translocator, Wang et al., 1995). HIF-1 
was originally identified through studying the hypoxic induction of erythropoietin. 
Several HIF-1 target genes have since been identified that are involved in 
angiogenesis, oxygen transport, iron metabolism, glycolysis, growth factor 
signalling, apoptosis and invasion and metastasis (Semenza et al, 1991, Semenza and 
Wang, 1992). Homologues of HIF-1 and ARNT have also been identified and 
include HIF-2, HIF-3, ARNT2, ARNT3/BMAL1 and ARNT4/BMAL2 (figures 
1.1 and 1.2, sections 1.2.2 and 1.2.3, respectively).  
 
1.2.1 bHLH-PAS domains 
 
All HIF- and ARNT subunits are members of the basic-helix-loop-helix-
Per/Arnt/Sim (bHLH-PAS) family of transcription factors. The term PAS is derived 
from the first letters of the founding members of the family: PER (the protein 
product of the Drosophila period gene), ARNT and SIM (the protein product of the 
Drosophila simple-minded gene). Accordingly, all members of the HIF family, apart 
from three splice variants of HIF-3, contain a conserved basic DNA binding 
sequence adjacent to a helix-loop-helix domain at the N-terminal end of the protein 
(Bardos and Ashcroft, 2005). The PAS domain also located at the N-terminal end of 
the HIF proteins is between 250-300 amino acids in length and contains two sub-
regions termed the A and B repeats (figures 1.1 and 1.2). The bHLH domain allows 
homo or heterodimerisation with other bHLH proteins in the formation of functional 
complexes and is also a requirement in DNA binding. For dimerisation to occur 
between HIF- and ARNT subunits the bHLH and part of the PAS A domains are 
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required (Jiang et al 1996; Chapman-Smith et al., 2004). Therefore, the PAS domain 
confers an additional level of regulation in the dimerisation process and is also 
involved in the binding of cellular chaperones (reviewed by Gu et al., 2000). 
1.2.2 The HIF  subunit family: structure and function 
 
There are three known HIF- subunits (figure 1.1); HIF-1/MOP1 (member of PAS 
superfamily 1), HIF-2, more commonly known as EPAS-1 (endothelial PAS 
protein 1), but also known as HRF (mouse HIF related factor), HLF (HIF-1 like 
factor) and MOP2 (member of PAS superfamily 2) and HIF-3 (Wang et al., 1995; 
Iyer et al., 1998; Tian et al., 1997; Ema et al., 1997; Hogenesch et al., 1997; Gu et 
al., 1998). Splice variants of HIF-1 and HIF-3 have also been identified (Chun et 
al., 2001; Maynard et al., 2003). 
 
HIF-1 is the most well studied of the three homologues and is the most global 
regulator of oxygen homeostasis. In normoxia HIF-1 is targeted for proteasomal 
degradation via an oxygen dependent degradation domain (ODDD). Within the 
ODDD domain are two conserved proline residues that are hydroxylated in normoxia 
by prolyl hydroxylases (PHDs). Prolyl hydroxylated HIF- subunits are recognised 
by the von Hippel Lindau tumour suppressor protein (pVHL). pVHL is a component 
of an E3 ubiquitin ligase complex which targets HIF- subunits for degradation via 
the proteasomal pathway (section 1.3). 
 
In hypoxia HIF-1 is up-regulated and translocates to the nucleus where it dimerises 
with ARNT via a bHLH-PAS domain (see section 1.2.1). The HIF-1 complex then 
binds to a consensus sequence in the target gene called a hypoxia responsive element 
(HRE). HIF-1 then recruits several co-activators, such as CREB binding protein/ 
adenovirus E1A associated 300kDA protein, steroid receptor co-activator 1 and 
transcriptional intermediary factor 2 (CBP/p300, SRC-1 and TIF2, respectively), in 
order to activate the expression of target genes. Both transcriptional activation and 
the recruitment of co-activators are mediated via the N-terminal and C-terminal 
transactivation domains (N-TAD and C-TAD, respectively, section 1.4). 
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Figure 1.1 A schematic representation of the human HIF- sub-units 
(hHIF-). 
 
There are three known human HIF-α subunits; HIF-1α, HIF-2α/EPAS and HIF-
3α. All are members of the bHLH-PAS family of transcription factors and are 
regulated in normoxic conditions via their oxygen dependent degradation 
domain. Transcriptional activation and recruitment of co-activators is mediated 
via the C-TAD domains of HIF-1α and EPAS. Splice variants of HIF-1α (hHIF-
1) and HIF-3α (HIF -3α2-6) have been identified and are shown above. 
 
Key: A/B, A and B repeats; bHLH, basic-helix-loop helix domain; C-TAD, C-terminal 
activation domain; EPAS,  Endothelial Pas protein; hHIF, human Hypoxia Inducible Factor 
protein; LZIP, leucine zipper domain; N-TAD, N-terminal activation domain; ODDD, oxygen 
dependent degradation domain; PAS, Per/Arnt/Sim domain.  
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A splice variant of HIF-1 was discovered during studies into the effect of zinc ions 
on HIF-1 induction. The splice variant, named HIF-1Z, was identical to HIF-1 
apart from a deletion of 434 base pairs of coding sequence corresponding to the loss 
of exon 12. HIF-1Z had a dominant-negative effect on HIF function by 
sequestering ARNT in the cytosol, preventing its translocation into the nucleus 
(Chun et al., 2001). 
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EPAS-1 only shares 48% homology with HIF-1, however, the pVHL binding site is 
conserved and in normoxia EPAS-1 is targeted for proteasomal degradation in the 
same manner as HIF-1 (section 1.3, Tian et al., 1997). Under hypoxic conditions 
EPAS-1 is up-regulated and, like HIF-1, binds to ARNT (Wiesener et al., 1998 and 
Tian et al., 1997, respectively). Under these conditions EPAS-1 recognises a hypoxia 
responsive element (HRE) in target genes before initiating transcription (section 1.4). 
 
Analysis of HIF-1 and EPAS-1 mRNA expression patterns revealed that HIF-1 
and EPAS-1 were expressed in all the tissues investigated which included heart, 
brain, smooth muscle, kidney, lung and liver, the only exception being leukocytes 
where HIF-1 mRNA alone was expressed. Tissues that were of a highly 
vascularised nature e.g. lungs, heart and placenta, exhibited higher levels of EPAS-1 
mRNA than HIF-1 mRNA (Tian et al., 1997). Research into the protein expression 
patterns of HIF-1 and EPAS-1 in hypoxic samples or samples treated with hypoxia 
mimetics has provided increasing amounts of evidence that these proteins have 
different roles within the body. For example, the accumulation of HIF-1 and EPAS-
1 protein in rat kidney was selective with respect to cell type. HIF-1 was 
predominantly expressed in tubular cells, whereas EPAS-1 was predominantly 
expressed in endothelial cells (Rosenberger et al., 2002). A difference in function 
between HIF-1 and EPAS-1 was also supported by studies in hif-1-/- and EPAS-1-/- 
mouse embryos. The hif-1-/- phenotype was lethal by embryonic day 10, with 
embryos exhibiting gross morphological and vascular abnormalities, whereas EPAS-
1-/- embryos did not exhibit gross morphological abnormalities but did exhibit 
grossly disorganised vasculature (Iyer et al., 1998; Kotch et al., 1999; Peng et al., 
2000, respectively). The EPAS-/- genotype was lethal in all embryos by embryonic 
day 11.5 (Peng et al., 2000).  
 
The final known member of the HIF- family is HIF-3, which was originally 
identified in mice (Gu et al., 1998). A human homologue of HIF-3 (hHIF-3) was 
later identified in human kidney and shown to share a high degree of sequence 
similarity with HIF-1 and EPAS-1 in the N-terminal region, but lacked the C-
terminal region of the protein. hHIF3, like HIF-1 and EPAS-1, was up-regulated 
in hypoxic conditions and able to bind to ARNT. However, unlike HIF-1 and 
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EPAS-1, hHIF-3 was able to repress HRE driven transcription of a reporter gene 
(Hara et al., 2001). Database searches identified six splice variants of hHIF-3 
(figure 1.1). The first three splice variants, hHIF31-3, contained ODDD domains 
closely resembling those of HIF-1 and EPAS-1 and were targeted for pVHL 
mediated proteasomal degradation (Maynard et al., 2003). The inhibitory PAS 
(IPAS) domain protein identified in mice is an alternative HIF-3 splice variant, 
with hHIF-34 exhibiting the closest sequence similarity (Makino et al., 2002; 
Maynard et al., 2003). In mice, experimentally overexpressed IPAS bound to HIF-1 
under hypoxic conditions and exhibited a dominant negative effect on HIF-1 
mediated gene expression. This resulted in retarded tumour growth and vascular 
density in vivo (Makino et al., 2001). In humans HIF-34 suppresses the 
transcriptional activity of HIF-1 thereby acting as a dominant negative regulator 
(Maynard et al., 2005). Both IPAS and hHIF-34 are oxygen regulated suggesting 
the existence of other mechanisms that contribute towards the control of HIF-1 
transcriptional activity. 
 
The existence of three HIF- homologues indicates their distinct functional roles. 
However, in certain situations it is possible that there is a functional overlap between 
the three homologues (Bardos and Ashcroft, 2005). 
 
1.2.3 The ARNT subunit family 
 
There are two known ARNT subunits and two ARNT like subunits (ARNTL). These 
are; - ARNT/ HIF-1, ARNT 2, ARNTL 1/ ARNT 3/ MOP3 (more commonly 
referred to as Brain-Muscle-ARNT-Like protein-1 [BMAL-1]) and ARNTL 2/  
ARNT 4/ MOP9 (more commonly referred to as BMAL2) (figure 1.2, Wang et al., 
1995; Hirose et al., 1996; Ikeda et al., 1997; Ikeda et al., 2000; Okano et al., 2001). 
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bHLH PAS
A B TAD
hARNT
789
hARNT 2
706
hBMAL1/MOP3
626
hBMAL2/MOP9
636
Figure 1.2 A schematic representation of the human ARNT related sub-
units (hARNT). 
 
Two ARNT and two ARNT like sub-units have been identified. All sub-units are 
members of the bHLH-PAS family of transcription factors. ARNT is the main 
dimerization partner for HIF-α subunits. The TAD domains of ARNT and 
ARNT2 mediate the transcription of HIF target genes. The protein length of each 
ARNT related subunit (in amino acids), is indicated. 
 
Key: A/B, A and B repeats; bHLH, basic-helix-loop helix domain; hARNT, human aryl 
hydrocarbon receptor  nuclear translocator; hBMAL, human, brain-muscle-ARNT-like protein; 
MOP, Member of PAS superfamily; PAS, Per/Arnt/Sim domain; TAD, transactivation domain  
 
 
ARNT is ubiquitously expressed and is the main dimerisation partner for HIF- 
subunits in hypoxia. Dimerisation occurs via the bHLH-PAS domain (section 1.2.1) 
and the transactivation (TAD) domain of ARNT is involved in the HIF-1 mediated 
transcription of target genes. The importance of the HIF--ARNT dimerisation 
partnership in hypoxic conditions has been illustrated by Arnt gene knockout studies 
performed in embryonic stem cells and mice (Maltepe et al., 1997). These studies 
particularly focussed on vasculogenesis and angiogenesis, processes regulated by 
HIF-1, due to the knowledge that ARNT has other functions within the cell. The 
Arnt-/- genotype was embryonically lethal, with death occurring at embryonic day 
10.5. These embryos exhibited normal vasculogenesis and organ development, but 
angiogenesis of the yolk sac and branchial arches was impaired and embryos showed 
stunted development. Loss of ARNT rendered embryonic stem (ES) cells unable to 
activate genes normally up-regulated in low oxygen, indicating ARNT is an essential 
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component of the hypoxic response. Arnt-/- ES cells also failed to respond to a 
decrease in glucose concentration, showing ARNT is also essential in the response to 
hypoglycaemia (Maltepe et al., 1997). Altered Arnt gene expression has also been 
identified as a potential factor in the development of human type II diabetes. 
Individuals with type II diabetes exhibit marked defects in their pancreatic β cell 
function and multiple alterations in gene expression. One of the genes which showed 
a marked decrease in expression was Arnt. Follow up experiments, which used 
siRNA to inhibit Arnt mRNA expression, resulted in severe impairment of glucose–
stimulated insulin secretion and alterations in mRNA expression levels. Pancreatic β 
cell specific deletion of Arnt in mice mirrored the results from in vitro studies. This 
data suggested that ARNT is a likely upstream regulator of many of the changes 
associated with type II diabetes (Gunton et al., 2005). 
 
ARNT has other functions within the cell in addition to its role in hypoxia signalling; 
in particular ARNT is involved in xenobiotic metabolism. Dioxin (2,3,7,8-
tetrachlorodibenzo-p-dioxin, TCDD) and other halogenated aromatic compounds are 
environmental pollutants. The metabolic response to these chemicals is mediated via 
the aryl hydrocarbon receptor (AhR), also known as the dioxin receptor, a bHLH-
PAS protein. Prior to ligand binding, the AhR is localised to the cytoplasm and is 
bound by two molecules of heat shock protein 90 (HSP90). Following ligand 
binding, the AhR/HSP90 complex translocates to the nucleus where HSP90 is 
exchanged for ARNT. The AhR-ARNT heterodimer mediates the transcription of 
xenobiotic metabolising enzymes from genes containing a xenobiotic response 
element (XRE) consensus sequence (reviewed by Gu et al., 2000; Kewley et al., 
2004). ARNT is also capable of forming homodimers however the functions of these 
have yet to be determined in vivo (Hirose et al., 1996). 
 
ARNT2 is the most similar protein to ARNT, sharing 57% sequence homology. The 
expression of ARNT2 is tightly regulated and to date has only been detected in the 
brain and kidney (Hirose et al., 1996; Drutel et al., 1996). ARNT2 was able to 
dimerise with HIF-1 and form a functional complex in vivo. ARNT2 was also able 
to restore hypoxia induced gene expression in Arnt-/- ES and hepatocyte cells 
(Maltepe et al., 2000). Expression of Arnt2 in Arnt-defective c4 mutant Hepa-1 cells 
was able to rescue XRE driven reporter gene activity. This evidence suggests that 
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ARNT2 is able to functionally replace ARNT in the tissues in which it is expressed 
(Hirose et al., 1996). 
 
BMAL1 and BMAL2 share 49% sequence homology between them and exhibit a 
lower level of sequence homology with ARNT and ARNT2 (Ikeda et al., 2000). The 
highest degree of similarity between the BMAL and ARNT proteins is observed in 
the bHLH-PAS domains. Both BMAL1 and BMAL2 bind to HIF-1 in vitro, 
however in the case of BMAL1 this was a weak interaction (Takahata et al., 1998; 
Gu et al., 2000; Hogenesch et al., 2000). Due to BMAL proteins binding HIF-1α in 
vitro, it was originally speculated that they may function in the hypoxia sensing 
pathway. However, more detailed research has revealed that both BMAL1 and 
BMAL2 are involved in the regulation of the circadian clock (Ikeda et al., 2000; 
Hogenesch et al., 2000; Gekakis et al., 1998). Both BMAL proteins have tightly 
restricted mRNA expression patterns with BMAL1 predominantly expressed in the 
brain and skeletal and cardiac muscle and BMAL2 expression occurs in adult brain 
and liver (Ikeda et al., 1997; Ikeda et al., 2000).  
 
1.3 The oxygen dependent regulation of HIF activity 
 
In normoxia HIF- subunits are subjected to two types of hydroxylation, prolyl 
hydroxylation of the ODDD and asparaginyl hydroxylation of the C-TAD (figure 
1.3). 
 
HIF-1 protein stability is regulated by the prolyl hydroxylation of Proline 564 
(P564), located in the C-terminal ODDD (CODDD) and/or Proline 402 (P402), located 
in the N-terminal ODDD (NODDD, Ivan et al., 2001; Jaakkola et al., 2001; Masson 
et al., 2001). Maximal regulation of HIF-1 subunits is achieved when both proline 
residues are hydroxylated (Masson et al., 2001). This reaction is catalysed by prolyl 
hydroxylase domain containing proteins (PHDs) and is a pre-requisite for pVHL 
recognition and binding to HIF- subunits, resulting in HIF- proteasomal 
degradation (Epstein et al., 2001; Bruick and McKnight, 2001, sections 1.3.1-1.3.5). 
Hydroxylation of asparagine 803 (N803), located in the C-TAD, is carried out by 
factor inhibiting HIF (FIH-1), an asparaginyl hydroxylase (section 1.3.2). 
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Asparaginyl hydroxylation abrogates HIF-1 C-TAD interaction with the 
transcriptional co-activator p300 and its paralogue CBP, thereby introducing a level 
of control that prevents the transcription of HIF regulated genes (section 1.3.2). Both 
PHDs and FIH-1 are oxygen dependent hydroxylases, therefore in hypoxia, neither 
prolyl or asparaginyl hydroxylation occurs, resulting in up-regulation of HIF- 
subunits, HIF-/ARNT dimerisation and the subsequent transcription of HIF/EPAS 
target genes (section 1.4). 
 
Figure 1.3 Regulation of HIF-1 by prolyl and asparaginyl hydroxylases 
 
In normoxia HIF-1 is subjected to prolyl and asparaginyl hydroxylation by 
prolyl hydroxylases (PHDs) and asparaginyl hydroxylases (FIH-1). The PHDs 
and FIH-1 are members of a family of iron and 2-oxoglutarate dependent 
dioxygenases. Hydroxylation of proline residues 402 and 564 of HIF-1α by 
PHDs1-3 is responsible for regulation of protein stability, while hydroxylation of 
asparagine residue 803 by FIH-1 reduces the transcriptional regulation of target 
genes by HIF-1.  
 
Key: bHLH-PAS, basic helix loop helix Per ARNT Sim domain; CBP, CREB binding protein; 
CODDD, C-terminal oxygen dependent degradation domain; C-TAD, C-terminal transactivation 
domain; FIH-1- factor inhibiting HIF; HIF, hypoxia inducible factor; N, asparagine; NODDD, N-
terminal oxygen dependent degradation domain; OH, hydroxyl; P, proline; pVHL – von Hippel 
Lindau protein; PHD- prolyl hydroxylase domain containing protein. 
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1.3.1 The prolyl hydroxylase domain containing protein (PHD) family 
 
HIF prolyl hydroxylase (HPH) was originally identified as the protein product of the 
egl 9 gene in Caenhorabditis elegans (C. elegans). Database analysis of egl 9 
identified a family of three homologous genes, phd 1-3 in humans and mice (Epstein 
et al., 2001). Several other researchers also identified the protein products of these 
genes and PHD1, PHD2 and PHD3 are also referred to as HPH3, HPH2 and HPH1 
and homologue of EGL nine 2 (EGLN2), EGLN1 and EGLN3, respectively (Bruick 
and McKnight, 2001). 
 
The PHDs belong to a superfamily of iron and 2-oxoglutarate dependent 
dioxygenases (McNeill et al., 2002). Recruitment of PHD2 (and presumably PHD1 
and 3, although no data is currently available) is dependent on the presence of 
leucine 574 (L574) of HIF-1 (Kageyama et al., 2004). This leucine residue is 
conserved between all three HIF- subunits. Once the HIF- subunit has been 
identified by the PHD, hydroxylation of the proline residue located at the end of an 
LXXLAP motif, corresponding to proline residues 402 and 564 in HIF-1, occurs. 
The LXXLAP motif has also been identified in EPAS and some splice variants of 
HIF-3. To date no evidence has been published to show prolyl hydroxylation of the 
HIF-3 isoform. However, it has been hypothesised that those HIF-3 splice 
variants with functional ODDD are targeted for pVHL mediated proteasomal 
degradation. This infers prolyl hydroxylation must occur for pVHL recognition of 
the ODDD containing HIF-3 splice variants. In vitro studies have determined the 
relative activities of the PHD proteins as PHD2>PHD3>PHD1. However, these 
results differ from other published findings where PHD2 and 3 showed similar 
specific activities and PHD1 exhibited a lower specific activity (Berra et al., 2006). 
 
All three PHDs are capable of hydroxylating P564 of HIF-1 but only PHD1 and 
PHD2 are able to hydroxylate P402 of HIF-1. The same trend is also observed in 
EPAS-1 (Appelhoff et al., 2004). Prolyl hydroxylation and subsequent proteasomal 
degradation of HIF- subunits is enhanced by the ubiquitously expressed protein, 
OS9, a protein with previously undefined function. OS9 binds to residues of HIF-1 
in both normoxic and hypoxic conditions and is also able to associate with PHD2 and 
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PHD3. OS9 binding to both PHD 2/3 and HIF-1 occurs in such a way as to allow 
the formation of a stable trimeric complex that does not prevent PHD hydroxylation 
of HIF- subunits (figure 1.4, Baek et al., 2005). 
 
hHIF-1 bHLH-PAS
NODDD CODDD
C-TAD
N803
P564P402 692-785
PHD
OS9
FIH
Figure 1.4 PHD and OS9 interaction with hHIF-1. 
 
HIF-1, PHD/PHD3 and OS9 form a ternary protein complex in 
normoxia. Formation of this complex enhances prolyl 
hydroxylation of P
402
 and P
564. 
OS9 binding to HIF-1 occurs 
between HIF-1 residues 692 and 785 (approximately) and does 
not obstruct binding of either PHD2 or 3 to HIF-1.  
 
Key: bHLH-PAS, basic-helix-loop-helix Per ARNT Sim domain; 
CODDD/NODDD, C-terminal/N-terminal oxygen dependent degradation 
domain; C-TAD- C-terminal transactivation domain; FIH- Factor inhibiting 
HIF; HIF, hypoxia inducible factor; P, proline; PHD, prolyl hydroxylase 
domain containing protein; N, asparagine 
 
Based on a figure by Flashman et al, 2005. 
 
In addition to the role of OS9 in HIF-α hydroxylation, studies using human 
homologues of OS9 have indicated a role in HIF-α transport (Flashman et al., 2005). 
 
The presence of three PHD proteins led to further research to determine the 
contribution each protein makes towards HIF- regulation. Overall, all three PHDs 
were shown to regulate HIF-1 and EPAS-1. However the degree of regulation is 
dependent on the relative abundance of each PHD protein. In the range of cell types 
investigated PHD2 is present in greater abundance than PHD1 and PHD3 (Appelhoff 
et al., 2004). This data would explain why PHD2 has been shown to be the major 
regulator of HIF-1 activity in normoxia, an observation that appears to be 
confirmed by the discovery that knockdown of phd2, but not phd1 or phd3, is lethal 
in mice (Berra et al., 2003 and 2006). However, evidence for differential roles of the 
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three proteins has been identified. PHD3 appears to preferentially regulate EPAS-1 
protein levels over HIF-1. PHD3 also appears to have a role in the regulation of 
HIF- subunits in hypoxia (Appelhoff et al., 2004). 
 
Differential roles for the three PHD proteins are also supported by the differences in 
intracellular localisation of the proteins. All three PHD proteins are expressed at 
different levels in all tissue types (Soilleux et al., 2005). However, differences are 
observed when expression levels within the cell are investigated. PHD1 is 
exclusively localised to the nucleus, PHD2 is mainly localised in the cytoplasm and 
PHD3 is distributed between the nucleus and the cytoplasm (Metzen et al., 2003). 
Despite the mainly cytoplasmic localisation of PHD2, it has been reported that it can 
shuttle between the cytoplasm and the nucleus of a cell (Berra et al., 2006). 
 
Several mechanisms have been identified that regulate the expression of the PHD 
proteins. In hypoxia there is an increase in both the mRNA and protein levels of 
PHD2 and PHD3, suggesting a feedback mechanism to prevent hypoxic responses in 
re-oxygenated cells (Epstein et al., 2001; Berra et al., 2003; Appelhoff et al., 2004). 
This increase in PHD2 and PHD3 expression is largely regulated by HIF-1, 
However, EPAS is also thought to be able to increase the expression of PHD3 (del 
Peso et al., 2003 and reviewed by Berra et al., 2006). Further regulation of PHD1 
and PHD3 is achieved by proteasomal degradation (section 1.3.3). Siah1a and Siah2 
(mammalian homologues of Drosophila seven in absentia) are specific E3 ubiquitin 
ligases for PHD1 and PHD3. In hypoxia Siah1a and Siah2 are upregulated in a HIF-
dependent manner (Nakayama et al., 2004).  
 
1.3.2 HIF asparaginyl hydroxylation by factor inhibiting HIF (FIH-1) 
 
The transcriptional activity of HIF- subunits is regulated, in normoxia, by the 
hydroxylation of asparagine residues 803, of HIF-1 and 851 of HIF-2, which are 
located ion the C-TAD of each protein (Lando et al., 2002a). This hydroxylation 
prevents the association of the C-TAD with the cysteine-histidine rich region (CH-1) 
domain of the transcriptional co-activators CBP/p300 (figure 1.3, Lando et al., 
2002b). Asparaginyl hydroxylation is carried out by factor inhibiting HIF-1 (FIH-
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1), a protein originally identified, in a yeast two hybrid screen, as binding to HIF and 
later confirmed as the HIF asparaginyl hydroxylase (Mahon et al., 2001; Lando et 
al., 2002b; Hewitson et al., 2002). Like the PHDs, FIH-1 is a dioxygen, iron and 2-
oxoglutarate dependent protein (Lando et al., 2002b). However, unlike the PHDs, 
only one isoform has been identified. FIH-1 has been shown to be localised in the 
cytoplasm in all analysed tissues and cell types (Metzen et al., 2003; Linke et al., 
2004; Soilleux et al., 2005). This is similar to the cellular localisation of PHD2, the 
prolyl hydroxylase predominantly responsible for HIF-1 prolyl hydroxylation 
(section 1.3.1). FIH-1 has at least two distinct sites of interaction with HIF-1 or 
HIF-2 and the active site is predicted to be located in a pocket at the C-terminal end 
of the protein. Both Fe (II) and 2-oxoglutarate are bound in the active site (Dann III 
et al., 2002). The amino acid residue adjacent to N803, V802, is conserved throughout 
HIF- sequences and is crucial for optimal asparagine hydroxylation by FIH-1. 
Molecular modelling has predicted that V802 is essential for the correct positioning of 
N803 in relation to the active site of FIH-1 (Linke et al., 2004). FIH-1 interacted with 
VHL at a distinct site from HIF interactions (Lee et al., 2003). This association 
facilitates HIF-1 recruitment to VHL for ubiquitination and subsequent degradation 
(section 1.3.5).  
 
1.3.3 The proteasomal degradation pathway 
 
It is now well established that HIF- subunits are degraded in normoxia via the 
ubiquitin proteasome degradation pathway which consists of ubiquitin (Ub), an 
ubiquitin activating protein (Uba/E1), an ubiquitin conjugating protein (Ubc/E2), an 
ubiquitin ligase protein/protein complex (E3 ligase), the 26S proteasome and a 
deubiquitylating enzyme (DUB, figure 1.5). Additionally, an E4 enzyme may be 
required for efficient multi-ubiquitin chain assembly (reviewed by Glickman and 
Ciechanover, 2002).  
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Figure 1.5 The ubiquitin proteasome pathway 
 
Ub is activated in an ATP dependent manner by E1. Activated Ub is then 
transferred to an E2 enzyme. From E2, Ub can either be transferred directly to 
S which is bound to an E3 belonging to the RING finger family of ligases. 
Alternatively, Ub is transferred from an E2 to an E3 belonging to the HECT 
domain containing family of ligases which is associated with the substrate. 
HECT E3s then transfer Ub to S. Additional Ub can then bind to the substrate 
associated Ub, generating a polyubiquitin chain. Polyubiquitinated substrate 
binds to the 26S proteasome (comprised of two 19S and a 20S sub-units) 
where the substrate is degraded into short peptides. Ub is released in a re-
usable form from the 26S proteasome by de-ubiquitinating enzymes. 
 
ATP, adenosine triphosphate; DUBs, de-ubiquitinating enzymes; E1, Ub activating enzyme; 
E2, Ub conjugating enzyme; E3, Ub ligase; HECT, homologous to E6-AP C-terminus; PPi, 
Pyrophosphate; Pi, inorganic phosphate; RING, really interesting new gene; S, substrate; Ub, 
ubiquitin. 
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The polyubiquitin chain acts as a signal that targets the substrate towards the 26S 
proteasome. The 26S proteasome is highly conserved among eukaryotes and is the 
predominant mediator of selective proteolysis (Miller and Gordon, 2005). The 26S 
proteasome is comprised of approximately 30 subunits that form a 20S core particle 
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(20S CP) and two flanking 19S regulatory complexes (19S RP, figure 1.6). The 20S 
subunit is a cylindrical pore particle consisting of 14 subunits,  1-7 and  1-7, that 
form a barrel shaped complex of four stacked heptameric rings. Two narrow 
channels at either end of the pore feed a central cavity comprised of  1-7 subunits, 
some of which have protease activity. These pores are gated by two 19S RP. The 19S 
RP are comprised of at least 19 different subunits that can be broken down into two 
sub-complexes, the ‘lid’ and the ‘base’. The lid consists of approximately nine 
subunits. The base directly contacts the α rings of the 20S CP and is comprised of 
approximately 10 subunits including six ATPases whose role is to gate the 20S CP 
and unfold the protein substrates before translocating them into the 20S proteolytic 
chamber.  
 
Li
d
Li
d
Ba
se
Ba
se
19S
regulatory
particle
19S
regulatory
particle
20S
core particle




Heptameric
rings
Figure 1.6 The structure of the 26S proteasome 
 
The 26S proteasome is comprised of a 20S core particle 
capped with two 19S regulatory particles. The 20S core 
particle is formed of four heptameric rings which are 
comprised from either  1-7 or  1-7 subunits, arranged 
as indicated above. The 19S regulatory particles are 
formed of two sub-complexes, the lid and the base. 
 
Based on figures by Glickman and Ciechanover, 2002 and Miller 
and Gordon, 2005). 
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The lid is composed of eight non-ATPase subunits many of which have undefined 
roles. However, at least one of the subunits, POH1, has de-ubiquitinating activity and 
two other subunits, Pus1/Rpn10/S5a and Rpt5/S6’, have ubiquitin interacting motifs 
(UIMs) that recognise poly-ubiquitin tags.  
 
Not all ubiquitinated proteins are recognised by the 19S RP or by chaperone proteins. 
In these instances, proteins with ubiquitin pathway associated domains (UBA 
domains) or ubiquitin like domains (UBL domains) have been implicated in the 
recognition of poly-ubiquitinated proteins and their delivery to the 26S proteasome.  
 
Once the substrate has been delivered to the 26S proteasome, the ubiquitin chain is 
removed and the protein unfolded before being fed into the 20S CP where it is 
degraded into short peptide sequences. The ubiquitin is recycled by de-ubiquitinating 
enzymes (DUBs) which reverse the ubiquitin conjugation process (reviewed by 
Glickman and Ciechanover, 2002; Hartmann-Petersen et al., 2003; Miller and 
Gordon, 2005; Navon and Ciechanover, 2009). 
 
1.3.4 pVHL as a component of an E3 ubiquitin ligase complex  
 
von Hippel-Lindau (VHL) disease is a rare inherited cancer syndrome where affected 
individuals exhibit a pre-disposition to retinal, spinal and cerebellar 
hemangioblastoma, clear cell renal carcinoma and pheochromocytoma (section 1.6.5 
reviewed by Bryant et al., 2003). Individuals affected by VHL disease inherit a 
single mutated gene and develop the above tumours if there is loss of expression or 
mutational inactivation of the second vhl allele (Pugh and Ratcliffe, 2003). 
 
The vhl tumour suppressor gene encodes for a protein which is ubiquitously 
expressed (Latif et al., 1993). Two different protein products, pVHL19 and pVHL30, 
are expressed from the vhl gene with apparent molecular weights of 19 and 30kDa, 
respectively (Schoenfeld et al., 1998; Iliopoulos et al., 1995, respectively). The 
smaller form is translated from an alternative in-frame initiation site. Both forms 
have tumour suppressor function and form the same complexes. The only differences 
between pVHL19 and pVHL30 that have been identified are in the cellular localisation 
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of the proteins. pVHL19 is equally distributed between the nucleus and the cytosol 
and does not associate with cell membranes, whereas pVHL30 is mainly localised to 
the cytoplasm with small amounts of the protein localised to the nucleus or found in 
association with cell membranes (Iliopoulos et al., 1998). 
 
pVHL (pVHL19 and pVHL30), is one component of a complex that acts as an E3 
ubiquitin ligase (Lisztwan et al., 1999; Iwai et al., 1999). The other members of the 
complex are elongin B, elongin C, Cullin 2 and Rbx1 (RING box protein 1, Duan et 
al., 1995; Kibel et al., 1995; Pause et al., 1997; Kamura et al., 1999, respectively). 
Crystallisation of the pVHL- elongin B-elongin C (VBC) complex (also referred to 
as the VHL E3 ligase, VBCC complex [pVHL-elongin B-elongin C-Cul2], VBC-CR 
{VBC-Cul2-Rbx1} or the HIF ubiquitin ligase) revealed pVHL has two domains, the 
 domain and the  domain (Stebbins et al., 1999). The  domain binds components 
of the E3 ligase complex and the  domain is mainly involved in substrate 
recognition. The  domain along with a small portion of the  domain interact with 
elongin C which in turn binds to elongin B. Folding of pVHL and incorporation into 
the VBC complex is assisted by chaperone proteins, in particular heat shock protein 
70 (Hsp70) or TCP-1 ring complex (TriC where TCP represents T-complex 
polypeptide), thus protecting pVHL from auto-ubiquitination (Czyzyk-Krzeska and 
Meller, 2004; Schoenfeld et al., 2000). Once the trimeric VBC complex is formed 
Cul2 can associate followed by Rbx1 (figure 1.7 Pause et al., 1999; Kamura et al., 
1999). Rbx1 is a RING finger protein and facilitates polyubiquitination of the 
substrate. Cul2 regulates the pVHL E3 ligase complex by undergoing neddylation. 
Nedd8 is a small ubiquitin like molecule that is covalently attached to lysine 689 of 
Cul2 (Czyzyk-Krzeska and Meller, 2004). This process enhances the ubiquitin ligase 
activity of the complex and is also thought to aid recruitment of the E2 enzyme to the 
pVHL E3 ligase complex (Kim and Kaelin Jr, 2003).  
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Figure 1.7 The pVHL E3 ubiquitin ligase complex 
 
pVHL binds to Elongin C through its  and part of its  
domains. Elongin B then binds to Elongin C. The pVHL-
Elongin B-Elongin C complex then recruits Cullin 2 and 
Rbx1. Neddylation of Cullin 2 enhances the ubiquitin 
ligase activity of the complex.  
 

 pVHL
Elongin C
Elongin B
Cullin 2 
Rbx1
Nedd8
 
1.3.5 The pVHL mediated ubiquitination and degradation of HIF- subunits 
 
The best documented pVHL E3 ligase targets are the HIF- family of proteins. This 
interaction was discovered following observations that pVHL-defective tumours 
were highly vascular and frequently overproduced angiogenic proteins e.g. vascular 
endothelial growth factor (VEGF; Semenza, 2000). VEGF was known to be a 
hypoxia responsive gene and it was also known that many hypoxia responsive genes 
were under the control of HIFs. This information, combined with the fact that HIF-
1 was polyubiquitinated and degraded in normoxia, led to the discovery that HIF-
1 bound to pVHL and was ubiquitinated by the pVHL E3 ligase complex (Salceda 
and Caro, 1997; Maxwell et al., 1999; Ohh et al., 2000; Kamura et al., 2000; 
Tanimoto et al., 2000; Cockman et al., 2000).  
 
In normoxia HIF-1 subunits containing an LXXLAP motif in the NODDD or 
CODDD are hydroxylated on conserved proline residues by one of three HIF specific 
PHDs (section 1.3.1). In a process aided by the association of FIH with pVHL, HIF-
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1 is recruited to the pVHL E3 ligase complex. Hydroxyproline residue 564 (Hyp564) 
is then recognised by the pVHL substrate recognition site, located in the -domain 
(Mahon et al., 2001). The presence of L574 in HIF-1 is essential for pVHL 
recognition (Huang et al., 2002). Structural studies of HIF-1-pVHL complexes 
have revealed that, once recognised, hydroxylated P564 is inserted into a hydrophobic 
pocket of pVHL. Inside the hydrophobic pocket hydroxylated P564 interacts with 
W88, Y98, W117, H115 and Ser111 of pVHL (Min et al., 2002; Hon et al., 2002). 
Mutations in three of these residues, Y98, S111 and W117, abrogate HIF-1 binding to 
pVHL and are often found in VHL disease associated tumours (Ohh et al., 2000). To 
prevent HIF-1 transcriptional activity while bound to the pVHL E3 ligase complex, 
pVHL associates with histone deacetylases 1-3 (HDAC1-3; Mahon et al., 2001). 
pVHL recognition of HIF-1 is assisted further by activator of RNA decay 1 (ARD-
1), which acetylates Lysine532 (K532) of HIF-1. This modification not only enhances 
HIF-1 interaction with pVHL but also stimulates ubiquitination of HIF-1 (Jeong 
et al., 2002). SSAT2 (Spermine/ Spermidine -N- Acetyltransferase 2) is another 
protein which assists in the HIF-1 degradation process. SSAT2 binds not only 
pVHL and Elongin C, in a process which stabilises this interaction, but also HIF-1, 
promoting its ubiquitination (Baek et al., 2007). After substrate recognition Rbx1 
facilitates the transfer of ubiquitin from the E2 enzyme, Ubc5, to HIF-1. A second 
ubiquitin is then conjugated to K48 of the first ubiquitin and so on. A minimum of 
four ubiquitin proteins must be conjugated to HIF-1 for degradation to occur 
(Pickart C., 2000). The  domain of pVHL also associates with Tat binding protein 1 
(TBP-1). This association occurs while pVHL is complexed with the other 
components of the E3 ubiquitin ligase and also with HIF-1 (Corn et al., 2003). 
TBP-1 is one of the six ATPases that are present in the 19S regulatory particle of the 
26S proteasome (Tanahashi et al., 1998). It is hypothesised that the association of 
TBP-1 with the  domain of pVHL (as part of the E3 ligase complex) allows for the 
efficient recruitment and degradation of HIF-1 by the 26S proteasome (figure 1.8). 
Once HIF-1 has been recruited to the 26S proteasome the polyubiquitin chain is 
removed and the protein unfolded before entry into the 20S core particle where 
degradation occurs (figure 1.8).  
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Figure 1.8 The HIF-1 degradation pathway. 
 
In normoxia HIF-1 is hydroxylated by a prolyl hydroxylase on proline 564 
(Hyp
564
). Hyp
564
 is recognised by pVHL which is a component of an E3 ubiquitin 
ligase complex also comprised of Elongins B and C, Cullin 2, Rbx-1 and SSAT2. 
Once HIF-1 has been recognised, Rbx-1 of the pVHL E3 ligase complex assists 
in the transfer of ubiquitin from the ubiquitin conjugating enzyme, Ubc5, to a 
lysine residue of HIF-1. Subsequent ubiquitination occurs on the previously 
attached Ub to form a poly-ubiquitin chain on HIF-1. 
 
pVHL as part of the E3 ligase complex also binds with TBP-1 an ATPase of the 
19S regulatory particle. This assists in poly-ubiquitinated HIF-1 recognition and 
recruitment to the 26S proteasome. Once recruited to the proteasome, HIF-1 is 
de-ubiquitinated and unfolded before entering the 20S core particle where protein 
degradation occurs. 
 
Key: ATP, adenosine triphosphate; CP, core particle; HIF, hypoxia inducible factor; Hyp, 
hydroxyproline; pVHL, von Hippel-Lindau protein; Rbx1, RING box protein 1; RP, regulatory 
particle; SSAT, Spermidine N1-Aceytltransferase 2; TBP-1, Tat binding protein-1; Ub, ubiquitin; 
Ubc5, ubiquitin conjugating enzyme 5. 
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EPAS-1/HIF-2 is degraded in the same manner as HIF-1. Presumably, HIF-3 
splice variants with LXXLAP motifs that are capable of binding to pVHL are also 
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degraded in the same manner however, no data is currently available to support this 
hypothesis. 
 
1.3.6 Additional pVHL E3 ligase complex substrates and alternative functions of 
pVHL.  
 
The role of pVHL as part of an E3 ubiquitin ligase is well documented and largely 
focuses on pVHL's interaction with the HIF- proteins. However, other pVHL 
binding partners have been identified, some as potential ubiquitination targets, others 
that indicate pVHL involvement in other signalling pathways and some that still 
require more research in order to understand their physiological relevance (Table 1.1, 
Leonardi et al., 2009; Kaelin, 2007). 
 
pVHL as part of the E3 ubiquitin ligase complex has been shown to regulate the 
ubiquitination of several other proteins. Interaction with some of these proteins 
involves pVHL recognition of a hydroxylated proline residue in a similar manner to 
the pVHL-HIF- interaction however, some interactions occur without proline 
hydroxylation. Two subunits of the RNA polymerase II complex, the main enzyme 
that synthesises cellular mRNA, have been identified as pVHL E3 ubiquitin ligase 
substrates. pVHL directly binds to the seventh subunit of RNA polymerase II (Rpb7) 
via its  domain. This interaction is not dependent on the hydroxylation of a proline 
residue but does result in the ubiquitination, proteasomal degradation and nuclear 
depletion of Rpb7 (Na et al., 2003). Rpb7 is found at high levels in the kidney 
suggesting a role for Rpb7 in the development of renal clear cell carcinoma, a tumour 
type often found in patients with von Hippel-Lindau disease (section 1.6.5). Rpb7 
regulates the transcription of VEGF, a protein often found up-regulated in tumours 
associated with VHL disease. Thus, loss of pVHL could cause up-regulation of 
VEGF in a HIF-independent manner (Czyzyk-Krzeska and Meller, 2004). 
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Table 1.1 pVHL protein association 
pVHL associated 
proteins 
Interacting protein 
function 
pVHL action (where 
known) 
Reference 
Elongin B (p14) pVHL stabilisation; 
ubiquitin ligase 
component  
Formation of E3 Ub 
ligase complex 
Duan et al., 1995; 
Kibel et al., 1995; 
Iwai et al., 1999; 
Lisztwan et al., 1999 
Elongin C (p18) pVHL stabilisation; 
ubiquitin ligase 
component  
Formation of E3 Ub 
ligase complex 
Duan et al., 1995; 
Kibel et al., 1995; 
Iwai et al., 1999; 
Lisztwan et al., 1999 
Cullin 2 Ubiquitin ligase 
component 
Formation of E3 Ub 
ligase complex 
Pause et al., 1997; 
Iwai et al., 1999; 
Lisztwan et al., 1999 
SSAT2 Stabilisation of 
pVHL:Elongin C 
interaction 
Formation of E3 Ub 
ligase complex 
Baek et al., 2007 
Rbx1 (ROC1) Ubiquitin ligase 
component 
Not Applicable Kamura et al., 1999 
Hsp70 Folding of pVHL and 
VCB complex 
Not Applicable Melville et al., 2003 
TRiC Folding of pVHL and 
VCB complex 
Not Applicable Melville et al., 2003 
HIF-α sub-units Regulation of hypoxia 
responsive genes 
Ubiquitination of HIF- 
 sub-units 
Maxwell et al., 1999; 
Cockman et al., 2000 
FIH-1 HIF- recruitment to 
pVHL E3 ligase 
complex/asparaginyl 
hydroxylation of HIF- 
Not Applicable Mahon et al., 2001 
TBP-1 Recruitment of pVHL 
ubiquitination targets  to 
26S proteasome 
Not Applicable Corn et al., 2003 
VHLaK Repression of HIF-1 
mediated transcription 
Recruits VHLaK to the 
HIF binding promotor 
Li et al., 2003 
VDU-1 and 2 HIF de-ubiquitinating 
enzymes 
Ubiquitination of VDU 
– 1 and VDU-2 
Li  et al., 2002; Li et 
al., 2003; Li et al., 
2005 
Rpb7 Transcription regulation  Ubiquitination of Rpb7 Na et al., 2003 
Rpb1 Transcription regulation/ 
possible DNA repair 
Ubiquitination of Rpb1 Kuznetsova et al., 
2003 
Sp1 Transcriptional activator Repression of Sp1-
dependent transcription 
Pal et al., 1998 
PKC,  PKC Immune response Inhibition of aPKC 
and  kinase activity; 
possible ubiquitination 
of these proteins 
Okuda et al., 1999 
PKC Tumour suppressor 
protein; Cell cycle 
progression; Apoptosis 
Inhibition of PKC 
kinase activity 
Pal et al., 1997 
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pVHL associated 
proteins 
Interacting protein 
function 
pVHL action (where 
known) 
Reference 
Jade-1 Possible tumour 
suppressor function;  
Jade-1 stabilisation 
leading to Wnt pathway 
regulation 
Zhou et al., 2005 
HuR (RNA binding 
protein) 
mRNA stabilisation Possible HuR 
regulation 
Danilin et al., 2009 
-tubulin Microtubule protein Microtubule 
stabilisation 
Hergovich et al., 
2003 
 - tubulin Microtubule protein Microtubule 
stabilisation 
Hergovich et al., 
2003 
Fibronectin Extracellular matrix 
protein 
Possible involvement in 
extracellular matrix 
assembly 
Ohh et al., 1998 
 
 
pVHL also targets subunit one of the RNA polymerase II complex (Rpb1) for 
ubiquitin mediated proteasomal degradation. This interaction requires hydroxylation 
of P1465, located at the end of an LXXLAP motif and hyperphosphorylation of the C-
terminal domain of Rpb1. The functional reason for pVHL mediated Rpb1 
degradation is still unknown (Kuznetsova et al., 2003). However, following findings 
that pVHL protects cells from UV induced apoptosis, it is hypothesised that pVHL 
mediated ubiquitination of Rpb1 may be involved in transcription regulation and 
DNA repair (Czyzyk-Krzeska and Meller, 2004).  
 
Two other proteins have been identified as potential targets of the pVHL E3 
ubiquitin ligase complex, atypical protein kinase C delta (aPKC) and VHL 
interacting de-ubiquitylating enzyme-1 (VDU-1). Both of these proteins interact with 
the  domain of pVHL but they do not contain prolyl hydroxylation motifs. The 
pVHL mediated interaction with VDU-1 may cause the ubiquitin mediated 
degradation of other proteins by inhibiting de-ubiquitination of specific pathways. 
pVHL interacts with the regulatory domain of aPKC. However this interaction only 
occurs when aPKC is in an active conformation as the regulatory domain is masked 
when aPKC is inactive. Loss of pVHL complex activity with regard to aPKC 
could lead to cytoskeletal disorganisation and affect cell-cell interactions (Czyzyk-
Krzeska and Meller, 2004).  
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Further experimental findings have implicated a role for pVHL in microtubule 
stabilisation, fibronectin matrix assembly, cell cycle control, PKC-dependent 
signalling, urokinase-type plasminogen activator system regulation and transcription 
repression in certain tissues (reviewed by Ivan and Kaelin Jr, 2001; Czyzyk-Krzeska 
and Meller, 2004). Of particular interest is the pVHL dependent repression of HIF-
1 transactivation by pVHL associated KRAB-A domain containing protein 
(VHLaK, KRAB, Kruppel associated box, Li et al., 2003). VHLaK appears to be 
recruited, by pVHL, to HIF bound to the hypoxia response element (HRE) of target 
genes. VHLaK also interacts with the transcriptional repressor KRAB associated 
protein 1 (KAP-1)/ KRAB interacting protein 1 (KRIP-1)/ transcription intermediary 
factor 1 which enhances the transcriptional repression conferred by the KRAB-A 
domain (figure 1.9). Once formed the pVHL-VHLaK-KAP-1 complex represses 
HIF-1 transcriptional activity and HIF-1 induced VEGF expression in HEK 293 
cells (Li et al., 2003). 
 
ARNT
HRE
VHLaK
KAP-1
pVHL
HIF-1 dependent genes
Transcription repression
HIF-1
Figure 1.9 The proposed mechanism of HIF transcriptional 
repression by pVHL and VHLaK. 
 
pVHL recruits VHLaK to the HIF-1 transcription complex 
(dimerised HIF-1 and ARNT bound to the HRE of a target gene). 
In turn VHLaK recruits KAP-1 a well known transcriptional 
repressor to inhibit HIF-1 dependent transcription. 
 
Key: ARNT, aryl hydrocarbon receptor nuclear translocator; HIF, hypoxia 
inducible factor, HRE, hypoxia response element; KAP-1, KRAB associated 
protein 1; KRAB, Kruppel associated box VHLaK, pVHL associated KRAB-A 
domain containing protein; pVHL, von Hippel Lindau protein 
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1.4 The effect of hypoxia on HIFs and the HIF transcriptional 
response 
 
In hypoxia HIF-1 and EPAS-1 are no longer hydroxylated by the PHDs due to lack 
of oxygen, a requirement for PHD activity. Un-hydroxylated proline residues are not 
recognised by pVHL and thus pVHL mediated HIF-1/EPAS-1 protein degradation 
cannot occur, resulting in HIF-1/EPAS-1 protein up-regulation. Whether hypoxia 
has a similar effect on the protein levels of HIF-3 remains to be determined. 
 
After the hypoxic stabilisation of HIF-1/EPAS-1 the proteins translocate to the 
nucleus in a process that occurs irrespective of the presence of ARNT (Chilov et al., 
1999). This process is mediated by the presence of a nuclear localisation signal 
(NLS) residing in the C-terminal portion of all three HIF- subunits (Kallio et al., 
1998; Luo and Shibuya, 2001). Once in the nucleus HIF-1/EPAS-1 subunits bind 
their dimerisation partner, ARNT/HIF-1, to form HIF-1 and EPAS, respectively. In 
certain cell types, dimerisation with ARNT2 may occur instead of ARNT (Maltepe et 
al., 2000). Dimerisation of HIF-1/EPAS-1 with ARNT occurs via the bHLH 
domain and the PAS domain appears to stabilise this interaction (section 1.2.1). Once 
ARNT has bound, a conformational change in HIF-1/EPAS-1 occurs that induces 
activation of the protein (Kallio et al., 1997). The activated HIF-1/EPAS 
transcription factor recognises a hypoxia response element (HRE) with the DNA 
consensus sequence; 3’ RCGTG 5’ (where R generally represents an A or G) in HIF 
target genes and binds to these sequences via the bHLH domain. The lack of 
available oxygen in a hypoxic environment also abrogates the function of FIH 
resulting in a decrease of HIF-1/EPAS-1 asparagine hydroxylation. Lack of 
asparagine hydroxylation activates the C-TAD of HIF-1/EPAS-1 resulting in 
increased transcriptor co-activator recruitment such as CBP/p300, SRC-1 and TIF2 
(section 1.4.1). The transcriptional co-activators then recruit components of the basal 
transcription machinery (BTM) to ensure efficient transcription by HIF-1/EPAS of 
their target genes (figure 1.10, sections 1.4.2 and 1.4.3).  
 
The transcriptional response of HIF-1/EPAS can be further influenced by 
phosphorylation of HIF-1, methylation of the HIF-1/EPAS binding site, the 
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sequence of the HRE and the presence of additional transcription factors such as 
activator protein-1 (AP-1, Wenger et al., 2005). 
 
HIF-1
N
C-TADbHLH-PAS ODDD
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PHDs FIH
Cytoplasm
p300/
CBP
Nucleus
HRE
Transcription 
of HIF-1 
target genes 
5’ 3’
ARNTHIF-1
BTM
HIF-1
 
Figure 1.10 HIF-1 in hypoxia 
 
In hypoxia the PHDs and FIH are no longer capable of hydroxylating HIF-1. 
Abrogated prolyl hydroxylation prevents pVHL mediated proteasomal 
degradation of HIF-1 resulting in increased HIF-1 protein levels. HIF-1 
then translocates to the nucleus where it dimerises with ARNT to form HIF-1. 
HIF-1 recognises a DNA consensus sequence known as the HRE in target 
genes. The C-TAD of HIF-1 is no longer hydroxylated by FIH in hypoxia 
and becomes activated, resulting in the recruitment of p300/CBP, a 
transcriptional co-activator. p300/CBP then recruits other proteins that form 
the BTM and transcription of HIF-1 target genes occurs. 
 
Key: ARNT, Aryl Hydrocarbon Nuclear Translocator; bHLH-PAS, basic helix-loop-helix-Per-
ARNT-Sim domain; BTM, basal transcription machinery; C-TAD, C-terminal transactivation 
domain; CBP, CREB binding protein; FIH, Factor inhibiting HIF; HIF, hypoxia inducible 
factor; HRE, hypoxia response element; ODDD, oxygen dependent degradation domain; 
PHDs, prolyl hydroxylase domain containing proteins 
 
1.4.1 HIF transcriptional co-activators and transcriptional activity enhancers 
 
CBP/p300 were the original transcriptional co-activators identified that bound to 
HIF-1 and increased the transcriptional activation of HIF target genes e.g. VEGF 
(section 1.4.4, Arany et al., 1996). CBP and p300 are ubiquitiously expressed, 
nuclear localised proteins, belonging to the CBP/p300 family of proteins. This family 
also includes the proteins p270 and p400 however, these have not been associated 
with HIF transcriptional activity (Giles et al., 1998).  
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There is a high degree of homology between p300 and CBP which suggests a high 
degree of functional redundancy. CBP was originally identified as a binding partner 
for cyclic adenosine monophosphate response element transcription factor (CREB) 
while p300 was discovered through its interaction with the adenoviral E1A protein. 
Further experiments showed that each protein was interchangeable for these 
functions. Due to the interchangeable nature of the two proteins they are generally 
referred to as CBP/p300 (Kalkhoven, 2004).  
 
CBP/p300 have several cellular functions, they act as transcriptional co-activators, 
forming a bridge between transcription factors like HIF-1/EPAS and the transcription 
initiation complex containing RNA polymerase II (section 1.4.3). The second 
important aspect of CBP/p300 co-activator function is their intrinsic histone 
acetyltransferase (HAT) activity. This allows CBP/p300 to acetylate nucleosomal 
histones that are in close proximity to gene promoters. It is thought that the 
acetylation of histones neutralises their positive charge thus loosening the 
histone:DNA interaction resulting in increased accessibility to the DNA for the 
transcription complex (section 1.4.3). CBP/p300 is also involved in multiple events 
that are central to cell growth, differentiation, transformation and apoptosis 
(Goodman and Smolik, 2000). Both CBP and p300 are essential in embryogenesis 
however, despite their high homology and interchangeable nature, in this role at 
least, they have some unique functions. In vivo studies have shown that homozygous 
CBP and p300 knockout mice die before birth and both sets of mice display open 
neural tube defects indicating CBP and p300 share some common functions. 
However, the phenotypes of the mice also show CBP and p300 have some unique 
functions. p300-/- mice display heart defects which CBP-/- mice do not exhibit, while 
CBP+/- mice exhibit craniofacial abnormalities and growth retardation, which is not 
observed in the p300+/- counterparts (reviewed by Kalkhoven, 2004). In addition, 
CBP and p300 are thought to be tumour suppressor proteins due to their inactivation 
by the adenoviral E1A oncoprotein (Mazure et al 2004). 
 
The physical interaction between HIF-1/EPAS-1 and CBP/p300 occurs via the 
activated C-TAD and CH1 domain of each protein, respectively (Kallio et al., 1998; 
Arany et al., 1996; Kung et al., 2000). The basis of this interaction is the hypoxic 
inhibition of FIH function. This results in asparagine 803 of HIF-1 being left 
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unhydroxylated (Sang et al., 2002). The CH 1 domain of CBP/p300 can then form a 
clamp around the unhydroxylated asparagine residue, in an energetically favourable 
reaction (Freedman et al., 2002). The CBP/p300:HIF-1 interaction is enhanced by 
s-nitrosation of cysteine 800 of HIF-1. L795, L818 and L822 of HIF-1 are also 
crucial for CBP/p300 recruitment (Yasinka and Sumbayev, 2003; Freedman et al., 
2002). 
 
Several proteins have been identified that interact with both CBP/p300 and HIF-1. 
Some of these proteins have transcriptional co-activator function e.g. SRC-1 and 
TIF-2 while others appear to enhance HIF-1 transcriptional activity in processes that 
still need to be determined e.g. c-Jun. SRC-1 and TIF2/SRC-2 are transcriptional co-
activators belonging to the p160 steroid receptor co-activator family (Xu and Li, 
2003). Both SRC-1 and TIF2 act in a synergistic manner with CBP/p300 to enhance 
transcriptional activation by HIF-1 (Carrero et al., 2000). SRC-1 does not interact 
directly with HIF-1 but is recruited by CBP to form a HIF-1/ARNT/CBP/SRC-1 
complex via its AD-1 domain (transcriptional activation domain 1, Ruas et al., 2005 
and Xu and Li, 2003). The mechanism by which SRC-1 and TIF2 enhance the 
transcriptional activation of HIF-1 responsive genes has yet to be elucidated but it 
may involve the recruitment of histone methyltransferases, such as protein arginine 
methyltransferase 1 (Xu and Li, 2003).  
 
The increase in HIF-1 transcriptional activity induced by SRC-1 or TIF2 was greatly 
potentiated by Ref-1 (redox-effector factor-1, Carrero et al., 2000). Ref-1 is involved 
in base excision repair, oxidative DNA damage repair and is known to stimulate the 
DNA binding activity of several transcription factors, including EPAS (Evans et al., 
2000). In pancreatic and prostate carcinomas, HIF-1, STAT3, CBP/p300 and Ref-1 
form a transcriptional complex to regulate Src-dependent hypoxia-induced 
expression of VEGF. This finding suggests Ref-1 may form the same complex in 
hypoxic cells (Gray et al., 2005).  
 
c-Jun is another transcription factor whose interaction with HIF-1 potentiates the 
transcriptional activity of HIF responsive genes (Alfranca et al., 2002). However, c-
Jun does not act as a transcription factor in this case and therefore does not bind to 
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DNA in order to increase the transcriptional activity of HIF responsive genes. 
Instead, c-Jun binds to the ODDD domain of HIF-1α, preventing HIF-1α 
ubiquitination and proteasome mediated degradation and resulting in an 
accumulation of functional HIF-1 (Yu et al., 2009). 
 
In addition, several transcriptional co-activators have been identified that are specific 
for either HIF-1α or HIF-2α. For example; HNF4 (hepatocyte nuclear factor 4), a 
liver and kidney specific transcriptional co-activator, acting in conjunction with HIF-
1, but not HIF-2/EPAS, has been reported to be essential for epo transcription. NF-
κB essential modulator (NEMO) and the transcription factor Ets1 interact exclusively 
with HIF-2α. NEMO enhances HIF-2α mediated transcription in normoxia while 
Ets1 interacts with HIF-2α to enhance the transcription of VEGF receptor 2 
(reviewed by Loboda et al., 2010). 
 
1.4.2 Regulation of HIF transcriptional activity by CITED2 (CBP/p300 interacting 
transactivator with ED rich tail). 
 
Although CBP/p300 are the central transcriptional co-activators of HIF-1/EPAS, a 
protein that can negatively regulate the CBP/p300:HIF-1/EPAS interaction has been 
identified, p35srj/CITED2 (CBP/p300 interacting transactivator with ED rich tail 2). 
All endogenous CITED2 binds to the CH1 domain of CBP/p300, thus competing 
with HIF-1 for CBP/p300 binding and inhibiting HIF-1 transactivation (Bhattacharya 
et al., 1999; Freedman et al., 2003). CITED2 protein levels are up-regulated by 
hypoxia, suggesting CITED2 participates in a negative feedback loop to down-
regulate HIF-1 mediated transcription. However, the low levels of endogenous 
CITED2, when compared to endogenous CBP/p300 levels, would not seem to 
support the competitive model hypothesis. Another hypothesis suggests that the 
availability of functional CH1 sites to HIF is limited by the binding of other 
transcription factors and other members of the CITED family (e.g. NFkB and 
CITED4, respectively) to the CH-1 domain of CBP/p300. This adds a level of 
complexity to the competitive model hypothesis (Bhattacharya and Ratcliffe, 2003; 
Fox et al., 2004). In support of a competitive model hypothesis are the findings in 
CITED2-/- mice embryos where inactivation of CITED2 results in the heightened 
expression of HIF target genes (Yin et al., 2002).  
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1.4.3 HIF dependent transcriptional regulation. 
 
Following HIF-α/HIF-β binding to form HIF-1/EPAS, translocation to the nucleus 
occurs. HIF-1/EPAS then binds to the HRE. Dissection of the epo enhancer 
identified two sequences essential for reporter activity the core HRE consensus 
sequence (A/G)CGTG and the HIF ancillary sequence (HAS), an imperfect repeat 
sequence that recruits transcription factor complexes other than HIF. Once 
HIF/EPAS has assembled on the HRE transcriptional co-activators are recruited by 
the C-TAD and N-TAD of HIF-1/EPAS (section 1.4.1) Once CBP/p300 have been 
recruited, they acetylate the histone octamers forming the nucleosomes that mask the 
appropriate gene promoter (reviewed by Lisy and Peet, 2008). Histone acetylation 
relaxes the histone:DNA interaction therefore making gene promoters more 
accessible for recruitment of the transcription factors that comprise the  basal 
transcription machinery binding (BTM). The BTM is comprised of the general 
transcription factors (GTFs) TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH 
(transcription factor for type II genes A, B, D-F and H, respectively), which are 
essential for RNA polymerase II (RNA pol II) mediated transcription. Once all of the 
TFII factors have assembled into the transcription initiation complex, RNA 
polymerase II mediated transcription of HIF-1/EPAS responsive genes can occur 
(Cosma, 2002). 
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1.4.4 HIF target genes 
 
Microarray analysis has shown that there are over 200 hypoxia responsive genes. 
However, not all of these genes are HIF regulated. Approximately 70 genes are 
known to be HIF-1 targets. The majority of these are involved in oxygen supply, 
cellular metabolism, cell growth and apoptosis. Other gene products regulated by 
HIFs include transcriptional co-factors, transcriptional repressors, chaperone proteins 
and proteins involved in oxygen sensing. Figure 1.11 shows the majority of known 
HIF-1/EPAS regulated genes. 
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Figure 1.11 Genes that are transcriptionally up-regulated following HIF 
activation. 
 
Based on information from Semenza, 2002; Lee et al., 2004; Bardos and 
Ashcroft, 2005. 
 
Key: ADM, adrenomedullin; AMF, autocrine motility factor; DEC1, deleted in esophageal cancer 1; 
DEC2, deleted in esophageal cancer 2; EG-VEGF, endocrine gland derived vascular endothelial 
growth factor; ENG, endoglin; ENO1, enolase 1; EPO, erythropoietin; ETS1, v-ets avian 
erythroblastsosis virus e26 oncogene homolog1; FN1, fibronectin 1; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase; GLUT 1 , glucose transporter 1; HIF, hypoxia inducible factor; HK1, 
hexokinase 1; HK2, hexokinase 2; IGF-2, insulin like growth factor 2; IGFBP -1, insulin-like growth 
factor binding protein 1; IGFBP -2, insulin-like growth factor binding protein 2; IGFBP -3, insulin-like 
growth factor binding protein 3; KRT14, keratin 14; KRT18, keratin 18; KRT19, keratin 19; LDHA, 
lactate dehydrogenase A; LEP, leptin; LRP1, lipoprotein receptor-related protein 1; MDR1, multidrug 
resistance protein 1; MMP2, matrix metalloproteinase 2; NIP3, BCL2/adenovirus E1B 19kDa 
interacting protein 3; NIX, BCL2/adenovirus E1B 19kDa interacting protein 3 like; NOS2, nitric oxide 
synthase 2; PAI1, plasminogen activator inhibitor 1; PFKL, phosphofructokinase liver type; PGK1, 
phosphoglycerate kinase 1; PHD, prolyl hydroxylase domain containing protein; PKM, pyruvate 
kinase muscle; RTP801, HIF-1 responsive protein 801; TGF-3, transforming growth factor 3; TGF-
α, transforming growth factor α; TPI, triosephosphate isomerise; UPAR, urokinase-type plasminogen 
activator receptor; VEGF, Vascular endothelial growth factor; VEGFR1, vascular endothelial growth 
factor receptor 1; VEGFR2, vascular endothelial growth factor receptor 2; VIM, vimentin; WAF1, 
wild-type p53-activated fragment 1 
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1.4.5 Regulation of HIF activity in hypoxia by other signalling pathways. 
 
Although hypoxia is the major mechanism through which HIF proteins are regulated, 
regulation by other signalling pathways also plays a role. This regulation can occur 
under both hypoxic and normoxic conditions (section 1.5). In hypoxia the MAPK 
signalling pathway (section 1.5.2), reactive oxygen species (ROS), p53 and heat 
shock protein 90 (HSP90) have all been identified as playing a role in HIF regulation 
(reviewed by Bardos and Ashcroft, 2005). 
1.5 Regulation of HIF activity in normoxia by other signalling 
pathways. 
 
Various stimuli induce the up-regulation of HIF- subunits in normoxic conditions. 
These include transition metals, nitric oxide (NO), reactive oxygen species (ROS), 
growth factors, cytokines and oncogenic activation (Semenza, 2002b; Bardos and 
Ashcroft, 2005). In particular the following growth factors and cytokines have been 
shown to up-regulate HIF-1 in normoxia: epidermal growth factor (EGF), insulin 
like growth factor 1 (IGF-1), insulin like growth factor 2 (IGF-2), insulin, heregulin, 
interleukin-1, follicle stimulating hormone (FSH), androgens, hepatocyte growth 
factor (HGF), tumour necrosis factor- (TNF-), angiotensin II, platelet derived 
growth factor (PDGF), transforming growth factor  (TGF-) and thrombin. Similar 
observations have also been made for induction of EPAS-1 (Bardos and Ashcroft, 
2005). Many of these stimuli can regulate HIF activity either by using reactive 
oxygen species as part of their signalling pathway or via the phosphatidylinositol 3-
kinase (PI3K) or the mitogen- activated protein kinase (MAPK) signalling pathways 
(sections 1.5.3, 1.5.1 and 1.5.2, respectively). Signalling via the PI3K or MAPK 
pathways can be dependent on a number of factors that include the nature of the 
signal, cell type and the targeted pathway that results in increased HIF- up-
regulation (Semenza, 2002b). 
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1.5.1 HIF-1 and the PI3K signalling pathway in normoxia 
 
The PI3Ks are a family of lipid kinases that phosphorylate the 3’ hydroxyl group of 
phosphatidylinositols and phosphoinositides. PI3Ks are classified into three groups 
(class I, II and III) based on their structure, substrate specificity, distribution and 
mechanism of activation. Of the three classes, the most information is known about 
Class I. Class I PI3Ks are further subdivided into Class IA and Class IB. Members of 
these groups are activated by receptor tyrosine kinases (RTKs) and G-protein 
coupled receptors, respectively. 
 
Growth factor signalling via the PI3K pathway is largely mediated via class IA 
PI3Ks. Growth factors known to stimulate Class IA PI3Ks include EGF, PDGF and 
IGF-1. Once a growth factor has bound to the relative RTK, this results in the 
recruitment of the appropriate PI3K from the cytoplasm to the cell membrane where 
the PI3K phosphorylates phosphatidylinositol 4,5 bisphosphate (PIP2) to generate 
phosphatidylinositol 3,4,5 trisphosphate (PIP3). Proteins with high affinity binding 
sites for these lipids are subsequently recruited by PIP3. Important downstream 
effectors of PIP3 are phosphoinositide dependent kinase 1 and Akt,, which is fully 
activated by PDK-1. Recruitment of these proteins to the cell membrane brings them 
into close contact with their substrates or target proteins, thus potentiating further 
downstream signalling (figure 1.12, reviewed by Chalhoub and Baker, 2009; Jiang 
and Liu, 2009). 
 
Class I PI3K signalling is antagonised by the action of dual specificity phosphatases/ 
3’-phosphoinositide phosphatases which have protein phosphatase and lipid 
phosphatase activity. Phosphatase and tensin homologue deleted on chromosome 10 
(PTEN) is one such dual specificity phosphatase and is able to specifically 
dephosphorylate PIP3 to PIP2. This means PTEN is a negative regulator of the PI3K 
pathway and is important in maintaining phosphatidylinositol homeostasis (Fry, 
2001; Chalhoub and Baker, 2009). 
 
The PI3K signalling pathway can regulate HIF-1 protein levels in normoxia. 
Several groups have published findings showing that growth factors mediated the up-
regulation of HIF-1 protein levels. This up-regulation was abrogated by PI3K 
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inhibitors thus supporting the hypothesis that the PI3K/Akt pathway is involved in 
normoxic HIF-1 activation (Jiang et al., 2001; Zhou et al., 2004; Fukuda et al., 2002; 
Zundel et al., 2000). Similarly, PTEN inactivating mutations or loss of PTEN results 
in high levels of HIF dependent VEGF expression and this can be inhibited by the 
reintroduction of wild type PTEN (Zundel et al., 2000). Constitutively active Akt 
results in the up-regulation of HIF-1 protein in normoxia whereas dominant 
negative mutants of both PI3K and Akt block HIF-1 dependent gene transcription 
(Zundel et al., 2000; Zhong et al., 2000).  
 
Several downstream targets of Akt have been implicated in the regulation of HIF-1 
activity in normoxia and hypoxia (reviewed by Bardos and Ashcoft, 2005). In 
particular, the mammalian target of rapamycin (mTOR) has been implicated in the 
regulation of HIF-1 activity. Treatment of PC-3 cells with rapamycin, an mTOR 
inhibitor, abrogates the accumulation of HIF-1, preventing HIF-1 dependent 
transcription in both hypoxia and normoxia (Hudson et al., 2002). Pore et al showed 
that activation of Akt resulted in an increase in HIF-1 translation under both 
hypoxic and normoxic conditions and that this response occurred via an mTOR 
independent pathway (Pore et al., 2006). 
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Figure 1.12 A schematic diagram of the PI3K signalling pathway 
 
Growth factors such as epidermal growth factor bind to their cognate 
tyrosine kinase receptor and activate it. This recruits PI3K from the 
cytoplasm to the cell membrane where phosphorylation of 
phosphoinositides occurs. This activates PDK-1 which then 
phosphorylates and activates Akt resulting in downstream Akt 
signalling. PTEN is a negative regulator of the PI3K pathway and 
acts by dephosphorylating 3-phosphoinositides. 
 
Key: BAD, BCL2 antagonst of cell death; GF, growth factor; GSK3, glycogen 
synthase kinase 3, HDM2, human double minute 2 homolgue; mTOR, mammalian 
target of rapamycin; P, phosphate; PDK, phosphoinositide dependent kinase; PI3K, 
phosphatidylinositol 3 kinase, PTEN, phosphatase and tensin homologue deleted on 
chromosome 10; 3-PtdIns, 3-phosphorylated phosphatidylinositols. 
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Therefore, it appears the PI3K signalling pathway regulates HIF-1 activity by 
increasing HIF-1 mRNA translation via mTOR dependent and independent 
mechanisms. However, the exact mechanism for either pathway has yet to be 
elucidated. 
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1.5.2 The regulation of HIF in normoxia via the MAPK pathway. 
 
Mitogen activated protein kinases (MAPK) belong to a large family of serine-
threonine protein kinases that are involved in the regulation of a variety of important 
cellular processes including gene expression, translation, cell proliferation, cellular 
differentiation, cell survival, cell death and cell motility (Fang and Richardson, 
2005). Classical MAP kinase signalling occurs via cascade pathways where a MAP 
kinase is activated by a MEK (MAPK kinase /MKK) which is in turn activated by a 
MEKK (MAPK kinase kinase/MKKK/MEKK). Often MEKK is activated by a 
GTPase which has itself been activated in response to a stimulus of the MAPK 
pathway. These stimuli include growth factors, cytokines and neurotransmitters, 
binding to the appropriate cell membrane receptor (Chang and Karin, 2001; 
Katsoulidis et al., 2005). In addition, certain viral oncoproteins signal via the MAPK 
pathway to HIF (Yoo et al., 2003; Sodhi et al., 2000). 
Mammals express three major sub-families of MAP kinases; the extracellular signal 
related kinases (ERK, also known as p42/p44 MAP kinases), the c-JUN amino 
terminal kinases (JNK, also known as stress activated protein kinases, SAPK) and 
the p38 proteins (p38, p38, p38 and p38). Each group of MAPKs are activated 
by specific MAPKKs (MEK/MKKs); MEK1 and 2 for ERK 1 and 2, MKK 4 and 7 
for the JNK proteins and MKK 3 and 6 for the p38 proteins. Each MAPKK can be 
activated by more than one MAPKKK and this added complexity is thought to be in 
response to different stimuli (figure 1.13, Chang and Karin, 2001).  
 
Of the three major MAP kinases, ERK1/2 and p38 have been shown to 
phosphorylate HIF-1 in vitro, with ERK1/2 also phosphorylating HIF-1 and 
EPAS in vivo in hypoxia (Richard et al., 1999; Sodhi et al., 2000; Conrad et al., 
1999). These phosphorylation sites have still to be elucidated but several candidate 
sites have been identified in vitro. These residues are serine 641, serine 643 and 
threonine 796 of HIF-1 and threonine 844 of EPAS (Mylonis et al., 2006; Gradin et 
al, 2002). The JNK MAP kinases have also been identified as playing a role in HIF-
1 regulation in normoxia although it has not yet been determined whether 
phosphorylation contributes to this regulation (Doronzo et al., 2006). 
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Figure 1.13 An overview of the MAPK signalling cascade. 
 
Once a ligand e.g. a growth factor or cytokine has bound to the target 
membrane receptor, a signalling complex is formed that often results in the 
activation of a small GTPase e.g. Ras. The small GTPase exchanges the 
phosphate with MAPKK kinase, thus leading to the activation of MAPKK 
kinase, which leads to the phosphorylation and activation of a downstream 
MAPK kinase which, in turn phosphorylates and activates the target MAP 
kinase of the ligand.. The activated MAP kinase can then signal to other 
downstream factors, such as transcription factors, which can then elicit a 
cellular response. 
 
ASK1, apoptosis signal-regulating kinase 1; ERK, extracellular signal related kinases; GDP, 
guanine diphosphate; GTP, guanine triphosphate; JNK, c-Jun amino terminal kinases; MAP, 
mitogen activated protein; MAPK, mitogen activated protein kinase; MAPKK/MKK, 
mitogen activated protein kinase kinase; MAPKKK/MEKK, mitogen activated protein 
kinase kinase kinase; TAK-1, transforming growth factor- activating kinase. 
 
IGF1, interleukin1-, insulin and bacterial lipopolysaccharide, all up-regulate HIF-
1 protein expression and the expression of HIF-1 target genes in HCT116 cells, 
normal human cytotrophoblast cells, human and rat vascular smooth muscle cells and 
human monocytes, respectively. Pre-treatment of all of these cell lines with 
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PD98059, a MEK inhibitor, significantly reduced HIF-1 protein up-regulation and 
expression of a HIF-1 target gene, providing evidence of ERK1/2 involvement in 
HIF regulation (Fukuda et al., 2002; Qian et al., 2004; Doronzo et al., 2006; Frede et 
al., 2006). The insulin mediated up-regulation of HIF-1 protein expression was also 
abrogated by SP600125, a JNK specific inhibitor. This showed that both the ERK1/2 
and JNK pathways were involved in HIF regulation in this instance. Cycloheximide 
abrogated the insulin mediated up-regulation of HIF-1 and expression of a HIF-1 
target gene, suggesting the MAP kinases may regulate HIF, in this instance, by 
increasing protein synthesis (Doronzo et al., 2006).  
 
1.5.3 Oncogenic activation of HIF-1 via signalling cascade pathways 
 
In addition to growth factor, hormonal, cytokine, RNI, ROS and heavy metal 
induction of HIF-1 in normoxia, HIF-1 expression can also be induced by 
oncogenic activation or the inactivation of tumour suppressors such as PTEN, 
succinate dehydrogenase B (SDHB) or pVHL (sections 1.5.1, 4.1.4 and 1.6.5, 
respectively). 
 
The activated protein products of the oncogenes ras, Src and Akt have been shown to 
induce HIF-1 protein expression in several cell culture systems. Mutations in the 
ras oncogene are present in around 30% of human cancers and can lead to an 
increase in VEGF expression (reviewed by Adjei, 2004; Bardos and Ashcroft, 2004). 
Mutations in Src are rare and the protein product c-Src is normally overexpressed in 
human cancers. However, small subsets of colon and endometrial tumours have been 
found to harbour mutations that cause the C-terminal truncation of c-Src resulting in 
a constitutively active protein (reviewed by Ishizawar and Parsons, 2004).  
 
Transformation of Rat-1 cells with H-ras led to an increase in Glut-1 mRNA levels in 
normoxia that could be further potentiated by hypoxia. The increase in Glut-1 mRNA 
levels corresponded with an increase in HIF-1 protein and activity levels in H-Ras 
transformed Rat-1 cells when compared to un-transformed cells (Chen et al., 2001). 
The absence of HIF-1 in H-Ras transformed mouse embryonic fibroblasts (mEFs) 
resulted in a decrease in tumour mass when compared to wild-type H-Ras 
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transformed mEFs (Ryan et al., 2000). Saos-2 cells overexpressing wild-type and 
constitutively active c-Src exhibited increased levels of HIF-1 protein in normoxia 
(Karni et al., 2002). 
 
Overexpression of HIF-1 co-transfected with Ras, v-Src, or Akt in HKO cells (HIF-
1 knockout mouse embryonic fibroblasts) resulted in the up-regulation of HIF-1 
protein levels in normoxia. HIF-1 induced by co-transfection with Ras and v-Src is 
not hydroxylated at proline 564. Therefore, Ras and v-Src up-regulated HIF-1 
protein levels by inhibiting prolyl hydroxylation and subsequent VHL-mediated 
ubiquitination and degradation. However, constitutively active Akt does not inhibit 
prolyl hydroxylation of HIF-1 and must act via an as yet unknown alternative 
mechanism (Chan et al., 2002). 
 
The protein products of several viral oncogenes also lead to the normoxic up-
regulation of HIF-1 via the MAPK pathway. The hepatitis B virus X (HBx) protein 
has been strongly implicated in angiogenesis and metastasis during 
hepatocarcinogenesis. HeLa (Chang liver) cells expressing a doxycycline inducible 
form of the HBx protein showed increased HIF-1 protein stability. HBx also 
induced phosphorylation of HIF-1, activation of ERK1/2, and enhanced the 
transcriptional response of a HIF-1 target reporter gene. This transcriptional response 
was abrogated by the MEK inhibitor PD98059, suggesting HBx activates HIF-1 
through the MAPK pathway (Yoo et al., 2003). A second viral protein product, a 
constitutively active G protein coupled receptor encoded by the Kaposi’s sarcoma-
associated herpes virus, enhanced the expression of VEGF through increased HIF-1 
activity in NIH 3T3 cells. The enhanced expression of VEGF was associated with an 
increased phosphorylation of HIF-1 by p38 and ERK MAP kinases (Sodhi et al., 
2000). It is probable that the up-regulation of HIF-1 and subsequent up-regulation 
of HIF-1 target genes by viral oncoproteins, confers a selective advantage to the cell 
infected with the virus, potentially resulting in tumour development (Ke and Costa, 
2006). 
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1.5.4 Normoxic regulation of HIF by nitric oxide (NO) 
 
Nitric oxide (NO) is produced by nitric oxide synthase (NOS) which converts L-
arginine to citrulline and nitric oxide. Three isoenzymes, inducible NOS 
(iNOS/NOS2), neuronal NOS (nNOS/NOS1) and endothelial NOS (eNOS/NOS3) 
have been identified and are named after the cell type from which they were first 
cloned. The major distinction between the three isoenzymes is the manner in which 
they are regulated. nNOS and eNOS are regulated by cytosolic calcium levels 
whereas iNOS is regulated by cytokine levels (Zhou and Brune, 2005). 
 
Until a few years ago, the biological effects of NO were unknown however the field 
has expanded and NO is known to have many biological attributes, including acting 
as an inflammatory molecule and in the regulation of gene expression. The majority 
of biological activities attributed to NO signalling are not due to the presence of NO 
itself, but to reactive nitrogen intermediates (RNI). RNI are oxidation states and 
adducts of the products of NOS and include NO radical (NO), NO-, NO+ and the 
adducts of these species such as NO2, NO2
-, NO3
-, N2O3, N2O4, peroxynitrite, 
nitrosyl-metal complexes and S-nitrosothiols such as S-nitroso-glutathione (GSNO), 
(Zhou and Brune, 2005).  
 
One of the impacts of NO is on the stabilisation and activity of HIF-1. However, this 
field is somewhat controversial due to the differing results obtained by independent 
researchers (Bardos and Ashcroft, 2005). For example, some researchers have 
reported an inhibitory function of NO in hypoxia however, the same response was 
not observed with the use of a hypoxia mimetic e.g. desferrioxamine (DFO) which 
was used to chemically induce HIF-1 (Huang et al., 1999). Others have described 
HIF-1 up-regulation in response to NO in normoxia (Sandau et al., 2001a). The 
effect of NO on HIF-1 protein levels and on HIF-1 activity has been further 
complicated by questions about the effects of the type of NO donor, concentration of 
the NO donor and incubation times of cells with the NO donor. However the 
drawback of using NO donors has been overcome due to the discovery that 
overexpression of iNOS in pig tubular LLC-PK1 cells triggered HIF-1 accumulation, 
as does co-culture with activated macrophages expressing activated iNOS. These 
results confirmed the positive effect of NO on normoxic HIF-1 and also provided 
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evidence of a positive feedback loop, as iNOS is a HIF-1 target gene (Sandau et al., 
2001; Bardos and Ashcroft, 2005). Further experimentation in HEK 293 cells, with a 
tetracycline inducible iNOS, have shown that the concentration of NO determines 
whether there is a positive or negative effect on HIF-1 protein levels. High 
concentrations of NO (>1 M) stabilise HIF-1, regardless of oxygen tension. In 
contrast to this, low concentrations of NO (< 400nM) result in a decrease of HIF-1 
protein levels in hypoxia (Mateo et al., 2003).  
 
Several studies have shown that NO, particularly in the form of GSNO, regulates the 
level of HIF-1 protein in normoxia by inhibiting the PHD enzymes (Metzen et al., 
2003 and Berchner-Pfannschmidt et al., 2007). HIF-1, PHD2 and PHD3 were 
induced in human osteosarcoma cells (U2OS) treated with GSNO under normoxic 
conditions. The accumulation of HIF-1 under these conditions was caused by 
transient GSNO inhibition of the PHD enzymes (Berchner–Pfannschmidt et al., 
2007). Another S-nitrosothiol, S-nitroso –N- acetylpenicillamine, stabilises HIF-1 
by inhibiting pVHL recruitment and asparagine hydroxylation by FIH (Park et al., 
2008). In addition to up-regulating HIF-1 in normoxia, NO also up-regulates p53 
protein levels in MCF 7 cells and causes the transient phosphorylation of ERK in 
MCF 7 and HEK293 cells (Thomas et al., 2004; Kasuno et al., 2004). The NO 
mediated up-regulation of normoxic HIF-1 protein levels was inhibited by PI3K 
and MAPK inhibitors as well as by dominant negative Ras. These results suggest the 
PI3K and MAPK pathways play a critical role in the NO mediated up-regulation of 
HIF-1 (Kasuno et al., 2004).  
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1.5.5 Normoxic regulation of HIF by reactive oxygen species (ROS). 
 
ROS are partially reduced oxygen species that are formed in mammalian cells. ROS 
are produced in response to exogenous toxic reagents or endogenously as the by- 
products of O2-utilising enzymes, such as mitochondrial respiratory chain enzymes, 
NADPH oxidases, cytochrome P450 family members, amino acid oxidases, xanthine 
oxidase, and glucose oxidases (figure 1.14). Transfer of an electron to O2 gives rise 
to a superoxide anion radical (O2
-). From the superoxide radical, formation of other 
ROS can occur including hydrogen peroxide (H2O2), hydroxyl radicals (OH), 
peroxynitrite (a RNI, section 1.5.3), singlet oxygen 1O2 and hypochlorous acid 
(HOCl, reviewed by Sauer et al., 2001; Kietzmann and Görlach, 2005). 
 
In normal physiological conditions the cell has several mechanisms in place that 
defend against endogenously produced ROS such as superoxide dismutase (SOD), 
catalase and glutathione peroxidase. The exogenous uptake of vitamins e.g. 
ascorbate, also helps to combat endogenously produced ROS. However, when ROS 
production exceeds normal physiological levels, damage to DNA, proteins, 
polysaccharides and lipids can occur as well as apoptosis and uncontrolled cellular 
proliferation. In comparison to the damaging effects of excessive ROS, there is 
increasing evidence that certain stimuli, such as growth factors and metal ions, can 
cause the generation of lower levels of ROS through enzymatic mechanisms (figure 
1.14). Generation of ROS in this way causes them to act as signalling molecules, thus 
activating certain signalling cascades and regulating the activity of certain 
transcription factors, including HIF-1 (Kietzmann and Görlach, 2005).  
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Several ROS generating non-hypoxic stimuli have been shown to induce HIF-1 in 
normoxia. These stimuli include; hydrogen peroxide, vanadate, chromium (VI), 
radiation, tumour necrosis factor- (TNF-), angiotensin II, thrombin, platelet 
derived growth factor (PDGF) and the overexpression of NADPH oxidase I (Chandel 
et al., 2000; Gao et al., 2002a; Gao et al., 2002b; Moeller et al., 2004; Haddad and 
Land, 2001; Richard et al., 2000; Goyal et al., 2004). Many ROS generated by non-
hypoxic stimuli act as secondary messengers that can, in some circumstances, 
activate the MAP kinase and PI3K signalling cascades. For example in vanadate 
treated DU145 human prostate cells H2O2 was identified as the major ROS 
Sources of ROS
Endogenous Exogenous
Mitochondria
NADPH oxidase
Myeloperoxidase
Cytochrome P450
Amino acid oxidases
Glucose oxidases
Xanthine oxidase
Peroxisomes
Environmental toxins
Ionising radiation
Ultraviolet light
Chemotherapeutics
Inflammatory cytokines
Growth factors
Metal ions
Antioxidant defence
Endogenous Exogenous uptake
Superoxide dismutase
Glutathione peroxidase
Catalase
Peroxiredoxins
Thioredoxins
Vitamins A, C and E
Micronutrients
Figure 1.14 Sources of ROS and intracellular 
defence mechanisms. 
 
Reactive oxygen species (ROS) are formed in 
mammalian cells in response to external stimuli or 
as by-products of oxygen utilising enzymes. The 
formation of ROS is counterbalanced by 
endogenous anti-oxidant defence mechanisms and 
by the up-take of exogenous components that act 
as antioxidant scavengers. Based on a figure by 
Sauer et al., 2001. 
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responsible for the induction of HIF-1 and subsequent expression of VEGF. In this 
cell type the vanadate mediated expression of HIF-1 and VEGF was dependent upon 
the PI3K/Akt pathway (Gao et al., 2002a). ROS activation of both the p38 MAP 
kinase and ERK1/2 pathways has also been observed. p38 signalling mediates the 
expression of HIF-1 and VEGF in response to chromium (VI) generated ROS in 
DU145 cells whereas ERK1/2 contributed towards angiotensin II dependent 
activation of HIF-1 in vascular smooth muscle cells (Gao et al., 2002b; Richard et 
al., 2000). 
 
1.6 HIF and Disease 
 
1.6.1 Angiogenesis  
 
Angiogenesis is the development of new blood vessels from the existing vascular 
system. During adulthood most blood vessels remain quiescent. However, 
angiogenesis is an essential process in wound healing and repair. Angiogenesis also 
plays an important role in several diseases (Bouis et al., 2006). In cancer (see section 
1.6.4), rheumatoid arthritis, psoriasis and diabetic eye disease, excessive 
angiogenesis feeds the diseased tissue, destroying normal tissue in the process. The 
opposite is true in stroke, heart disease and delayed wound healing where there is 
insufficient angiogenesis which can lead to poor circulation and tissue death 
(Carmeliet, 2005).  
 
Angiogenic signalling is stimulated by hypoxia, nutrient deprivation and ROS (North 
et al., 2005). During angiogenesis proteins belonging to the VEGF family, FGF 
family, PDGF family and angiopoietins are up-regulated. All of the genes encoding 
these proteins are targets of HIF signalling. 
 
1.6.2 Ischaemia 
 
Ischaemia is defined as an inadequate blood supply to a local area as a result of 
blockage in the blood vessels supplying the area and results in hypoxia of the tissue 
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downstream of the blockage. As a result of ischaemia, there is an increase in 
angiogenesis in the affected area, often as a result of induced HIF-1 mediated 
transcription of angiogenic factors. However, in the case of stroke and heart disease 
the angiogenic response is often not sufficient to overcome the oxygen and glucose 
deprivation resulting in ischaemic injury of the tissue or in the case of heart disease, 
a heart attack (section 1.6.1, reviewed by Semenza, 2001; Semenza, 2010).  
 
The induction of HIF-1 as a result of ischaemia is a factor in many types of 
ischaemia. For example in myocardial ischaemia induction of HIF-1 protein and 
VEGF protein expression was observed resulting in an angiogenic response (see 
section 1.6.1, reviewed by Semenza, 2000; 2001). Cerebral ischaemia resulting in 
either focal ischaemic stroke or transient global ischaemia resulted in elevated levels 
of HIF-1 and the expression of several HIF-1 target genes including those encoding 
for iNOS, VEGF and GLUT-1. The up-regulation of these proteins ensures increased 
blood flow, increased blood vessel formation and increased metabolism, 
respectively. These responses contribute to the recovery of the injured area (reviewed 
by Sharp and Bernaudin, 2004). Chronic retinal ischaemia related to diabetes causes 
HIF-1 dependent VEGF mediated neovascularisation of the retina (Sharp and 
Bernaudin, 2004). 
 
1.6.3 Pulmonary Hypertension 
 
Pulmonary hypertension is the result of sustained vasoconstriction and pulmonary 
vascular remodelling. One of the underlying stimuli that can lead to pulmonary 
hypertension is chronic alveolar hypoxia, a feature of chronic obstructive pulmonary 
disease. During the early period of hypoxic exposure pulmonary vascular resistance 
is elevated due to vasoconstriction. However, following sustained hypoxic exposure 
remodelling of the pulmonary vasculature occurs (reviewed by Hopkins and 
McLoughlin, 2002). Under sustained hypoxic conditions non-muscular arterioles 
become muscularised, and partial or completely muscular arterioles undergo medial 
wall thickening. The effect of medial wall thickening is to reduce the luminal 
diameter of pulmonary arterioles resulting in the constriction of blood flow and 
hence increased pulmonary resistance (reviewed by Semenza, 2004). Sustained 
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hypoxia also causes a reduction in the total number of blood vessels in the vascular 
bed (reviewed by Hopkins and McLoughlin, 2002). 
 
Studies perfumed in mice have shown the involvement of HIF-1 and HIF-2 in the 
development of pulmonary hypertension. Mice heterozygous for the Hif1a locus 
(Hif1a+/-) and exposed to 10% O2 for 1-6 weeks demonstrated a delayed 
development of polycythemia (increase in red blood cell mass), pulmonary 
hypertension and pulmonary vascular remodelling when compared to Hif1a+/+ 
littermates (Yu et al, 1999). Similar experimental studies performed in Hif2a+/- mice 
exposed to 10% O2 for 4 weeks indicated that the mice were not fully protected 
against pulmonary hypertension and vascular remodelling when compared to 
Hif2a+/+ mice. However, HIF2a+/- mice did not show impaired development of 
polycythemia (Brusselmans et al., 2003). The greater impairment of pulmonary 
hypertension and pulmonary vascular remodelling in HIF-2 partially deficient mice 
and the delayed development of polycythemia in HIF-1 partially deficient mice 
suggests distinct roles for both proteins in the development of pulmonary 
hypertension.  
 
1.6.4 HIF and tumourigenesis 
 
Tumour progression can be associated with both physiological responses to 
environmental stimuli e.g. hypoxia, or genetic alterations e.g. oncogenic 
transformation (reviewed by Knowles and Harris, 2001). These alterations have 
extremely important consequences. For a tumour to proliferate initially there must be 
adequate oxygen delivery. As tumours proliferate oxygen becomes sparse and 
tumour cells adapt their metabolism to a reduced oxygen environment via an increase 
in glucose transport and glycolysis. The lack of oxygen in the proliferating tumour 
results in tumour vascularisation which occurs after the metabolic switch to 
glycolysis. This is followed by tumour cells shifting the balance between pro and 
anti-apoptotic factors, promoting tumour cell survival. HIF-1 controls the expression 
of genes that are involved in all of these processes.  
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Typically, when a tumour has a diameter of a few millimetres, tumour hypoxia 
occurs. Up-regulation of HIF-1 signalling in hypoxic tumour areas results in the up-
regulation of proteins involved in glucose transport (e.g. GLUT-1 and GLUT-3) and 
glycolysis (e.g. aldolase A and C, lactate dehydrogenase and phosphoglycerate 
kinase 1, Semenza, 2002a). Up-regulation of these proteins allows a tumour to adapt 
its metabolism to reduced oxygen availability resulting in a switch from the oxidative 
respiratory pathway to anaerobic glycolysis. This switch ensures the production of 
ATP and the precursors of anabolic pathways (e.g. amino acids, lipids and nucleic 
acids) are maintained, which enables tumour cells to grow and proliferate in hypoxia. 
 
In addition to increased glycolysis, tumour hypoxia also stimulates angiogenesis 
however, when angiogenesis is initiated depends on the type of malignancy and the 
tumour microenvironment (Blouw et al., 2003). Once a tumour becomes hypoxic 
there is an increase in transcription of HIF-1 target genes (reviewed by Esteban and 
Maxwell, 2005). Several HIF-1 target genes encode for pro-angiogenic proteins 
including VEGF, PDGF and FGF (reviewed by Knowles and Harris, 2001). The up-
regulation of these proteins changes the balance of pro and anti-angiogenic factors 
secreted from the tumour and surrounding cells, resulting in vascularisation of the 
tumour. However, these vessels are structurally and functionally abnormal resulting 
in transient vessel occlusion which leads to more areas of transient acute hypoxia 
within the proliferating tumour (reviewed by Brown, 2002).  
 
The more hypoxic a solid tumour becomes the poorer the prognosis when compared 
to well oxygenated tumours, mainly due to the difficulties of delivering 
chemotherapeutic drugs to hypoxic areas with a limited blood supply (reviewed by 
Shannon et al., 2003). The effectiveness of radiotherapy is also reduced in hypoxic 
tumours. This is because the ionizing radiation used in radiotherapy causes cell death 
by producing free radicals that react with DNA. Oxygen rapidly reacts with these 
free radicals making the DNA damage permanent. Cells with low oxygen levels are 
more likely to repair the damage, thus evading cell death (Brown, 2002). HIF 
signalling also plays a part in this process by up-regulating target genes whose 
protein products are involved in cell survival for example insulin-like growth factor 2 
(IGF2, Feldser et al., 1999). 
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1.6.5 von Hippel-Lindau (VHL) Syndrome 
 
von Hippel-Lindau (VHL) syndrome is a dominantly inherited disease that is 
characterised by the presence of central nervous system and retinal 
hemangioblastomas, clear cell renal carcinomas and pheochromocytomas. 
Hemangioblastomas comprise a mixture of stromal cells and blood vessels, and 
pheochromocytomas are catecholamine secreting tumours of the sympathetic 
nervous system (Ivan and Kaelin Jr, 2001; Elder et al., 2005; Maher et al., 2011). 
The development of vhl associated tumours is dependent on the loss or inactivation 
of both the maternally derived and paternally derived vhl alleles. Thus vhl acts as a 
classic tumour suppressor gene that conforms to the two-hit hypothesis of 
carcinogenesis. Patients with von Hippel-Lindau syndrome normally carry a 
mutation in one vhl allele, tumours arise when the second allele is mutated or deleted 
in a susceptible cell (Friedrich, 2001). 
 
Families with von Hippel-Lindau syndrome can be sub-divided into categories based 
on the presence (type 2) or absence (type 1) of pheochromocytomas. Families with 
type 2 VHL disease can be further sub-categorised based on the risk of developing 
renal cell carcinoma. Those at low risk suffer from type 2A VHL syndrome and 
those at high risk suffer from type 2B VHL syndrome. Patients with type 2A or 2B 
disease often have other VHL associated tumours such as retinal and cerebral 
hemangioblastomas. Type 2 VHL disease also has a third sub-categorisation, type 
2C, patients in this category present with familial pheochromocytoma but no renal 
cell carcinoma or hemangioblastomas (Maher et al., 2011).  
 
The protein product of the vhl gene is a component of the ubiquitin ligase complex 
responsible for targeting HIF- protein subunits for proteasomal degradation (section 
1.3.4 and 1.3.5). Consequentially, tumours associated with VHL syndrome types 1, 
2A and 2B are often highly vascularised and overproduce angiogenic factors due to 
vhl inactivation and the resulting de-regulation of HIF- degradation (Kim and 
Kaelin Jr, 2004). However, individuals suffering with type 2C VHL syndrome retain 
the ability to regulate HIF- degradation suggesting that loss of an additional 
function of pVHL is responsible for pheochromocytoma development in these 
patients (Hoffman et al., 2001; Clifford et al., 2001). 
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1.7 Project Aims 
 
Several groups of researchers have carried out proof of principle blockade 
experiments using peptides (Kung et al., 2000; Li et al., 2000; Williams et al., 2002). 
The results of these experiments have shown that small molecule blockade of 
important HIF-1α sequences such as the ODDD or p300 interaction sequences offers 
the opportunity to develop a small molecule with the potential for use in a 
therapeutic setting. Therefore, one aim of this project is to develop RNA aptamers, 
small molecules with high target affinity, towards the ODDD of HIF-1α.  
 
Germ-line and somatic mutations in 3 of the 4 genes (SDHB, SDHC and SDHD) that 
encode mitochondrial complex II/succinate ubiquinone oxidoreductase (SQR) 
predispose affected individuals to head and neck paragangliomas (HNPs) and/or 
pheochromocytomas, tumours of the autonomic nervous system. These tumours 
display a high degree of vascularity which is similar in structure to 
pheochromocytomas harbouring vhl mutations (Maher and Eng, 2002). Therefore, a 
further aim of this project is to determine whether inactivation of SDH results in 
increased HIF-1α protein levels using another small molecule technology – small 
interfering RNAs. 
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Chapter 2: Materials and Methods. 
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2.1 General materials and methods. 
 
2.1.1 Tissue Culture. 
 
Renal carcinoma 786-O cells (ATCC, Manassas VA, USA), hepatocellular 
carcinoma Hep G2 cells and cervical adenocarcinoma HeLa cells were grown in 
RPMI 1640 medium (Invitrogen, Paisley, UK) supplemented with 10% (v/v) foetal 
calf serum (FCS, Invitrogen), penicillin, streptomycin and glutamine (100 units/ml, 
100g/ml and 2mM, respectively, Invitrogen). Cells were sub-cultured at a ratio of 
1:4-1:6 except Hep G2 cells which were sub-cultured at a ratio of 1:3. Rat 
pheochromocytoma PC12 cells (ATCC) were grown in Dulbeccos modified eagle 
medium (DMEM, Invitrogen) supplemented with 10% (v/v)  foetal calf serum, 5% 
(v/v)  heat inactivated horse serum (Invitrogen) and penicillin, streptomycin and 
glutamine (100 units/ml, 100g/ml and 2mM, respectively). PC12 cells were sub-
cultured at a ratio of 1:3. All cells were grown at 37C and 5% CO2 in an Heraeus 
Hera Cell Incubator (Kendro Laboratory Products Plc, Bishops Stortford, Herts, 
UK). 
 
2.1.2 Plating of Cells. 
 
Cell numbers were determined before plating at the densities indicated using an 
improved neubauer haemocytometer (Scientific Laboratory Supplies, Nottingham, 
UK). 
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2.1.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE). 
 
Protein samples were run on 8, 10 or 15% resolving gels based on the method of 
Laemmli (1970). The chemical compositions of each percentage of resolving gel are 
shown in the table below.  
 
Component 8% resolving 
gel 
10% resolving 
gel 
15% resolving 
gel 
ddH2O  4.6ml 4.0ml 2.3ml 
30% Acrylamide/Bis 
Solution  
2.7ml 3.3ml 5.0ml 
1.5M Tris-HCl pH8.8  2.5ml 2.5ml 2.5ml 
10%SDS  0.1ml 0.1ml 0.1ml 
10% Ammonium Persulfate 
(APS) 
0.1ml 0.1ml 0.1ml 
TEMED (N,N,N’,N’ – 
Tetramethylethylenediamine) 
0.006ml 0.004ml 0.004ml 
 
1 hour after pouring the resolving gel a stacking gel (2.1ml ddH2O, 0.5ml 30% 
acrylamide/bis solution, 0.38ml 1M Tris-HCl pH6.8, 0.03ml 10% SDS, 0.1ml 
10%APS and 0.003ml TEMED, all chemicals were purchased from Sigma, Poole, 
Dorset, UK except 30% acrylamide/bis solution which was purchased from Bio-Rad 
Laboratories Ltd., Hemel Hempstead, UK) was poured. A comb was inserted into 
liquid stacking gel before being left to set for 1 hour. Protein samples were mixed 
with an equal volume of 2X sample loading buffer (100mM Tris, 4% (w/v) sodium 
dodecyl sulphate, 20% (v/v) glycerol, 600mM -mercaptoethanol, and bromophenol 
blue to colour) and heated at 100 C for 2 min before loading onto a stacking gel. 
Samples were separated at a constant current of 40mA per gel in 1X running buffer 
(25mM Tris, 250mM Glycine and 0.1% (v/v) sodium dodecyl sulphate). Molecular 
weight markers were Seeblue (Invitrogen) or Precision Plus protein standards (Bio-
Rad Laboratories Ltd.) as indicated. Protein samples were either transferred to 
nitrocellulose or coomassie stained and destained (sections 2.1.4 and 2.1.8, 
respectively). 
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2.1.4 Western Blotting. 
 
Protein samples were transferred from the SDS-polyacrylamide gels to a 
nitrocellulose membrane (Hybond-C, Amersham Biosciences UK Ltd., Little 
Chalfont, Bucks, UK) at a constant current of 400mA in 1X transfer buffer (0.19M 
glycine, 0.025M Tris and 20% (v/v) methanol) for 2 hours. Membranes were stained 
in Ponceau S solution (0.1% (w/v) Ponceau S and 5% (v/v) acetic acid, Sigma,) to 
detect protein transfer, then washed in 1X Tris buffered saline (TBS, 150mM NaCl 
and 50mM Tris-HCl pH 7.6) before antigen detection. 
 
Membranes were blocked in 5% (w/v) non-fat milk powder (NFDM, Marvel 
produced by Premier International Foods (UK) Ltd., Spalding, UK) in TBS-0.1 % 
(v/v) tween-20 (TBS-T) at room temperature (rt) for 1 hour before incubation in 
primary antibody (section 2.1.5) at the appropriate dilution in 5% (w/v) NFDM in 
TBS-T for 1 hour or 1.5 hours at rt or overnight (o/n) at 4C. Membranes were 
washed three times for 15 minutes each in TBS-T at rt before incubation with 
secondary antibody (section 2.1.6) diluted at the appropriate dilution in 5% (w/v) 
NFDM in TBS-T for 1 hour at rt. Membranes were washed 3 times in TBS-T before 
detection by enhanced chemical luminescence (ECL, Supersignal West Pico 
Chemiluminescent Substrate, Perbio Science UK Ltd., Cramlington, UK). 3ml of 
enhancer solution was combined with 3ml of stable peroxide solution and mixed 
before addition to the membrane. Membranes were washed in substrate for 1 minute 
before signal detection using Biomax light film (Kodak Ltd., Hemel Hempstead, 
UK). Membranes probed with an anti-VHL antibody were subjected to detection 
using a supersensitive ECL (Supersignal West Dura extended duration substrate, 
Perbio Science UK Ltd.). 1ml of enhancer solution was combined with 1ml of stable 
peroxide solution and mixed before addition to the membrane. Membranes were 
washed in substrate for 45 seconds before signal detection using Biomax film. 
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2.1.5 Primary antibodies.  
 
Name of 
antibody 
Antibody 
Type 
Final usage 
concentration 
Incubation 
Conditions 
Supplier 
ARNT Mouse 
monoclonal 
0.25g/ml Overnight 
(o/n) at 4 
C 
BD Biosciences (Oxford, 
UK) 
ARNT Mouse 
monoclonal 
0.93g/ml 1.5 hours at 
room 
temperature 
(rt) 
NB100-124, Novus 
Biologicals, Littleton, 
CO, USA 
GLUT-1 Rabbit 
polyclonal 
10g/ml o/n at 4 C Calbiochem, San Diego, 
CA, USA 
HIF-1 Mouse 
monoclonal 
1g/ml o/n at 4 C BD Biosciences 
HIF-1 Mouse 
monoclonal 
5.9g/ml o/n at 4 C NB100-105, Novus 
Biologicals 
P53 
(DO-1) 
Mouse 
monoclonal 
0.4g/ml 1 hour at rt Santa Cruz, Santa Cruz, 
CA, USA 
PTEN Rabbit 
polyclonal 
Diluted 
1:1000 
1 hour at rt Upstate Biotechnology, 
Cambridge, UK 
SDH A Mouse 
monoclonal 
0.1g/ml 1 hour at rt Molecular Probes Inc, 
Eugene, OR, USA 
SDH B Mouse 
monoclonal 
5g/ml 1 hour at rt Molecular Probes Inc 
VHL Mouse 
monoclonal 
1g/ml 1 hour at rt BD Biosciences 
 
All Novus Biologicals antibodies were incubated in 5% NFDM in 1X western wash 
(5mM Tris-HCl pH 7.6, 35mM NaCl, 0.1% (v/v) Tween-20). 
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2.1.6 Secondary antibodies. 
 
Name of 
antibody 
Final usage 
concentration 
Incubation 
Conditions 
Supplier 
HRP linked 
rabbit anti-
mouse IgG 
1.3g/ml 1 hour at 
room 
temperature 
(rt) 
DAKO, Ely, UK 
HRP linked 
swine anti-
rabbit IgG 
0.28g/ml 1 hour at rt DAKO 
 
2.1.7 Densitometry. 
 
Bands from western blots were analysed as indicated using GEL BASE/ GEL BLOT 
PRO densitometry software (Ultra Violet Products/UVP, Cambridge, UK). 
2.1.8 Coomassie staining of SDS-PAGE gels. 
 
SDS-PAGE gels were stained in coomassie blue solution (0.6mM coomassie brilliant 
blue G250, 0.3M methanol and 0.1M glacial acetic acid, Sigma) for 1 hour before 
de-staining with de-stain solution (0.3M methanol and 0.1M glacial acetic acid) for 
2-4 hours with de-stain changes as required until stained protein bands were of 
required intensity. 
 
2.1.9 Agarose gel electrophoresis. 
 
Molecular biology grade agarose (Sigma) was dissolved in 100ml 1X TAE (0.04M 
Tris, 0.02M acetic acid and 1mM EDTA, Sigma) containing 0.2g /ml ethidium 
bromide. Linearised DNA was separated on a 0.7% (w/v) agarose gel and DNA 
inserts were separated on a 3% (w/v) agarose gel. DNA samples were mixed with 6X 
agarose gel loading buffer (1X TAE, 30% [v/v] glycerol and bromophenol blue to 
colour) before loading onto the appropriate percentage agarose gel, as indicated 
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above. Gels were run at a constant 100V in 1X TAE buffer containing 0.2g/ml 
ethidium bromide. Double stranded DNA size markers were either a 1 kilobase 
ladder (1Kb ladder, Invitrogen) or hyperladder V (Bioline Ltd.. London, UK), as 
indicated. 
 
2.1.10 Visualisation of DNA in agarose gels. 
 
Agarose gels were visualised under high energy UV light in a GDS7600 benchtop 
transilluminator using GRAB-IT gel capturing software (UVP). 
 
2.1.11 DNA purification from agarose gels. 
 
Using a Qiaex II Gel Extraction Kit (Qiagen Ltd., Crawley, UK) – The DNA was 
excised in agarose from the gel under low energy UV light using a dual intensity 
transilluminator (UVP), weighed and re-suspended in buffer QX1 (a high salt 
containing buffer) at a ratio of 1 volume of gel to 3 volumes of buffer for DNA 
between 100bp – 4kb. For fragments over 4kb an additional 2 volumes of H2O were 
added. 10l of re-suspended QIAEX II silica particles were added to the sample and 
incubated at 50 C for 10 min with vortexing every 2 min. The sample was 
centrifuged for 30 sec and the supernatant discarded. The pellet was washed with 
500l of QX 1 buffer with vortexing to re-suspend the pellet. The sample was 
centrifuged for 30 sec and the supernatant discarded. The pellet was washed twice in 
500l of PE buffer (an ethanol containing buffer). The pellet was air dried for ~ 20 
min or until the pellet became white. To elute DNA between 100bp and 4kb, 20l of 
H2O was added to the pellet and incubated at rt. For DNA longer than 4kb the pellet 
and 20l of H2O were incubated at 50 C for 5 min. Samples were centrifuged for 30 
sec and the supernatant containing purified DNA retained. 
 
2.1.12 HRE dependent transcription of a luciferase reporter gene. 
 
Hep G2 cells were seeded 100 000 cells/well in 6 well plates as indicated (Triple Red 
Ltd., Triple Red Ltd., Long Crendon, Bucks, UK). Cells were seeded in triplicate for 
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each test plasmid and condition. 24 hours after seeding cells were transfected in 
triplicate with 1g of either pGL3prevPGK (OBM), pGL3control (Promega) or 
pCMVluc (OBM). All wells were co-transfected with 0.02g pRL-SV40 (Promega). 
 
pGL3prevPGK (OB HRE) and pCMVluc were constructed as described by Boast et 
al., (1999). pGL3prevPGK contains an hypoxia responsive HRE trimer from the 
gene encoding murine phosphoglycerate kinase (PGK) located upstream of a 
minimal SV40 promoter. This promoter directs transcription from a cDNA sequence 
encoding firefly luciferase. pGL3-control contains an SV40 promoter and enhancer 
that results in the strong expression of firefly luciferase (Photinus pyralis). pCMVluc 
contains an SV40 promoter and enhancer and a CMV immediate early (CMV IE) 
promoter resulting in the strong expression of firefly luciferase. pRL-SV40 contains 
an SV40 early enhancer and promoter which provides strong constitutive expression 
of renilla luciferase (Renillla reniformis or sea pansy). 
 
Transcription reporter assays were utilised to investigate the effect of RNA aptamers 
targeted to the ODDD of HIF-1, chemical treatment of Hep G2 cells and the effect 
of SDH B targeting siRNAs in Hep G2 cells on a HIF-responsive luciferase reporter 
gene encoded by pGL3prevPGK (sections 2.2.18, 2.3.3 and 2.3.4). Each of the three 
treatments involved a different form of transfection protocol; however cells were 
seeded in the same manner and the assay to detect luciferase reporter activity 
remained the same. 
 
2.1.13 Analysis of luciferase reporter gene activity. 
 
Whole cell lysates were centrifuged at 17950g for 5min before the addition of 20l 
of each lysate to an opaque ELISA plate. Samples were analysed for luciferase 
reporter activity using the Dual-luciferase reporter assay system (Promega). 
 
The luciferase assay reagent was prepared by re-suspending lyophilised luciferase 
assay substrate in 10ml luciferase assay buffer II. The ‘Stop and Glo’ reagent was 
prepared by adding 200l of ‘Stop and Glo’ substrate solvent to the ‘Stop and Glo’ 
substrate making a 50X stock solution. 1 volume of 50X stock solution was added to 
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50 volumes of ‘Stop and Glo’ buffer. Reagent injectors of the MRX microtiter plate 
luminometer (Dynex Technologies Ltd., Worthing, West Sussex, UK) were primed 
with both luciferase reagents. 100l of luciferase assay reagent was dispensed into 
the first well of the ELISA plate. Emitted luminescence from firefly luciferase 
(Photinus pyralis) was measured before the addition of 100l of ‘Stop and Glo’ 
reagent. ‘Stop and Glo’ reagent quenches the luminescence from the firefly 
luciferase while providing the substrate for the Renilla (Renillla reniformis or sea 
pansy) luciferase. Emitted luminescence was measured. The above process was 
carried out for all sample wells and the firefly luciferase to renilla luciferase ratio 
calculated. 
 
2.2 RNA aptamer specific methods. 
 
2.2.1 pGEX fusion vectors. 
 
pGEX-HIF-1-ODDD (GHO) –  PCR was used to amplify a 390 base pair region 
encoding residues 519-647 of the oxygen dependent degradation domain of human 
HIF-1 from the expression vector pCI-neo-HIF-1a (Oxford Biomedica (OBM), 
Oxford, UK) using the sense primer HIF1NTADS 
(5’ GGAGGATCCCCATATTGTTTTTATGTGGATAG 3’) and antisense primer 
HIF1NTAD-AS (5’ GGACTCGAGGTATGTGGGTAGGAGATGGAG 3’). The 
amplified product was digested with Bam H I and Xho I, and subcloned into         
pGEX-4T-3 (Amersham Biosciences UK Ltd.) at the same sites. 
 
pGEX-EPAS-ODDD (GEO) – PCR was used to amplify a 390 base pair  region 
encoding residues 488-617 of the oxygen dependent degradation domain of human 
HIF-2 (based on sequence homology to HIF-1) from the expression vector pCI 
EPAS (OBM) using the sense primer EPASNTAD S (5’ 
GGAGGATCCCCATATTACACATCTTTGGATAAC 3’) and antisense primer (5’ 
GGACTCGAGGCAGGGATGCTTTGCTTCCGG 3’). The amplified product was 
digested with Bam H I and Xho I, and subcloned into pGEX-4T-3 at the same sites. 
 
 83 
2.2.2 PCR amplification of ODDD-encoding cDNA fragments from pCI-neo 
vectors. 
 
Each PCR reaction mixture contained 5l of 10X Pfu buffer, 1l 10mM dNTPs, 1l 
Pfu polymerase (2.5U/l, Stratagene Ltd.), 0.1 nmoles of each primer, 1l of pCI-
neo-HIF-1a, pCI EPAS or H2O and H2O to a final volume of 50l. Reactions were 
carried out in 0.5ml microfuge tubes. Mixes were overlayed with 50l mineral oil.  
 
The PCR cycle was as follows: -  
Step Temp C Time (in min) 
1 94 1 
2 94 1 
3 45 2 
4 72 2 min, cycle to step 2, 30 
X 
5 72 5 
6 4  
 
2.2.3 Subcloning of ODDD sequences. 
 
PCR products were sub-cloned into pCR4-TOPO from the ‘Zero Blunt TOPO PCR 
Cloning Kit’ (Invitrogen). 1l PCR product, 1l of salt solution (1.2M NaCl and 
0.06M MgCl2), 1l of TOPO vector (10ng/l) and H2O to a final volume of 5l were 
gently mixed and incubated for 5 min at rt then placed on ice. 2l of the cloning 
reaction was added to one vial of ‘Top10 One Shot Chemically Competent’ E. coli, 
gently mixed and incubated on ice for 30 min. Cells were heat pulsed at 42 C for 30 
seconds, then immediately transferred to ice. 250l of Luria-Bertani media (LB, 
Sigma) was added to cells, which were then incubated at 37 C for 1 hour with 
shaking at 225 – 250 rpm. 25l of each transformation was spread onto LB-
ampicillin (100g/ml) agar plates. The remaining transformation was micro-
centrifuged and the cell pellet re-suspended in LB and plated as before. Plates were 
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incubated o/n at 37 C. Colonies were picked and grown o/n in 5ml LB-ampicillin 
(100g/ml). DNA was purified using a ‘QIAprep Spin Miniprep kit’ (Qiagen Ltd.). 
2.2.4 Plasmid purification. 
 
A QIAprep Spin Miniprep Kit (Qiagen Ltd.) was used to purify plasmid DNA from 
bacterial cultures. Single colonies picked from LB-ampicillin (50g/ml) agar plates 
were grown in 5ml LB-ampicillin (50g/ml) o/n at 37 C with shaking at 225-250 
rpm. 3ml of o/n cultures were centrifuged in 1.5ml aliquots and the supernatant 
discarded. The bacterial pellet was re-suspended in 250l buffer P1 (resuspension 
buffer: 50mM Tris-HCl (pH 8.0), 10mM EDTA, 10g/ml RNase A) followed by the 
addition of 250l of buffer P2 (lysis buffer: 200mM NaOH, 1% (w/v) SDS) with 
mixing. 350l buffer N3 (neutralisation buffer: 3.0M potassium acetate pH 5.5) was 
added with mixing then micro-centrifuged for 10 min. Following centrifugation the 
supernatant was applied to a QIAprep spin column and micro-centrifuged for 60 sec. 
Flow through was discarded. The column was washed with 0.75ml of PE buffer and 
micro-centrifuged; the flow through was discarded. The column was micro-
centrifuged for a further minute to remove any residual wash buffer. The QIAprep 
column was placed in a clean micro-centrifuge tube. DNA was eluted by adding 50l 
H2O to the centre of the QIAprep column and incubating at RT for 1 min then micro-
centrifuged for 1 min to collect the purified DNA.  
 
2.2.5 Restriction digests. 
 
5l of DNA was added to 1l (10U/l) of restriction enzyme (XhoI or Bam HI, 
Promega, Southampton, UK), 2l of 10X reaction buffer, BSA to a final 
concentration of 0.1g/l and water to a final volume of 20 l. Samples were 
incubated at 37 C for 2 hours. 1l of calf alkaline phosphatase (Promega) was added 
to linearised vectors giving a final concentration of 0.05u/l and incubated at 37 C 
for a further 30 minutes. 10l of digested DNA was mixed with 5l of agarose gel 
loading buffer and run on an 0.7% (w/v) agarose gel. DNA bands were excised and 
purified using a Qiaex II Gel Extraction Kit (Qiagen Ltd., section 2.1.11). 
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2.2.6 Ligation. 
 
For ligation the mass ratio of DNA cloning vector to insert was 1:3. Ligation 
reactions contained vector DNA, insert DNA, 1l 10X ligation buffer and 1l of T4 
DNA ligase (New England Biolabs, Hitchin, UK). The final volume was 10l. 
Reactions were incubated at 16 C o/n. To 100l aliquots of supercompetent XL1-
blue E.coli cells (Stratagene Ltd. Ltd., Amsterdam, The Netherlands) (thawed on ice) 
1.7l of -mercaptoethanol was added giving a final concentration of 25mM in each 
tube. The contents of each tube were swirled gently and incubated on ice for 10 min, 
swirling gently every 2 min. To each aliquot of cells 5l of ligation reaction was 
added. Tubes were incubated on ice for 30 min, heat pulsed at 42 C for 45 sec then 
incubated on ice for 2 min. 0.9ml of preheated LB was added to each tube and 
incubated at 37 C for 1 hour with shaking (225-250 rpm). 100l of transformed 
cells was plated onto LB-ampicillin (50g/ml) agar. The remaining transformation 
was micro-centrifuged and the pellet re-suspended in 100l of LB and plated as 
before. Plates were incubated at 37 C o/n. Colonies were picked and grown up in 
5ml LB-ampicillin (50g/ml) o/n at 37 C with shaking (225-250rpm). Plasmid 
DNA was purified using a QIAprep Spin Miniprep Kit (Qiagen Ltd.). 
 
2.2.7 Transformation of BL21-DE3 E.coli with GST fusion vectors. 
 
BL21-DE3 E. coli cells were cultured in 5ml of LB o/n at 37 C with shaking.and at 
225-250rpm. O/n cultures were added to 100ml LB and incubated for 2.5 hours at 37 
C with shaking and at225-250rpm. The culture was split into two 50ml aliquots and 
centrifuged for 20 minutes at 1380g and 4 C in a Beckman GS-6R centrifuge 
(Beckman Coulter UK Ltd., High Wycombe, Bucks, UK). The supernatants were 
discarded and bacterial cell pellets were re-suspended in 10ml of cold 0.1M CaCl2 
before re-centrifugation for 10 min at 1380g and 4 C. Supernatants were discarded 
and bacterial cell pellets were re-suspended in 2ml of cold 0.1M CaCl2 containing 
20% (v/v) glycerol. Aliquots were frozen at -80 C. 
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Competent BL21-DE3 E. coli (Stratagene Ltd.) were transformed with either pGEX-
4T-3, GHO or GEO. For each transformation, 1l of plasmid DNA was added to 
30l of competent bacterial cells and incubated on ice for 1 hour. Transformations 
were heat pulsed at 42C for 1.5 min and immediately chilled on ice for 2 min. 1ml 
of LB was added to each transformation and incubated at 37 C for 1 hour with 
shaking at 225-250 rpm. The 1ml recovery cultures were added to 5ml of LB-
ampicillin (50g/ml) and incubated at 37 C o/n with shaking at 225 – 250 rpm. 1ml 
of transformed cultures were stored in 20% (v/v) glycerol at –80 C. 
 
2.2.8 GST fusion protein expression and purification. 
 
BL21-DE3 E. coli transformed with pGEX-4T-3, GHO or GEO were cultured o/n in 
5ml LB-ampicillin (50g/ml). 1ml of each o/n culture was sub-cultured into 9ml LB-
ampicillin (50g/ml) and grown for 1 hour at 37 C with shaking at 225-250 rpm. 
Isopropyl -D galactopyranoside (IPTG) was added, to induce fusion protein 
expression, to each culture, to a final concentration of 1mM and cultures were grown 
for a further 3 hours. Cells were centrifuged at 1380g, 4 C for 5 min. Cell pellets 
were re-suspended in 10 ml of PBS and centrifuged as before. Pellets were frozen o/n 
at -80 C.  
 
Pellets (thawed on ice) were re-suspended in PBS – 0.5% (v/v) triton X-100 (PBS-T) 
containing 100l of a protease inhibitor cocktail for bacterial cells (18mM AEBSF, 
86mM EDTA, 1.7mM bestatin, 0.29mM pepstatin A and 0.22mM E-64, Sigma), 
where indicated, with rotation at 4 C for 30 min. Suspensions were sonicated at 
7MHz for 30 sec with a probe sonicator and centrifuged at 1380g, 4 C for 5 min. 
Supernatants from each tube were added to 20l of PBS-T washed glutathione 
sepharose 4B beads (Amersham Biosciences UK Ltd.) and incubated at rt for 1 hour 
with rotation. Supernatants were discarded and the beads washed 3X in 0.5ml PBS. 
Beads were re-suspended in 2X SDS-PAGE loading buffer and subjected to SDS-
PAGE. 
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Alternatively, GST fusion proteins were made as above except cultures containing 
transformed BL21-DE3 cells were grown up in 10ml of LB-ampicillin (50g/ml) o/n 
before being sub-cultured into 90ml LB-ampicillin (50g/ml). Pellets were lysed in 
100ml of PBS-T. 250l of PBS-T washed glutathione sepharose 4B beads were 
added to the supernatant and incubated at room temp for 2 hours. After washing, 
beads were re-suspended in 250l PBS/20% (v/v) glycerol and frozen in 50l 
aliquots at –80 C.  
 
2.2.9 pVHL pull down assay. 
 
Two 50l aliquots of GST fusion proteins bound to beads were washed 3X in PBS 
and incubated with either 50l of rabbit reticulocyte lysate (Promega) or 50l of 
NP40 lysis buffer (0.5% (v/v) Nonidet-P40, 10mM Tris and 250mM NaCl pH7.5) at 
30 C for 90 min with gentle agitation every 15 min. Incubations were washed 3X in 
NP40 lysis buffer. Treated/untreated fusion protein beads were washed 3X in cold 
lysis buffer and incubated with 200l of Hela whole cell lysate (section 2.2.10), at 4 
C for 1 hour. Fusion protein beads were washed 3X in NP40 lysis buffer before 
being subjected to SDS-PAGE and western blotting.  
 
2.2.10 Cell lysates for VHL binding assay. 
 
Hela and 786-O cells were seeded into T75 flasks (Orange Scientific, Braine-
l’Alleud, Belgium), grown to ~80% confluent, washed three times in cold PBS and 
lysed for 20 minutes in 2ml of NP40 lysis buffer (0.5% (v/v) Nonidet-P40, 10mM 
Tris and 250mM NaCl pH 7.5) at 4 C. Lysates were micro-centrifuged at 604 g, 4 
C for 5 min and supernatants stored on ice. 
 
2.2.11 Thrombin protease cleavage of GST fusion proteins. 
 
GST bound to glutathione beads was diluted at a ratio of 1:3 with fresh glutathione 
sepharose beads to standardise the amount of protein relative to fusion proteins 
purified on beads in parallel. Two 50l aliquots of both GST bound to beads and 
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GST-HIF-1-ODDD (GHO) bound to beads, were rotated at rt for 1 hour in 300l 
binding buffer containing BSA (BB-BSA; 50mM Tris-HCl pH 7.6, 120mM NaCl, 
2mM EDTA, 0.5% (v/v) Nonidet P-40, 10mg/ml BSA) to reduce non-specific 
binding. Aliquots were washed 3X in PBS. Thrombin protease (Amersham 
Biosciences UK Ltd.) was supplied as 500 units of a lyopholised powder which was 
reconstituted in PBS to a final concentration of 1unit/l before use in the cleavage 
assay. Thrombin protease was prepared for the cleavage assay by adding 5% (v/v) 
thrombin protease to PBS. One aliquot of either GST bound to beads or GHO bound 
to beads was incubated with rotation with 25l of either PBS or thrombin protease in 
PBS (giving a final thrombin protease concentration of 0.05U/l) at rt for 16 hours 
unless indicated otherwise. Thrombin protease in PBS was also incubated. Reactions 
were centrifuged (Gentofuge 16M, 8163g, 5min) and supernatants transferred to 
separate tubes. 50l of 2X SDS-PAGE loading buffer was added to all samples 
before incubating for 5 min at 100 C. Samples were stored at -20C. 
 
2.2.12 PCR amplification of DNA oligonucleotide pool to produce aptamer library. 
 
DNA oligonucleotide pool sequence 5’ GGGCGCTAAGTCCTCGCTCA-N40-
ACGCGCGACTCGGATCCT 3’ was PCR amplified using the sense primer FOR 
POOL 5’ TCTAATACGACTCACTATAGGGCGCTAAGTCCTCGCTCA 3’ and 
antisense primer REV POOL 5’GTAGGATCCGAGTCGCGCGT 3’. 
 
10 PCR reactions were performed containing 5l of 10X Taq polymerase buffer, 2l 
of 50mM MgCl2, 1l 10mM dNTP’s, 0.5l Taq polymerase (5U/l, Invitrogen), 0.8 
nmoles of sense primer and 1.5 nmoles of antisense primer, 30ng DNA 
oligonucleotide pool and H2O to a final volume of 50l. Reactions were carried out 
in 0.5ml microfuge tubes. Mixes were overlayed with 50l mineral oil. To control 
for amplification, reactions containing all reagents, primers and no DNA 
oligonucleotide, all reagents, DNA oligonucleotide and no primers or DNA 
oligonucleotide, primers and all reagents except Taq DNA polymerase were 
prepared. This gave a pool of double stranded DNA oligonucleotides with 
approximate starting complexity of 7.455  1012 oligonucleotides. The PCR cycle 
was as follows: -  
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Step Temp C Time (in min) 
1 94 4 
2 42 7 
3 72 7 min, cycle to step 1 six 
times 
4 4  
 
2.2.13 Purification of PCR products. 
 
PCR products were purified using a MinElute PCR purification kit (Qiagen Ltd.).Up 
to three 50l PCR reactions (not including oil) were mixed with five times the 
volume of buffer PB, applied to a MinElute column and micro-centrifuged for 1 
minute. Flow through was discarded. The column was washed in 750l of PE buffer 
and micro-centrifuged for 1 minute, flow through was discarded. The column was 
centrifuged for a further minute to remove any residual wash buffer. DNA was eluted 
by adding 10l of H2O to the centre of the MinElute column and incubating at rt for 
1 minute before micro centrifuging for 1 minute to collect purified DNA. 
 
2.2.14 T7 RNA polymerase transcription from DNA oligonucleotide pool. 
 
Each transcription reaction contained 20l 5X transcription optimised buffer 
(200mM Tris pH 7.9, 30mM MgCl2, 10mM spermidine and 50mM NaCl), 10l 
100mM DTT, 20l 2.5mM rNTPs (Promega), 5g DNA template, 2.5l RNasin 
ribonuclease inhibitor (40U/l, Promega), 2.7l T7 RNA polymerase (20U/l, 
Promega) and nuclease free H2O to a final volume of 100l. Reactions were carried 
out in 0.5ml micro-centrifuge tubes. To control for transcription reactions containing 
all reagents and H2O instead of DNA template were prepared. Reactions were 
incubated at 37 C for 2 hours. 5l of RQ1 RNase free DNase (1U/l, Promega) was 
added to each reaction and incubated at 37 C for 15 mins. RNA aptamers 
synthesised in transcription reactions were purified using a QIAquick nucleotide 
removal kit. 
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2.2.15 Purification of RNA aptamers. 
 
RNA aptamers were purified using a QIAquick Nucleotide Removal Kit (Qiagen 
Ltd.). 10 volumes of buffer PN was added to 1 volume of T7 RNA polymerase 
transcription reaction and mixed. The sample was applied to a QIAquick spin column 
and micro-centrifuged at 2939g for 1 min to bind DNA. The flow through was 
discarded and the Qiaquick column was washed in 750l of buffer PE. The column 
was micro-centrifuged at 2939g for 1 min. The flow through was discarded and the 
column was centrifuged for a further minute at 8163g. 100l of HPLC purified H2O 
was added to the column and incubated at rt for 1 min before centrifugation to elute 
the DNA. 
 
2.2.16 RNA aptamer selection. 
 
50l of GST bound to beads (see sections 2.2.8) were washed in 100l of PBS 
micro-centrifuged for 1 min at 8163g and the supernatant discarded. This wash step 
was performed three times. 60l of purified RNA aptamer pool (see sections 2.2.12 – 
2.2.15) was incubated with GST bound to beads for 1 hour at rt with rotation. The 
RNA aptamer:GST bound to beads incubation mixture was micro-centrifuged as 
above and the supernatant transferred to a 50l aliquot of GST-HIF-1-ODDD 
(GHO) bound to beads, prepared in the same way as for GST bound to beads. The 
RNA aptamer pool was incubated with GHO bound to beads at rt for 1 hour with 
rotation before micro-centrifugation as described previously. The supernatant was 
discarded and aptamers bound to GHO beads were subjected to thrombin protease 
cleavage as described in section 2.2.11 for 4 hours at rt. The thrombin protease 
cleavage incubation was micro-centrifuged as above and supernatant retained for one 
step RT-PCR of the selected RNA aptamer pool. 
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2.2.17 One step RT-PCR of selected RNA aptamer pool. 
 
Selected RNA aptamers were subjected to one step RT-PCR (Roche, Lewes, UK). 
Six reactions were performed in total with each reaction being performed in RNase 
and DNase free 0.5ml micro-centrifuge tubes (Sarstedt Ltd., Leicester, UK). Each 
reaction contained 10l 5X RT-PCR buffer, 0.8l 25mM dNTPs, 2.5l 100% 
DMSO, 2.5l 100mM DTT, 1.6l RNasin ribonuclease inhibitors (40U/l, 
Promega), 0.1 nmoles of both sense and anti-sense primers (described in section 
2.1.12), 2l of a mixture of Carboxydothermus hydrogenoformans and Taq DNA 
polymerase (‘C. therm polymerase’), 1l selected RNA aptamer pool and HPLC 
purified RNase and DNase free H2O to a final volume of 50l. To control for 
reverse-transcriptase dependent amplification ‘C. therm polymerase’ was replaced 
with H2O. 
 
The aptamer pool was reverse transcribed and then PCR amplified as a one-step 
reaction. Reactions were incubated at 72 C for 30 min before PCR using the same 
cycle conditions as in section 2.1.9 except the PCR cycle was performed 10 times. 
PCR reactions were purified using a MinElute PCR purification kit (Qiagen Ltd., 
section 2.2.13). 
 
2.2.18 RNA aptamer mediated HIF responsive HRE driven transcription of a 
luciferase reporter gene. 
 
Hep G2 cells were seeded 100 000 cells/well in 4ml/well of SFQ supplemented with 
10% FCS in six well plates. 24 hours after seeding the media from each well was 
replaced with 1ml SFQ supplemented with 10% FCS. Cells were transfected using 
Lipofectamine 2000 (Invitrogen). 4l/well of Lipofectamine 2000 was diluted in 
96l/well Opti-MEM I (Invitrogen) and incubated at RT for 5 min. 100l/well of 
diluted Lipofectamine 2000 was added to six pre-prepared reaction mixtures 
containing 1g/well test plasmid (pGL3prevPGK/pGL3-control/pCMVluc, described 
in section 2.1.12), 0.02g/well pRL-SV40 (described in section 2.1.12), 0.2g/well 
RNA aptamers (r0 starting pool of aptamers or r4 aptamer pool after four rounds of 
selection) and Opti-MEM to a final volume of 100l/well. Lipofectamine 
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2000:DNA:RNA mixtures were incubated at RT for 20 min. Hep G2 cells were 
transfected in triplicate for each test plasmid with 200l/well of appropriate 
Lipofectamine 2000:DNA:RNA complexes. 4 hours after transfection, media was 
replaced on all wells with 2ml warm SFQ supplemented with 10% FCS. 48 hours 
after transfection cells were washed twice in PBS and lysed in 200l/well of cold 1X 
passive lysis buffer (Promega). Lysates were stored at -80C before assaying for 
luciferase reporter activity (described in section 2.1.13). 
 
2.3 RNA interference specific materials and methods. 
 
2.3.1 Preparation of siRNAs and FITC labelled DNA oligonucleotide. 
 
Small interfering RNAs (siRNAs) were designed to a human SDH B mRNA 
sequence. The sequences were designed following the recommendations of Elbashir 
et al., (2001). Each strand contained two 3’ deoxythymidines. 
 
The sequences of the SDH B sense and anti-sense strands were 5’ 
UAAAUGUGGCCCCAUGGUA dTdT 3’ and 5’ UACCAUGGGGCCACAUUUA 
dTdT 3’ respectively. The control sequence used in this experiment was the inverse 
of the SDH B sense strand. The sequences of the control siRNA sense and anti-sense 
strands were 5’ AUGGUACCCCGGUGUAAAU dTdT 3’ and 5’ 
AUUUACACCGGGGUACCAU dTdT 3’ respectively (Dharmacon, Chicago, IL, 
USA). 
 
Cy3-luciferase GL2 duplex (Dharmacon) was used as a control for the optimization 
of transfection. The sense sequence was modified with Cy3 at the 5’ end and two 3’ 
deoxythymidines and had the following sequence; - 
5’CGTACGCGGAATACTTCGA3’.  
 
SDH B, SDH B control and Cy3-luciferase pre-annealed siRNA duplexes were 
reconstituted in 1ml de-ionised and distilled H2O (ddH2O) to give a concentration of 
20M.  
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A fluorescein labelled DNA oligonucleotide (FITC-DNA) with sequence 5’Fluo-
TCGAAGTATTCCGCGTACG3’ (a gift from M. Pohlschmidt) was also used as a 
control for transfection optimization. 
 
2.3.2 Transfection of cells with small interfering RNAs (siRNA). 
 
Cells were seeded 100 000 cells/well in 6 well plates (Triple Red). 24 hours after 
seeding each well was washed three times in RPMI 1640 medium (Invitrogen) 
supplemented with 2mM glutamine (SFQ, Sigma) then covered in 0.4ml of SFQ. 
3l/well of Oligofectamine (Invitrogen) was incubated with 7l/well of SFQ for 10 
minutes. 6l/well (1l/well FITC-DNA) of annealed siRNAs were diluted in 
84l/well (89l/well for FITC-DNA) of SFQ. Diluted Oligofectamine was added to 
diluted siRNAs and incubated at rt for 20 minutes. 100l/well of either 
Oligofectamine-test siRNA complex, Oligofectamine-control siRNA complex, 
Oligofectamine-FITC-DNA complex, Oligofectamine-Cy3-siRNA complex, 
Oligofectamine only or FITC-DNA/Cy3-siRNA only, as indicated, was then added 
to cells and left for four hours before the addition of 250l/well of RPMI 1640 
medium supplemented with 30% FCS (Invitrogen) and 2ml/well of RPMI 1640 
medium supplemented with 10% FCS and 2mM glutamine. 24 hours after the first 
siRNA transfection a second transfection was carried out in the same way as 
described above unless otherwise indicated. 
 
Triplicate wells were counted for transfected cells and control cells on the day of the 
first transfection then 24 hours after the first transfection and at 24 and 48 hours after 
the second transfection. Duplicate wells were lysed for test cells and control cells 24 
and 48 hours after the second transfection. Cells were lysed in 200l of boiling 2X 
SDS-PAGE loading buffer. Lysates were analysed by SDS-PAGE and western 
blotting. 
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2.3.3 Fluorescent cell photography. 
 
Cells transfected with FITC-DNA or Cy3-siRNA were visualised 24 hours after 
transfection using a Leica DM1RB inverted fluorescence microscope. Cells were 
photographed with a TS100 inverted colour cool view CCD camera using Photolite 
Image acquisition software (Photonic Science, Robertsbridge, EastSussex, UK). 
 
2.3.4 siRNA mediated HIF responsive HRE driven transcription of a luciferase 
reporter gene. 
 
Hep G2 were seeded 100 000 cells/well in 2ml/well of SFQ supplemented with 10% 
FCS in six well plates. Cells were transfected 24 hours after seeding using 
Lipofectamine 2000 (Invitrogen). 4l/well of Lipofectamine 2000 was diluted in 
96l/well Opti-MEM I (Invitrogen) and incubated at RT for 5 min. 100l/well of 
diluted Lipofectamine 2000 was added to reaction mixtures containing 1g/well test 
plasmid, 0.02g pRL-SV40, 240nmol siRNA as indicated and Opti-MEM I to a final 
volume of 100l/well. 48 hours after seeding media was replaced on cells with 1ml 
SFQ supplemented with 10% FCS. 4l/well of Lipofectamine 2000 was diluted in 
96l/well Opti-MEM I and incubated at rt for 5 min. 100l/well of diluted 
Lipofectamine 2000 was added to 240nmol/well siRNA as indicated, diluted to a 
final volume of 100l/well in Opti-MEM I and incubated at RT for 20 mins. 
200l/well of Lipofectamine 2000:siRNA complexes were added to appropriate 
wells. Media was changed 4 hours after transfection for 2ml SFQ supplemented with 
10% FCS. 24 hours after the second transfection cells were washed twice in PBS and 
lysed in 200l/well of cold 1X passive lysis buffer. 
 
2.3.5 Total RNA extraction from cultured cells. 
 
Total RNA was extracted from cells using an RNeasy kit (Qiagen Ltd.). Cells seeded 
in 6 well plates were washed twice in PBS before the addition of 350l/well of 
buffer RLT containing -mercaptoethanol (10l (v/v) 14.5M -mercaptoethanol per 
1ml buffer RLT). Cells lysates were passed 10 times through a 21G needle fitted 
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onto a 1ml syringe. 350l 70% ethanol was added to each homogenised sample and 
mixed. Each sample was applied to an RNeasy mini spin column and micro-
centrifuged at 8163g for 15 sec. Flow through was discarded before the addition of 
700l buffer RW1 to the spin column. The spin column was centrifuged as described 
previously. The RNeasy column was transferred to a clean collection tube before the 
addition of 500l of buffer RPE. The RNeasy column was centrifuged as before and 
the flow through discarded. This step was repeated and the RNeasy column micro-
centrifuged for 2 min at maximum speed. The flow through was discarded and the 
RNeasy column was centrifuged for a further 1 min at maximum speed. RNA was 
eluted into a clean 1.5ml micro-centrifuge tube by the addition of 30l RNase free 
H2O onto the RNeasy membrane and micro-centrifugation for 1 min at 8163g. 
 
2.3.6 DNase digestion of total cellular DNA.  
 
To remove any cellular DNA present in the samples a DNAse digestion was 
performed. For each g of RNA in the sample the following volumes of components 
were added, 1l 10X reaction buffer, 1l DNase I (1U/l, Invitrogen) and RNase and 
DNase free H2O to a final volume of 10l. Reactions were incubated for 15 min at rt 
before the addition of 1l 25mM EDTA. Reactions were incubated for 10 min at 65 
C. RNA was purified using an RNeasy kit (Qiagen Ltd., section 2.1.14). 
 
2.3.7 Purification of cellular RNA from DNase digestion reactions. 
 
RNA was purified following the protocol for RNA cleanup using an RNeasy kit 
(Qiagen Ltd.). Each RNA sample was adjusted to 100l with RNase free H2O before 
the addition of 350l buffer RLT containing -mercaptoethanol (10l (v/v) -
mercaptoethanol per 1ml buffer RLT). Each sample was mixed thoroughly before the 
addition of 250l 100% ethanol. Lysates were mixed by pipetting and each sample 
was applied to an RNeasy spin column and micro-centrifuged at 8163g for 15 sec. 
Flow through was discarded and each column was transferred to a clean collection 
tube. 500l buffer RPE was added to each column before centrifugation as described. 
Flow through was discarded and the wash step repeated. RNeasy columns were 
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micro-centrifuged for 2 min at maximum speed. RNeasy columns were placed in 
clean 1.5ml micro-centrifuge tubes before the addition of 50l RNase free H2O to the 
RNeasy membrane. RNeasy columns were micro-centrifuged for 1 min at 8163g to 
elute RNA. 
 
2.3.8 Reverse transcription of cellular RNA. 
 
Each reaction contained 1g total RNA, 1l RNaseOUT RNase inhibitor (40U/l, 
Invitrogen), 1l random primers (3g/l, Invitrogen) and RNase and DNase free 
H2O to a final volume of 10l. Reactions were prepared in duplicate for each RNA. 
Reactions were pulse centrifuged, incubated for 10 min at 70 C and then chilled on 
ice. Reactions were pulse centrifuged before addition of 10l per reaction of reverse 
transcriptase (RT) positive (RT+ve) or negative (RT-ve) master mix consisting of 
2l of RNase and DNase free H2O, 4l 5X first strand buffer, 1l 10mM dNTPs, 2l 
0.1M DTT and 1l Superscript II RT (Invitrogen) for RT+ve reactions and 1l 
RNase and DNase free H2O for RT-ve reactions. RT+ve and RT-ve reactions were 
incubated for 1 hour at 42 C followed by 10 min at 70 C. Reactions were chilled on 
ice and pulse centrifuged. cDNA was amplified as described in section 2.1.16. 
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2.3.9 PCR amplification of cDNA. 
 
Each PCR reaction containing 5l 10X reaction buffer, 1.5l 50mM MgCl2, 1l 
10mM dNTPs, 1l sense primer (40pmol/l), 1l anti-sense primer (40pmol/l), 
0.5l Taq DNA polymerase (5U/l, Invitrogen), 2l cDNA and RNase and DNase 
free H2O to a final volume of 50l was covered in 20l of mineral oil and performed 
in a 0.5ml RNase and DNase free micro-centrifuge tube using the following PCR 
cycle: - 
 
Step Temperature C Time (min) 
1 94 3 
2 94 1 
3 55 1 
4 72 1.5  
cycle to step 2 30X 
5 72 10 
6 4  
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Chapter 3: The development of HIF targeted RNA 
aptamers. 
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3.1 Introduction 
 
Experiments performed by several groups have demonstrated blockade experiments 
are a viable option in the search for therapeutic strategies capable of modulating HIF 
function. For instance proof of principle experiments showed, the p300/HIF-1 
interaction was disrupted by the overexpression of a polypeptide encoding the HIF-
1 C-TAD domain (Kung et al., 2000, section 1.7.1). Peptide blockade experiments 
showed peptide overexpression prevented proteasomal degradation of ubiquitinated 
HIF-1. Peptide blockade experiments carried out by a second group showed 
overexpression of prolyl hydroxylated peptides, based on the HIF-1 ODDD, 
saturated the proteasomal degradation process resulting in upregulation of 
endogenous HIF-1 and consequently the upregulation of HIF target genes 
(described in section 1.7.2, Li et al., 2000; Williams et al., 2002).  
 
RNA aptamers are another type of small molecule that could be utilised in blockade 
experiments. They offer an advantage over short peptides because they have higher 
affinity and specificity for their targets (reviewed by Gold et al., 1995). 
 
3.1.1 RNA aptamers and SELEX (the systematic evolution of ligands by 
exponential enrichment). 
 
RNA aptamers have emerged as an oligonucleotide technology that can exploit the 
abilities of RNA to form three-dimensional structures and interact with other 
molecules e.g. proteins. RNA aptamers themselves are random pieces of folded 
single stranded RNA that are selected from large combinatorial pools of sequences, 
based on their capacity to bind a specific target, for example, a protein domain 
(Famulok, 1994). The RNA aptamer selection method requires a sequence of steps 
and has been named the systematic evolution of ligands by exponential enrichment 
(SELEX, figure 3.1). The first step in the SELEX procedure is the chemical synthesis 
of a random pool of single stranded DNA oligonucleotides. Each oligonucleotide has 
two fixed sequences at the 5’ and 3’ end, with a randomly synthesised set of 
nucleotides in the middle. The single stranded RNA aptamer pool is synthesised by 
PCR amplification of the single stranded DNA oligonucleotide into a double 
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stranded DNA library followed by in vitro transcription into the RNA aptamer pool. 
The starting pool typically has a complexity of 1014 or 1015 oligonucleotides. Once 
the RNA aptamer pool has been synthesised, the aptamers are incubated with the 
target molecule. Unbound aptamers are removed and discarded while bound 
aptamers are recovered from the target. The recovered (previously bound) RNA 
aptamers then undergo RT-PCR followed by in vitro transcription before undergoing 
further rounds of the selection process. Typically the selected pool will undergo 
between 4 and 20 rounds of selection. During these selection rounds, RNA aptamers 
will evolve towards those that are best able to withstand the selection criteria. The 
final step in the SELEX procedure is the cloning, sequencing and testing of the 
aptamers (Gold et al., 1995). 
  
Figure 3.1 The general principle of SELEX. 
 
A random pool of RNA oligonucleotides is synthesised to form an aptamer 
library. The aptamer library is then incubated with the protein target. 
Unbound aptamers and bound aptamers are partitioned. Bound aptamers are 
eluted from the target and amplified by RT-PCR. The selected aptamer pool 
can then undergo a new round of selection. Throughout the following rounds 
of selection the aptamer population evolves towards the sequences that are 
best able to withstand the selection process. Once the desired number of 
selection rounds have been carried out individual aptamers are cloned 
sequenced and tested. 
Aptamer library
Protein target
Incubation of target with 
aptamer library
Removal of unbound 
sequences
Individual aptamers
Amplification
Recover bound 
sequences
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RNA aptamers isolated from SELEX have a high efficiency of binding to their target 
sequences, typically in the low nanomolar to high picomolar range. This range is 
similar to the affinities of monoclonal antibodies for their targets. However, aptamers 
are advantageous when compared to monoclonal antibodies because they can be 
chemically synthesised in large quantities for in vivo applications. They can also be 
chemically modified to protect against nucleases or extend blood circulation time and 
appear to have low toxicity and immunogenicity, all properties that are invaluable in 
vivo. In certain circumstances RNA aptamers can be modified and injected directly 
into the area where treatment is required. An example of this is an RNA aptamer 
targeted to VEGF-165 which is injected in to the vitreous humour of the eye and is 
used for the treatment of age-related macular degeneration (Sullenger and Gilboa, 
2002). However, it is anticipated that most RNA aptamer related therapeutics will be 
incorporated into gene delivery vectors in order to reach the treatment area. One such 
gene delivery technology that could be utilised in this study is LentiVector®, a 
lentiviral gene delivery system developed by our collaborators OBM.  
 
3.1.2 Hypothesis. 
 
It is hypothesised that the development of RNA aptamers towards the ODDD of non-
proline hydroxylated HIF-1 and EPAS-1 could prevent the action of the PHDs on 
these proteins. This favourable outcome is hypothesised to result in the stabilisation 
of HIF-1 and EPAS-1 and a subsequent upregulation in transcription which would 
be measured by a transcription reporter assay. Therefore the aims of this project are 
to develop RNA aptamers targeted towards the ODDD of non-proline hydroxylated 
HIF-1 and EPAS-1 and to determine whether selected targeted apatamers can up-
regulate a HIF responsive transcription reporter assay.  
 
3.2 Experimental strategy 
 
The aim of this study was to develop RNA aptamers using SELEX towards known 
sequences of both the HIF-1 and EPAS ODDD. These sequences represented the 
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minimal motif of amino acids required to elucidate an oxygen dependent response 
and for the purposes of this study were not subjected to prolyl hydroxylation. 
 
Before the development of the RNA aptamers could begin it was necessary to 
synthesise the target peptide sequences and develop a method in which RNA 
aptamers bound to the target protein sequence could be released (Section 3.3). DNA 
sequences encoding for HIF-1-ODDD or EPAS ODDD were incorporated into 
expression vectors that introduced a GST moiety. The GST fusion vectors were 
expressed in bacteria and the resulting GST fusion proteins were purified using 
affinity chromatography, in this instance glutathione Sepharose 4B beads. A 
thrombin protease cleavage assay was developed which would be used to release 
RNA aptamers bound to the target protein sequence from GST. GST remained bound 
to the affinity chromatography column. Once these initial experimental steps had 
been undertaken the development, enrichment and testing of the RNA aptamers was 
carried out (section 3.4).  
 
3.3 Target protein synthesis and purification 
 
3.3.1 GST fusion protein vector development 
 
Experiments carried out by Huang et al (1998) and O’Rourke et al (1999) identified 
the sequences of amino acids within HIF-1α and EPAS that were responsible for 
elucidating oxygen dependent degradation of HIF-1α and EPAS, respectively. Pugh 
et al (1997) identified that the minimal sequence of amino acids that could result in 
independent oxygen regulated activity of HIF-1α was 549 -582. Based upon Huang 
et al (1998) and Pugh et al’s (1997) findings sequence determined upon for HIF-1α 
encompassed amino acid residues 519 -647 of HIF-1α. Based upon findings by 
O’Rourke et al (1999) and sequence similarity analysis between HIF-1α and EPAS 
using BLAST the EPAS sequence spanned amino acid residues 488-617. These 
sequences also encompassed the prolyl hydroxylation sites P564 of HIF-1α and P572 of 
EPAS.  
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XL1-blue competent E. coli cells were transformed with pCI-neo-HIF-1a and pCI-
EPAS using the same method as described for BL21-DE3 E. coli cells (sections 2.2.7 
and 2.2.1). DNA plasmids were purified and sequences encoding amino acid residues 
519 – 647 of HIF-1 and 488 – 617 of EPAS 1 were amplified by PCR (sections 
2.2.4 and 2.2.2, respectively). PCR products were resolved by agarose gel 
electrophoresis. DNA was excised and purified then sub-cloned into the TOPO 
vector (sections, 2.1.9, 2.1.11 and 2.2.3). TOPO vectors containing the appropriate 
PCR-generated inserts were sequenced to confirm their identity, restriction digested 
and the resulting inserts ligated into the p-GEX-4T-3 vector to produce the vectors p-
GEX-HIF-1-ODDD or p-GEX-EPAS-ODDD (sections 2.2.5, 2.2.6 and 2.2.1). 
 
3.3.2 Expression of GST fusion proteins 
 
BL21-DE3 competent E.coli cells were either transformed with p-GEX–4T-3, p-
GEX-HIF-1-ODDD or p-GEX-EPAS-ODDD (section 2.2.7.) GST fusion protein 
expression was induced by the addition of IPTG to a final concentration of 1mM.  
 
Bacterial cell lysates were prepared 3 hours after the addition of IPTG and resolved 
by SDS-PAGE (section 2.1.8 and 2.1.3). The SDS-PAGE gel was coomassie stained 
and destained to visualise the proteins (section 2.1.8, figure 3.2). 
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Figure 3.2 Expression of GST fusion proteins in E. coli 
 
BL21-DE3 cells transformed with p-GEX-4T-3, p-GEX-
HIF-1-ODD or p-GEX-EPAS-ODD were incubated with 
or without IPTG to a final concentration 1mM, as 
indicated to induce GST fusion protein expression 
Bacterial cell lysates, prepared 3 hours after IPTG 
inoculation, were resolved by SDS-PAGE. The SDS-
PAGE gel was coomassie stained and destained to 
visualise proteins (N=2; sections 2.2.7, 2.1.8 and 2.1.3). 
Mobilities of standard proteins are indicated (Seeblue, 
Invitrogen,) 
 
Key: EPAS, endothelial PAS protein; GEO, GST-EPAS-ODD; GHO, 
GST-HIF-1-ODD; GST, glutathione-s-transferase; HIF, hypoxia 
inducible factor; IPTG, isopropyl -D galactopyranoside; kDa, 
Kilodaltons 
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The glutathione-s-transferase (GST) and GST-HIF-1-ODDD (GHO) fusion 
proteins were both expressed in the absence of IPTG. However, the addition of IPTG 
resulted in a higher fold induction of both the GST and GHO fusion proteins. The 
GST-EPAS-ODDD fusion protein was only modestly expressed in the absence of 
IPTG. A much higher fold induction of the GEO protein was observed following the 
addition of IPTG. These results showed that addition of IPTG resulted in a greater 
expression of all three fusion proteins than when IPTG was not added. Therefore in 
all subsequent cultures GST fusion protein expression was induced using IPTG. 
 
3.3.3 Purification of GST fusion proteins 
 
Theoretically, development of GST fusion proteins allows for their purification using 
glutathione Sepharose 4B beads or a glutathione Sepharose 4B column. To ensure 
the GHO and GEO fusion proteins could be purified, a batch purification procedure 
using glutathione Sepharose 4B beads (henceforth referred to as beads) was 
performed. BL21-DE3 cells either untransformed, or transformed with pGEX-4T-3, 
pGEX-HIF-1-ODDD or pGEX-EPAS-ODDD, were grown in culture as before and 
bacterial cell lysates were prepared (section 2.2.8). Lysates were sonicated before 
micro-centrifugation. The insoluble protein pellets (I) were retained for analysis, 
while the supernatants, containing soluble proteins, were mixed with a slurry of 
beads. 10% of each supernatant was retained for analysis (S-soluble protein). After 
incubation with beads the mixtures were micro-centrifuged. Supernatants from this 
step contained soluble proteins that did not bind to the beads (NB). The glutathione 
Sepharose bead pellet from this step contained proteins bound to beads (B). 
Equivalent proportions of all the fractions (I, S, NB and B) were analysed by SDS-
PAGE. The SDS-PAGE gel was coomassie stained and de-stained to visualise the 
proteins (figure 3.3). Proteins of the approximate expected mobilities of GST, GHO 
and GEO, bound to beads (figure 3.3, lower panel). However, there appeared to be 
some degradation of the GST fusion proteins, in particular GEO, possibly caused by 
proteases in the BL21-DE3 cells (figure 3.3, lower panel).  
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Figure 3.3 Purification of GST fusion proteins 
 
BL21-DE3 cells and BL21-DE3 cells transformed with p-
GEX-4T-3, p-GEX-HIF-1-ODD or p-GEX-EPAS-ODD 
were incubated with 1mM IPTG to induce GST fusion 
protein expression (GST, GHO and GEO, respectively). 
Cell lysates were prepared and the supernatant incubated 
with glutathione sepharose 4B beads. Insoluble protein (I), 
soluble protein (S), proteins not bound to beads (NB) and 
proteins bound to beads (B) were resolved using SDS-
PAGE and coomassie stained (N=1; section 2.2.8).. 
Mobilities of standard proteins are indicated (Seeblue, 
Invitrogen).  
 
Key: B, Proteins bound to beads; EPAS, endothelial PAS protein; 
GEO, GST-EPAS-ODD; GHO, GST-HIF-1-ODD; GST, glutathione-
s-transferase; HIF, hypoxia inducible factor; I, insoluble protein; IPTG, 
isopropyl -D galactopyranoside; NB, proteins not bound to beads; S, 
soluble protein. 
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To determine whether this apparent degradation of the GST fusion proteins could be 
prevented, BL21-DE3 cells transformed with p-GEX-4T-3, pGEX-HIF-1-ODDD 
or p-GEX-EPAS-ODDD were cultured as before.  
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Figure 3.4 The effect of bacterial protease inhibitors on GST fusion 
protein purification. 
 
BL21-DE3 cells and BL21-DE3 cells transformed with p-GEX-4T-3, p-
GEX-HIF-1-ODD or p-GEX-EPAS-ODD were incubated with or without 
IPTG to a final concentration of 1mM. Bacterial cell lysates were prepared 3 
hours after IPTG inoculation in lysis buffer with (+) or without (-) bacterial 
protease inhibitors, as indicated. Soluble proteins were bound to glutathione 
sepharose 4B beads. Proteins bound to beads were resolved using SDS-
PAGE. The SDA-PAGE gel was coomassie stained and destained to 
visualise proteins (N=2; sections 2.2.7, 2.2.8, 2.1.3 and 2.1.8). Mobilities of 
standard proteins are indicated (Seeblue, Invitroge).  
 
Key: EPAS, endothelial PAS protein;; GEO, GST-EPAS-ODD; GHO, GST-HIF-1-ODD; 
GST, glutathione-s-transferase; HIF, hypoxia inducible factor; IPTG, isopropyl -D 
galactopyranoside; kDa, kilodalton 
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A bacterial protease inhibitor cocktail containing serine protease, metalloprotease, 
aminopeptidase, acid protease and cysteine protease inhibitors was added to the lysis 
buffer before proteins were extracted. Bacterial cell lysates were resolved by SDS-
PAGE. The SDS-PAGE gel was coomassie stained and destained in order to 
visualise the proteins (figure 3.4). 
 
Bacterial protease inhibitors appeared to have very little effect on the apparent 
degradation products of GST and GHO (figure 3.4). The weaker staining of GEO and 
GEO related fusion protein products in the bacterial protease treated sample appears 
to be due to protein loading error. The apparent failure of the bacterial protease 
inhibitors to prevent the breakdown of the GST, GHO and GEO fusion proteins 
could be because the bacterial protease inhibitor cocktail is not comprehensive. Due 
to the higher proportion of GEO related fusion protein products compared to GHO 
related fusion protein products and growing evidence in the published literature that 
HIF-1 was the more globally expressed protein, it was decided to perform all 
further experiments only using the GHO fusion protein (section 1.2.2). GST 
continued to be used as the control. Bacterial protease inhibitors were also omitted 
from subsequent experiments because they appeared to have no effect on GHO 
related fusion protein products (figure 3.4). 
 
3.3.4 Optimisation of thrombin protease cleavage of recombinant HIF-1-ODDD 
from the GST fusion protein. 
 
RNA aptamers were to be bound to GST fusion proteins. Before the amplification of 
the specifically bound aptamers could be undertaken they had to be released from the 
fusion proteins. The pGEX-4T-3 vector encoded a thrombin protease cleavage site 
between the GST and fusion partner encoding regions. Therefore, the cleavage of the 
HIF-1-ODDD from GST using thrombin protease was attempted. It was 
hypothesised that this would allow aptamers only binding to HIF-1-ODDD to be 
released, preventing a mixed pool of aptamers that would require a further 
purification step to isolate those that could only bind to HIF-1-ODDD. BL21-DE3 
cells transformed with either pGEX-4T-3 or pGEX-HIF-1-ODDD were grown in 
culture, lysed and fusion proteins were bound to glutathione transferase 4B beads, as 
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previously described. GST proteins bound to beads were equalised for loading. 
Aliquots of GST and GHO bound to beads were incubated with binding buffer 
containing BSA (BB-BSA) then washed in PBS. Fusion proteins were incubated 
with or without thrombin protease for 16 hours. Thrombin protease was incubated 
alone as a control. Samples were resolved by SDS-PAGE before the gel was 
coomasie stained and destained in order to visualise the proteins (section 2.2.11, 
figure 3.5). 
 
Figure 3.5 Thrombin protease cleavage of HIF-1-ODD from GST. 
 
BL21-DE3 cells transformed with either pGEX-4T-3 or pGEX-HIF-1α-ODD 
were grown in culture inoculated with IPTG to a final concentration of 1mM to 
induce GST fusion protein expression. 3 hours after IPTG inoculation bacterial 
cells were lysed and fusion proteins were bound to glutathione transferase 4B 
beads. GST and GHO fusion proteins bound to beads were incubated with 
binding buffer containing BSA and washed in PBS before incubation with (+) or 
without (-) thrombin protease, as indicated. Samples were incubated at room 
temperature for 16 hours. Beads (B) and supernatants (S) from beads were 
separated. Proteins were resolved by SDS-PAGE. The SDS-PAGE gel was 
coomassie stained and destained to visualise proteins (N=1; sections 2.2.7, 2.2.8, 
2.2.11, 2.1.8 and 2.1.3). Mobilities of standard proteins are indicated (Seeblue, 
Invitrogen).  
 
Key: B, beads; BSA, bovine serum albumin; GHO, GST-HIF-1-ODD; GST, glutathione-s-
transferase; HIF, hypoxia inducible factor; IPTG, isopropyl -D galactopyranoside; kDa, 
kilodalton; PBS, phosphate buffered saline; S, supernatants from beads. 
GST
GHO
98kDa
64kDa
50kDa
36kDa
30kDa
250kDa
16kDa
BSA
Truncated GHO
+ + + ++- ---Thrombin protease
B B B B SS S S
GHO GST
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The GST moiety is approximately 26kDa therefore any HIF-1-ODDD that had 
been cleaved from bead bound GST would have a predicted weight of 24kDa. 
However, although cleavage of the HIF-1-ODDD from GST was the only cleavage 
process observed there appeared to be no protein band that corresponded solely to the 
HIF-1-ODDD in the thrombin protease treated GHO supernatant (S) sample. It is 
possible that the presence of the HIF-1-ODDD protein band had been masked by 
GST wash off, due to the similarity in molecular weight.  
 
Another explanation for the lack of a HIF-1-ODDD specific band could be due to 
the processes that resulted in truncated GHO, as seen in the thrombin protease treated 
GHO bead (B) sample. Truncated GHO had an approximate molecular weight of 
33kDa and was still connected to GST as the larger proportion remained bead 
associated. The truncation was the result of non-specific enzymatic cleavage because 
truncation was not present in protease free GHO samples. The cleavage was non-
specific because the HIF-1-ODDD sequence does not have a specific thrombin 
protease cleavage site. However, the non-specific cleavage of GHO and cleavage of 
the remaining HIF-1-ODDD from bead associated GST would result in two small 
peptide fragments. These fragments may have been so small that they ran off of the 
SDS-PAGE gel or be of so low an abundance that they do not readily stain with 
coomassie.  
 
RNA aptamer enrichment begins with the selection of aptamers towards bead bound 
GST. This is a negative selection process which removes aptamers that bind to beads, 
GST or GST and beads. The positive selection of RNA aptamers towards GHO 
bound to beads follows the negative selection process. The thrombin protease 
cleavage assay resulted in three possible HIF-1-ODDD derived species; - full 
length HIF-1-ODDD and two smaller fragments as a result of truncated GHO. The 
cleavage of full length HIF-1-ODDD from GST or the truncated HIF-1-ODDD 
protein from GST would select two types of RNA aptamer species, those that 
specifically bound HIF-1-ODDD and those that bound GST-HIF-1-ODDD. 
Future enrichment of the RNA aptamers would result in the removal of GST-HIF-
1-ODDD associated aptamers through the negative selection process. Aptamers 
released from truncation of GHO, where the larger proportion of the GHO protein 
 111 
remained bead associated, would only bind the HIF-1-ODDD moiety. Therefore 
although thrombin protease non-specifically cleaved GHO it was hypothesised that 
the RNA aptamer selection protocol was stringent enough to remove any aptamers 
that did not specifically target HIF-1-ODDD. As a result of this the thrombin 
protease cleavage assay was optimised. A time course of the incubation was 
performed as for the 16 hour experiment, except aliquots of the reactions were taken 
at 2, 4, 6 and 8 hour intervals (figure 3.6). The majority of the cleavage reaction was 
completed within eight hours, based on the disappearance of the GHO band with an 
apparent molecular weight of 50kDa (figure 3.6D) 
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3.3.5 Binding of recombinant HIF-1-ODDD to pVHL. 
 
In vivo the oxygen dependent degradation domain of HIF-1 is bound by pVHL 
causing ubiquitination of the protein and hence its degradation by the 26S 
proteasome (section 1.3). To assess whether the recombinant HIF-1-ODDD protein 
was correctly folded, it was necessary to test whether the protein could associate with 
pVHL. Aliquots of GST and GHO bound to glutathione 4B Sepharose beads were 
incubated in reticulocyte lysate or NP40 lysis buffer as a negative control. The 
reticulocyte lysate was used to ensure post-translational modification of proline 564 
to hydroxy-proline in the HIF-1-ODDD (Maxwell et al., 1999; Masson et al., 
2001). Samples were then incubated with Hela whole cell lysates. Hela cells, a 
cervical adenocarcinoma cell line, have a known wild type pVHL genotype and have 
been used for similar experiments by other investigators (Yu et al., 2001). 786-O 
cells, a renal carcinoma cell line, lack one VHL allele while the other allele encodes 
a non-functional truncated VHL protein. 
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Figure 3.7 pVHL binding assay 
 
BL21-DE3 cells transformed with either pGEX-4T-3 or pGEX-HIF-1α-ODD 
were grown in culture inoculated with IPTG to a final concentration of 1mM to 
induce GST fusion protein expression. 3 hours after IPTG inoculation bacterial 
cells were lysed and fusion proteins were bound to glutathione transferase 4B 
beads. GST and GHO bound to beads were incubated with either reticulocyte 
lysate (+) or NP40 lysis buffer (-), as indicated for 90 minutes at 30C. 
Samples were subsequently incubated with Hela whole cell lysate for 1 hour at 
4C. 786-O whole cell lysate, Hela whole cell lysate and proteins bound to 
beads were resolved by SDS-PAGE. Proteins were western blotted and probed 
with an anti-VHL antibody (N=1; sections 2.2.7, 2.2.8, 2.2.9, 2.2.10, 2.1.3 and 
2.1.4).. Mobilities of standard proteins are indicated (Seeblue, Invitrogen).  
 
Key: GHO, GST-HIF-1-ODD; GST, glutathione-s-transferase; HIF, hypoxia inducible 
factor; IPTG, isopropyl -D galactopyranoside; kDa, kilodalton. 
98kDa
64kDa
50kDa
36kDa
30kDa
250kDa
16kDa
+ +- -Reticulocyte lysate
GHOGST786-O Hela
Non-specific 
binding
Anti-pVHL
reactive band
 
786-O whole cell lysates were used as a negative control for identification of pVHL. 
Proteins associated with bead bound GST and GHO, Hela whole cell lysate and 786-
O whole cell lysate were resolved by SDS-PAGE, western blotted and probed with 
an anti-pVHL antibody (figure 3.7). 
 
GHO treated with reticulocyte lysate (GHO+) retained two anti-VHL reactive protein 
bands, the lower of which was not present in the GHO- sample (GHO not treated 
with reticulocyte lysate). This could have been pVHL however failure to detect the 
endogenous pVHL in Hela whole cell lysate precluded an assignment based on gel 
mobility. GST also runs at the same mobility as the band in the GHO + lane. If a 
similar band was present in the GST +/- lane it would be masked by the non-specific 
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GST signal. Further experiments to eradicate the non-specific binding of the anti-
pVHL antibody to GST were performed (data not shown). However, the above data 
(figure 3.7) could not be replicated due to a large amount of non-specific binding and 
high background levels on western blots which masked the presence of any results 
and made interpretation impossible. This precluded any further controls due to the 
unreliability of the anti-pVHL antibody. Despite this set-back it was decided to use 
the GHO protein in subsequent experiments. 
 
3.4 RNA aptamer development and their effect on a HIF responsive 
transcriptional reporter assay. 
 
3.4.1 DNA oligonucleotide pool synthesis and purification 
 
A double stranded DNA pool was synthesised by a specific 6 cycle PCR of a DNA 
oligonucleotide template shown below. 
 
The DNA oligonucleotide template consisted of two known primer site sequences at 
the 5’ and 3’ ends represented by boxes A and B, respectively. These known 
sequences were either side of a random sequence of 40 nucleotides represented 
above by N40 (section 2.2.12). The 5’ primer for this PCR introduced an in vitro T7 
polymerase promotor sequence for T7 RNA polymerase transcription of the DNA. 
oligonucleotide pool into an RNA aptamer pool (section 3.3.2). The starting 
sequence complexity of the DNA pool was estimated to be 7.161012 
oligonucleotides. This was determined as shown below: 
 
Moles of DNA oligonucleotide template X Avogadro’s number (6.022 x 1023) = Total number of oligonucleotides 
3.348     in 1mg of single stranded DNA 
 pool 
Total Number of oligonucleotides X amount of DNA pool per PCR reaction (in mg) X number of PCR reaction 
= Estimated starting pool complexity 
 
The PCR products were resolved by agarose gel electrophoresis and visualised under 
ultra violet light to confirm synthesis had occurred (section 2.1.9, figure 3.8). A PCR 
A N40 B 5’ 3’ 
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product of a size consistent with the predicted 78 base pair length of the double 
stranded transcription template was detected in the test reaction. No PCR products 
were detected in the negative control lanes. 
 
 
Figure 3.8 PCR synthesis of DNA oligonucleotide pool transcription 
template. 
 
A DNA oligonucleotide pool was synthesised by PCR using specific 
primers from a DNA oligonucleotide template consisting of 40 random 
nucleotides with a known primer site sequence at the 5’ and 3’ ends. The 5’ 
primer site introduced a T7 polymerase promotor sequence. Negative 
control PCR reactions were undertaken, as indicated. PCR products were 
resolved by agarose gel electrophoresis and visualised under ultra violet 
light (N=2; sections 2.2.12 and 2.1.9). Molecular weight markers are 
indicated. 
 
Key: bp, base pairs; DNA, deoxyribonucleic acid; PCR, polymerase chain reaction. 
78bp DNA 
oligonucleotide
pool
506bp
396bp
344bp
298bp
220bp
201bp
154bp
134bp
75bp
PCR reagents
Primers
Taq DNA polymerase
DNA template
+ + + +
+++
+
-
+
+ ++
+
-
-
Negative control lanes Test lane
 
In order to prevent any PCR reagents or primers from interfering with subsequent T7 
transcription of the amplified DNA oligonucleotide pool, it was necessary to purify 
the PCR product. This was accomplished by size exclusion purification through a 
silica gel membrane. A buffer with a high salt concentration was mixed with the PCR 
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reaction. This enabled DNA to adsorb to the silica gel membrane while contaminants 
passed through. The DNA was then washed and eluted from the silica gel membrane 
(section 2.2.13). Synthesis of the DNA oligonucleotide pool required 10 individual 
PCR reactions in order to provide the appropriate degree of complexity, the PCR 
products were pooled before purification. Purified and unpurified PCR products were 
analysed by agarose gel electrophoresis and visualised under ultraviolet light, to 
determine the success of the purification (figure 3.9). 
 
No primers were detectable in either the purified or unpurified PCR product 
indicating that all primers were consumed in the PCR reaction. However, the 
purification of the amplified DNA oligonucleotide pool is still necessary in order to 
remove any remaining PCR reagents that may interfere with subsequent 
transcription. Following purification, the concentration of DNA present in the 
transcription template was determined to be 0.75ng/l. 
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3.4.2 RNA aptamer pool synthesis and purification. 
 
RNA aptamers were synthesised by transcribing purified DNA oligonucleotide pool 
using T7 RNA polymerase. The transcription reaction was then subjected to DNase 
digestion and purified using a nucleotide removal kit (sections 2.2.14 and 2.2.15). 
Samples from each step of the T7 RNA polymerase transcription, DNase digestion 
and purification were analysed by agarose gel electrophoresis and visualised under 
ultraviolet light (figure 3.10). 
 
The same volume of both the negative control and test transcription reactions was 
visualised on the agarose gel (T7 RNA polymerase – and T7 RNA polymerase +, 
 
Figure 3.9 Purification of DNA oligonucleotide pool PCR product. 
 
A DNA oligonucleotide pool was synthesised by PCR from a DNA oligonucleotide 
pool template consisting of 40 random nucleotides using sense and antisense primers 
to known primer site sequences at the 5’ and 3’ ends of the template. The 5’ primer 
introduced a T7 polymerase promotor sequence. The DNA oligonucleotide pool 
PCR product was purified using a Qiagen Minelute PCR purification kit. Unpurified 
and purified DNA oligonucleotide pool PCR products were subjected to agarose gel 
electrophoresis and visualised under ultra violet light (N=1; sections 2.2.13, 2.2.14 
and2.1.9). Molecular weight markers are indicated. 
 
Key: bp, base pairs; DNA, deoxyribonucleic acid; DNA pool, DNA oligonucleotide pool; PCR, 
polymerase chain reaction. 
78bp DNA 
oligonucleotide pool
220bp
201bp
154bp
134bp
75bp
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respectively). As expected a band was present in the negative control transcription 
reaction. This band represented the DNA oligo pool template and was completely 
removed by DNase digestion (figure 3.10, lane 3). Purification of the negative 
control transcription reaction after DNase digestion resulted in no visible DNA on 
the agarose gel (figure 3.10, lane 5). The test transcription reaction (figure 3.10, lane 
2) had a higher intensity band than the negative control transcription reaction which 
suggested T7 dependent RNA transcription had taken place. The band shift visible in 
this reaction was due to the T7 RNA polymerase transcription complexes. DNase 
digestion of the test transcription reaction resulted in a low intensity band 
representing the RNA aptamer pool (figure 3.10, lane 4). Purification of the RNA 
aptamer pool resulted in the visualisation of a very low intensity band, representing 
the RNA aptamer pool, on the agarose gel (figure 3.10, lane 6). The results from this 
experiment showed the transcription and purification steps were successful. The low 
intensity of the RNA aptamer pool visualised on the agarose gel represents a small 
portion of the overall starting pool. However, the purification procedure does appear 
to result in some loss of RNA aptamers which represents a loss of complexity from 
the starting RNA aptamer pool. However, due to the high level of estimated RNA 
aptamer starting pool complexity (7.16 x 1012 aptamers) a small loss of RNA 
aptamers in the purification procedure was deemed acceptable.  
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Figure 3.10 Transcription and purification of the RNA aptamer pool 
 
A DNA oligonucleotide pool was synthesised via PCR. The PCR products 
were purified using a Qiagen Minelute PCR purification kit. The purified 
DNA oligonucleotide pool was then transcribed using T7 RNA polymerase, as 
indicated to produce the RNA aptamer starting pool. Transcribed and 
untranscribed reactions were subjected to DNase digestion (lanes 3-6) before 
purification using a Qiaquick nucleotide removal kit (lanes 5 and 6). Samples 
from each stage of the transcription and purification process were subjected to 
agarose gel electrophoresis and visualised under ultra violet light (N=2; 
sections 2.2.12, 2.2.13, 2.2.14, and 2.1.9). Molecular weight markers are 
indicated. 
 
Key: bp, base pairs; DNA, deoxyribonucleic acid; RNA, ribonucleic acid; PCR, polymerase 
chain reaction. 
T7 RNA polymerase + + +
+ ++ +DNase digestion
-
- -
---
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3.4.3 Optimisation of one-step RT-PCR. 
 
Once the RNA aptamer pool had been transcribed, DNase digested and purified it 
was subjected to the selection procedure. The original experimental design of the 
selection procedure entailed the negative selection of RNA aptamers against GST 
bound to beads. This removed any aptamers that only bound to the beads, GST or a 
combination of the beads and GST, respectively. Unbound RNA aptamers were then 
incubated with GHO. Aptamers bound to GHO were released from the beads by 
thrombin protease cleavage. A further experimental step would then be required to 
remove the aptamers from GHO before RT-PCR could take place. The need for this 
additional step was negated by the use of a one-step RT-PCR procedure using C. 
therm polymerase. C. therm polymerase is comprised of the Klenow fragment of 
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DNA polymerase from Carboxydohermus hydrogenoformans and Taq DNA 
polymerase. This mix allows reverse transcription to occur between 60°C and 70°C, 
a higher temperature than conventional reverse transcription which is performed at 
42°C. The higher temperature reverse transcription reaction is beneficial to the RNA 
aptamer selection procedure because it was hypothesised that this would cause the 
RNA and protein to dissociate due to conformational changes in the secondary and 
tertiary structure of the protein, therefore replacing the need for an additional 
purification procedure to separate the aptamers from GHO. Before embarking on the 
RNA selection procedure the one-step RT-PCR reaction was optimised using the 
starting RNA aptamer pool r0. This pool was subjected to one step-RT-PCR with 
either 10 or 20 PCR cycles (section 2.2.17). Samples were analysed by agarose gel 
electrophoresis and visualised under UV light (figure 3.11).  
 
Figure 3.11 Optimisation of one step RT-PCR – part 1. 
 
The starting RNA aptamer pool (RNA template) was subjected to one-step RT-
PCR with or without C. therm polymerase, as indicated. The PCR step of the 
reaction was performed for either 10 or 20 cycles, as indicated. Negative control 
RT-PCR reactions were undertaken for the 10 and 20 cycle reactions. RT-PCR 
products were resolved by agarose gel electrophoresis and visualised under ultra 
violet light (N=1; sections 2.2.12 - 2.2.15, 2.2.17 and 2.1.9). Molecular weight 
markers are indicated. 
 
Key: bp, base pairs; DNA, deoxyribonucleic acid; PCR, polymerase chain reaction; RNA, 
ribonucleic acid; RT-PCR, reverse transcription polymerase chain reaction. 
75bp
220bp
201bp
154bp
134bp
C. therm polymerase +++ +- -
RNA template + + -- ++
10 PCR cycles 20 PCR cycles
78bp DNA oligonucleotide pool
134bp RT-PCR product
 
RNA and C. therm dependent products were seen in both the 10 cycle RT-PCR and 
20 cycle RT-PCR reactions. However, unexpectedly a doublet was seen in the 10 
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cycle RT-PCR with the lower band of the doublet corresponding to the expected 
78bp product. The higher band of the doublet corresponded to approximately 134bp. 
The 134bp product was seen again in the 20 cycle RT-PCR. However in this RT-
PCR reaction no 78bp product was visualised. The 134bp product in either cycle 
reaction could not have been caused by contamination as indicated by the negative 
control lanes. It is possible that the 134bp product could be artifactual concatamers 
caused by high levels of substrate and non-specific hybridisation (Crompton M, 
personal communication). 
 
To try and eliminate the 134bp product, one-step RT-PCR of r0 was carried out with 
primer concentrations of 0.1nmoles and 0.2nmoles and a 10 cycle PCR (section 
2.2.17). Reactions were separated by agarose gel electrophoresis and visualised 
under UV light (figure 3.12).  
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Primer: 
0.1nmoles 
Primer: 
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Figure 3.12 Optimisation of one-step RT-PCR – part 2. 
 
The starting RNA aptamer pool (RNA template) was subjected to one-step RT-
PCR with or without C. therm polymerase, as indicated. . The PCR step of the 
reaction was performed with either 0.1 nmoles or 0.2nmoles of primers, as 
indicated. Negative control RT-PCR reactions were undertaken for both primer 
concentrations. RT-PCR products were resolved by agarose gel electrophoresis 
and visualised under ultra violet light (N=1; sections 2.2.12 - 2.2.15, 2.2.17 and 
2.1.9). Molecular weight markers are indicated. 
 
bp, base pairs; DNA, deoxyribonucleic acid; PCR, polymerase chain reaction; RNA, ribonucleic 
acid; RT-PCR, reverse transcription polymerase chain reaction. 
 
As expected all negative control lanes were devoid of any DNA for both primer 
concentrations. Reverse transcription and amplification with 0.1nmoles of primer 
resulted in only one visible band at approximately 78bp. However, reverse 
transcription and amplification of r0 with 0.2nmols of primer resulted in the 
appearance of a doublet with the lower band corresponding to approximately 78bp 
and the higher band corresponding to approximately 134bp. Therefore from the 
results in figures 3.11 and 3.12 the conditions used for subsequent one-step RT-PCR 
are 0.1nmoles of primers combined with a 10 cycle PCR. 
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3.4.4 RNA aptamer selection and enrichment. 
 
A starting pool of RNA aptamers (r0) was transcribed, DNase digested and purified 
as previously described. r0 was then incubated with GST bound to beads, in the 
presence of an RNase inhibitor, for 1hr. The supernatant was removed and incubated 
with GHO bound to beads. The GHO and aptamer incubation was microcentrifuged 
and the supernatant discarded. Aptamers and GHO were released from the 
glutathione Sepharose 4B beads by thrombin protease cleavage before being 
subjected to one-step RT-PCR (sections 2.2.16 and 2.2.17). Samples from the RT-
PCR were analysed by agarose gel electrophoresis and visualised under UV light 
(figure 3.13). 
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Figure 3.13 First round of RNA aptamer selection. 
 
A starting pool of RNA aptamers was negatively selected against GST bound to 
beads. RNA aptamers were then positively selected against GHO bound to beads 
(section 2.2.16). Bound aptamers and GHO were released from glutathione 
sepharose 4B beads via thrombin protease cleavage (section 2.2.11). This first 
round of selected RNA aptamers (r1) was then subjected to one-step RT-PCR 
either with or without C. therm polymerase (r1+ or r1-, as indicated; section 
2.2.17). A negative (H2O) control reaction was undertaken. RT-PCR products 
were analysed by agarose gel electrophoresis and visualised under ultra violet 
light. A reverse transcribed sample of the starting aptamer pool (r0) was 
visualised on the gel for positive identification of the r1+ product. Molecular 
weight markers are indicated (N=1; section 2.1.9) 
 
Key: bp, base pairs; DNA, deoxyribonucleic acid; GST, glutathione-s-transferase; GHO, GST-
HIF-1-ODD; H2O, water; PCR, polymerase chain reaction; r0, starting RNA aptamer pool; r1, 
1st round of selected RNA aptamers; RNA, ribonucleic acid; RT-PCR, reverse transcription 
polymerase chain reaction.  
75bp
220bp
201bp
154bp
134bp
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134bp RT-PCR product
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As expected both negative control lanes were devoid of any visible band. However, a 
band of approximately 78bp was observed in the reverse transcribed and amplified 
1st selection lane (r1+). r0 was run next to r1 in order to positively identify the r1 pool. 
The same proportions of both the r1 and r0 RT-PCR reactions were run on the 
agarose gel. When compared together the 78bp band representing r1 is of a much 
lower intensity than r0 suggesting a lower amount of DNA in the r1 sample. 
Therefore, an additional PCR was incorporated into the selection process using the 
same reaction criteria as the PCR stage of the one-step RT-PCR (section 2.1.9). 
Following the additional PCR, The r1 DNA oligonucleotide pool was purified using a 
MinElute PCR purification kit. 
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The second round of aptamer selection had some additional control incubations 
introduced as a proof of principle of the chosen selection criteria. r1 DNA 
oligonucleotides were T7 RNA polymerase transcribed with or without T7 RNA 
polymerase (T7+ or T7-, respectively) to form the r1 RNA aptamer pool. The r1 pool 
was subjected to DNase digestion and purified using a QiaQuick nucleotide removal 
column. The T7+ and T7- r1 pools were then negatively selected against GST bound 
to glutathione sepharose beads before half of each pool was positively selected 
against GHO bound to beads. The remaining halves of the T7+ and T7- r1 pools were 
incubated with separate aliquots of glutathione sepharose 4B beads. The T7+GHO, 
T7-GHO, T7+beads and T7-beads incubations were microcentrifuged and the 
supernatants discarded before undergoing thrombin protease cleavage. The second 
round of selected RNA aptamers (r2) from the four incubation reactions underwent 
one-step RT-PCR either with or without RT (+RT and -RT, respectively).  
 
Samples from the one-step RT-PCR were analysed by agarose gel electrophoresis 
and visualised under UV light before the subsequent PCR and purification steps 
(figure 3.14). 
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75bp
220bp
201bp
154bp
134bp
78bp DNA oligonucleotide pool
GHO Beads
-T7 RNA polymerase + + + +- - -N/A N/A
H2O r0r2+ r2- r2- r2- r2-r2+r2+r2+RNA template
Figure 3.14 RT-PCR of RNA aptamers from the second round of selection. 
 
DNA oligonucleotides from the first round of selection were subjected to a 
transcription reaction either with or without T7 RNA polymerase, as indicated, 
to create the r1 RNA aptamer pool (sections 2.2.13 - 2.2.15). Each transcription 
reaction was negatively selected against GST bound to beads. Half of each 
transcription reaction was incubated with GHO bound to beads while the other 
half was incubated with beads only, as indicated (section 2.2.16). RNA aptamers 
were released from each incubation condition through thrombin protease 
cleavage (section 2.2.12). The second round selected RNA aptamers (r2) were 
then subjected to one-step RT-PCR either with or without C. therm polymerase 
(r2+ or r2-, as indicated). A negative (H2O) control reaction was undertaken 
(section 2.2.17). RT-PCR products were analysed by agarose gel electrophoresis 
and visualised under ultra violet light. A reverse transcribed sample of the 
starting aptamer pool (r0) was visualised on the gel for positive identification of 
the r2+ product (section 2.1.9). Molecular weight markers are indicated. (N=1) 
 
Key: bp, base pairs; DNA, deoxyribonucleic acid; GST, glutathione-s-transferase; GHO, GST-
HIF-1-ODD; H2O, water; PCR, polymerase chain reaction; r0, starting RNA aptamer pool; r1, 
1st round of selected RNA aptamers; r2, 2
nd
 round of selected RNA aptamers; RNA, ribonucleic 
acid; RT-PCR, reverse transcription polymerase chain reaction.  
 
No contamination was present in any of the reagents used for the RT-PCR reaction 
as can be seen in the H2O lane. It was anticipated that only the GHOT7+r2+ lane 
would have had a visible product. However, upon visualisation of the gel both the 
GHOT7+r2+ and GHOT7-r2+ lanes had a visible product. However, when compared 
together the intensity of the GHOT7-r2+ product was very minor when compared to 
the GHOT7+r2+ lane. In the case of the GHOT7+r2+ lane, the product was RT 
dependent as can be seen by comparing lanes GHOT7+r2+ and GHOT7+r2- together. 
Positive identification of this product was made by comparing it to the original r0 
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pool. The GHOT7-r2+ lane should not have contained any template because the r1 
DNA oligonucleotide pool was not transcribed in this lane and all reactions were 
subjected to DNase digestion. The intensity of this product is very low when 
compared to GHOT7+r2+ and is therefore probably due to an incomplete DNase 
digestion of the r1 DNA oligonucleotide pool. A positive result in the GHOT7-r2+ 
lane suggested the possibility that a mixed RNA and DNA aptamer pool was 
occuring. However, all other lanes were devoid of any RT-PCR product suggesting 
that DNase digestion had been successful in those lanes. This indicated a low 
probability of a mixed RNA and DNA aptamer pool occurring.  
 
The lack of an RT-PCR product in the beadT7+r2+ lane indicated there were no bead 
associated aptamers. This suggested the negative selection criteria being used in the 
RNA aptamer enrichment process was removing aptamers that had a preference for 
glutathione Sepharose 4B beads before positive aptamer selection against GHO. 
However, some aptamers that bound only to GST may be incorporated into the 
positive selection process because there is some wash off of GST from beads (figure 
3.6A, B and C). 
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Figure 3.15 RT-PCR of RNA aptamers from the third round selection. 
 
RNA aptamers from the second round of selection were negatively selected 
against GST bound to beads. Unbound RNA aptamers were then positively 
selected against GHO bound to beads (section 2.2.16). Bound aptamers and 
GHO were released from glutathione sepharose 4B beads via thrombin 
protease cleavage giving the third round of selected RNA aptamers (r3) 
(section 2.2.12).The r3 pool was then subjected to one-step RT-PCR either 
with or without C. therm polymerase (r3+ or r3-, as indicated; section 
2.2.17). RT-PCR products were analysed by agarose gel electrophoresis 
and visualised under ultra violet light. A reverse transcribed sample of the 
starting aptamer pool (r0) was visualised on the gel for positive 
identification of the r3+ product (section 2.1.9). Molecular weight markers 
are indicated. (N=1) 
 
Key: bp, base pairs; DNA, deoxyribonucleic acid; GST, glutathione-s-transferase; GHO, 
GST-HIF-1-ODD; H2O, water; PCR, polymerase chain reaction; r0, starting RNA 
aptamer pool; r3, 3rd round of selected RNA aptamers; RNA, ribonucleic acid; RT-PCR, 
reverse transcription polymerase chain reaction.  
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Once this proof of principle experiment had proven the RNA aptamer selection 
process was adequate, rounds 3 and 4 of the selection process were undertaken as 
described for round 1 of the selection process. Samples from the one-step RT-PCR 
were taken after each round of selection, analysed by agarose gel electrophoresis and 
visualised under UV light (figures 3.15 and 3.16, respectively). 
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Figure 3.16 RT-PCR of RNA aptamers from the fourth round 
selection. 
 
RNA aptamers from the third round of selection were negatively selected 
against GST bound to beads. Unbound RNA aptamers were then 
positively selected against GHO bound to beads (section 2.2.16). Bound 
aptamers and GHO were released from glutathione sepharose 4B beads 
via thrombin protease cleavage giving the third round of selected RNA 
aptamers (r4; section 2.2.12).The r4 pool was then subjected to one-step 
RT-PCR either with or without C. therm polymerase (r4+ or r4-, as 
indicated; section 2.2.17). RT-PCR products were analysed by agarose 
gel electrophoresis and visualised under ultra violet light. A reverse 
transcribed sample of the starting aptamer pool (r0) was visualised on the 
gel for positive identification of the r4+ product (section 2.1.9). 
Molecular weight markers are indicated (N=1). 
 
Key: bp, base pairs; DNA, deoxyribonucleic acid; GST, glutathione-s-transferase; 
GHO, GST-HIF-1-ODD; H2O, water; PCR, polymerase chain reaction; r0, starting 
RNA aptamer pool; r4, 4th round of selected RNA aptamers; RNA, ribonucleic acid; 
RT-PCR, reverse transcription polymerase chain reaction.  
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Both round 3 and round 4 of aptamer selection produced reverse transcriptase 
dependent products. These products were approximately 78bp in size and were 
positively identified as such by comparison with the original r0 pool.  
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3.4.5 The effect of RNA aptamer enrichment on the transcriptional activity of an 
HRE driven transcription reporter gene. 
 
The most effective RNA aptamers are produced on average between 4 and 10 rounds 
of aptamer pool selection (Marshall and Ellington, 2000). Therefore after the fourth 
round of aptamer selection a transcription reporter assay was performed to determine 
the effectiveness of the RNA aptamers produced so far. If no difference in the results 
between r0 and r4 aptamers was observed the selection process could be repeated to 
further enrich the RNA aptamers. 
 
Hep G2 cells were used in the transcription reporter assay because they were readily 
available and had a known hypoxia response and the ability to respond to 
desferrioxamine (DFO) a hypoxia mimetic (data not shown). The transcription 
reporter assay was based on a method that involved co-transfecting cells with 
reporter plasmids and small interfering RNAs using lipofectamine (Elbashir et al., 
2001). 
 
Hep G2 cells seeded at low density (100 000 cells/well) were transfected in 
triplicate 24 hours after seeding with either the r0 aptamer pool or the r4 aptamer 
pool. Cells were co-transfected with an SV40 control plasmid, a CMV control 
plasmid or a test plasmid (pGL3 control, pCMVluc or pGL3prevPGK, respectively). 
All wells were also co-transfected with a plasmid expressing Renilla luciferase (pRL-
SV40), as an internal control to normalise transfection efficiencies. The test plasmid 
(pGL3prevPGK/ OB HRE) and CMV control plasmid (pCMVluc ) were constructed 
as described by Boast et al., (1999). The test plasmid contains an hypoxia responsive 
HRE trimer from the gene encoding murine phosphoglycerate kinase (PGK) located 
upstream of a minimal SV40 promoter. This promoter directs transcription from a 
cDNA sequence encoding firefly luciferase. The SV40 control plasmid (pGL3-
control) contains an SV40 promoter and enhancer that results in the strong 
expression of firefly luciferase (Photinus pyralis). CMV control contains an SV40 
promoter and enhancer and a CMV immediate early (CMV IE) promoter resulting in 
the strong expression of firefly luciferase. SV40 control contains an SV40 early 
enhancer and promoter which provides strong constitutive expression of renilla 
luciferase (Renilla reniformis or sea pansy, section 2.1.12). 
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48 hours after transfection cells were lysed. Cell lysates were analysed for 
firefly luciferase activity and corrected against Renilla luciferase activity (sections 
2.1.12, 2.1.13 and 2.2.18). Figure 3.17 shows the results of two independent 
experiments. The smaller inset panels of the upper and lower panels show the test 
plasmid results on a larger scale. Two control plasmids with different promotor 
sequences were used in this assay because previous experimentation performed by 
Oxford Biomedica had revealed the SV40 control plasmid was not always 
significantly expressed in all cell types (Binley K, personal communication), 
therefore the CMV control plasmid was utilised in these experiments. 
 
The test plasmid results from two independent experiments indicated cells with r4 
aptamers had a reduced level of luciferase expression compared with those 
transfected with r0 aptamers (fig. 3.17, inset panels). However, although these results 
when taken on their own appear significant, this significance is lost when compared 
with the control plasmid results. 
 
The CMV and SV40 control plasmid results vary when the two independent 
experiments are compared to each other. For example results in the upper panel of 
figure 3.17 indicate the r4 aptamer pool increases the level of luciferase expression 
from cells transfected with the CMV or SV40 control plasmids when compared to 
the r0 aptamer pool. However, in the lower panel although the results from cells 
transfected with the CMV control plasmid are the same as the upper panel, the result 
is not nearly as pronounced. Another difference between the two experiments is that 
in the lower panel the r4 aptamer pool reduces the level of luciferase expression in 
cells transfected with the SV40 control plasmid when compared to the r0 pool. This is 
the reverse of the results obtained in the first experiment (fig 3.17 upper panel). 
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Figure 3.17 The effect of starting and enriched RNA aptamer pools on HIF 
responsive HRE dependent transcriptional reporter assays. 
 
Hep G2 cells seeded at low density (100 000 cells/well) were either left untreated or 
transfected in triplicate 24 hours after seeding with r0 pool or r4 pool. All cells were 
co-transfected with either CMV control, SV40 control or test (HRE) plasmid. All 
wells were co-transfected with pRL-SV40. 72 hours after seeding whole cell lysates 
were prepared. Lysates were assayed for firefly luciferase activity and corrected 
against Renilla luciferase activity to normalize transfection efficiencies. Inset panels 
(*) represent Test (HRE) plasmid results on a larger scale. N=2 - Results shown are 
from two independent experiments. Error bars are  S.D. 
 
Key: CMV, cytomegalovirus: HIF, hypoxia inducible factor; HRE, hypoxia responsive element; r0, 
starting RNA aptamer pool; r4, 4
th
 round of selected RNA aptamers 
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In all instances the level of luciferase expression in cells transfected with an RNA 
aptamer pool and a control plasmid are greater then those achieved in the test 
plasmid. 
 
The variability of the interdependent results make any conclusions difficult to 
discern. More repetitions of each stage of the selection process, the luciferase 
reporter assay and further optimisation of the luciferase reporter assay or 
investigation into other assays that can determine the effectiveness of the selected 
RNA aptamers would be necessary in order to further this work. However, as no 
phenotypic response was observed from a challenging transcription reporter assay, 
careful consideration was given to the time and resources that would be required to 
undertake further experimentation to try and determine the cause of the variability 
and also the cloning of the RNA aptamer pool. As a consequence of these 
considerations it was decided that further experimentation including the cloning of 
the RNA aptamer pool was not the best use of the time and resource remaining.  
 
3.5 Discussion 
 
The hypothesis outlined in section 3.1.2 stated that RNA aptamers would be 
designed with affinity to the HIF-1 ODDD thus preventing the action of the PHDs 
and preventing pVHL mediated ubiquitin dependent degradation of HIF-1. This 
would result in an HIF dependent increase in transcription. Aptamers that achieved 
this result could be therapeutically useful in ischaemia and pulmonary hypertension 
(sections 1.6.2 and 1.6.3).  
 
3.5.1 The function of an enriched RNA aptamer pool was undeterminable. 
 
The enrichment of the RNA aptamer pool appeared to be successful with 
optimisation of the selection process occurring as any problems arose, for example 
the appearance of the 134bp non-specific RT-PCR product (section 3.3.3). However, 
verifying whether the selected aptamers were functional and conformed to the 
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proposed hypothesis (section 3.1.2) was very difficult due to the variable results 
obtained in the transcription reporter assay (section 3.3.5, figure 3.17). One possible 
explanation of the variable results seen in the transcription reporter assay is the 
culture conditions of the Hep G2 cells. Although all controllable culture conditions 
(with the exception of cell passage number, see below) were the same for both 
reporter assay experiments, it is possible an unknown variable in the culture 
conditions affected the results.  
 
Another explanation for the experimental variation observed in the transcription 
reporter assay, is the passage number of the cells. The Hep G2 cells used for both of 
these experiments were of unknown passage number and each experiment was 
performed on Hep G2 cells of different passage numbers. Although no evidence has 
been published that shows variation in experimental results with regard to the use of 
Hep G2 cells, data is accumulating in other cell types that shows the same 
experiments performed in higher passage number cells give different results from 
those carried out in lower passage cells. Many of these experiments have focussed on 
the Caco-2 colon cancer cell line and cell line specific characteristics. However 
experiments have also been performed in MCF7 human breast cancer cells and 
LNCaP prostatic adenocarcinoma cells (reviewed by Hughes et al., 2007).  
 
High passage number cells can exhibit differences in cell morphology, growth rate, 
protein expression and cell signalling when compared to low passage number cells of 
the same type (reviewed by Hughes et al., 2007; ATCC technical bulletin no.7). Two 
ways of determining whether Hep G2 passage number was responsible for the 
experimental variation observed in figure 3.17 are to monitor cell morphology and 
undertake a growth curve analysis (ATCC technical bulletin no.7). Hep G2 cell 
morphology was regularly observed and compared with examples shown on the 
ATCC website (data not shown). However, regular growth curve analysis was not 
undertaken. Further experimentation to determine whether passage number was a 
factor in the transcription reporter assay results could involve performing a growth 
curve analysis on existing Hep G2 cells or purchasing new Hep G2 cells and 
repeating the transcription reporter assays. 
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Although the experimental results of the transcription reporter assay may have been 
affected by the passage number of Hep G2 cells, there is also the possibility that no 
conclusive results were gained due to enzymatic attack of the RNA aptamer pool 
once it had been transfected e.g. by nucleases and it is known that un-modified RNA 
oligonucleotides are extremely unstable in biological fluids and have a half life of 
less than one minute (de Smidt et al., 1991). However, by chemically modifying 
components of RNA aptamers this can increase their biological stability. For 
instance, incorporating 2’-O-methyl nucleotides into RNA aptamers resulted in their 
nuclease resistance (Green et al., 1995). This kind of modification can now be easily 
incorporated due to the discovery of T7 RNA polymerase variants capable of 
utilising modified nucleotides as substrates (Chelliserrykattil and Ellington, 2004). 
Incorporation of this form of modification in future RNA aptamer selection rounds 
could achieve a more beneficial outcome from the transcription reporter assay if 
coupled with the use of new Hep G2 cells. In contrast to this hypothesis is RNA 
interference (RNAi) which is a highly successful technology, utilising unmodified 
small interfering RNAs, which is used for target validation and gene function 
analysis including determining the differential roles of HIF-1α and HIF-2α in colon 
cancer (Imamura et al., 2009). The success of an un-modified RNA technology 
suggests that the methods used in order to carry out the RNA aptamer transcription 
reporter assay may also play a part in affecting the experimental results. 
 
It is possible that the use of the transcription reporter assay could be negated 
completely by optimising the pVHL binding assay (section 3.5.2) or following the 
methods of other researchers in the aptamer field. Typically, other investigators clone 
the aptamer pool and then sequence the resulting aptamer clones. Representative 
aptamers are then used in binding assays to determine binding affinity to the target 
molecule, characterise their binding features and determine any specialised features 
the aptamer may have. Truncation and mutation experiments can then be performed 
in order to determine the smallest functional region of the aptamer before any post-
translational modifications, such as the incorporation of modified nucleotides to 
increase aptamer stability, are performed. These modifications are often carried out 
before the use of the individual aptamers in assays which determine the usefulness of 
the selected aptamer as a future therapeutic agent, in the case of 
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medical/pharmaceutical research (reviewed by Stoltenburg et al., 2007; Marshall and 
Ellington, 2000; Gold et al., 1995). 
 
3.5.2 Further experimentation. 
 
Although enrichment of the RNA aptamer pool appeared to be successful, some 
additional experimentation could have been carried out to confirm certain steps in the 
selection process were performing the functions they had been designed for. 
However, it is unlikely that these experiments would affect the overall interpretation 
of results (section 3.5.1). For instance, an experiment that was overlooked during the 
RNA aptamer selection process was testing whether the negative selection of RNA 
aptamers against GST bound to beads was successful. This process was employed in 
order to remove RNA sequences that preferentially bound to GST, GST:beads or 
beads from the RNA aptamer pool. Testing of the negative selection step would 
simply have involved thrombin protease cleavage of GST from beads after a negative 
selection of the RNA aptamer pool, followed by one-step RT-PCR; the same process 
was also employed for aptamer recovery from GHO (section 3.4.4). Although the 
negative selection process was never properly assessed, experiments were conducted 
that showed RNA aptamers were not binding to beads alone (figure 3.14). However, 
use of a negative selection method has been corroborated in the experiments of other 
researchers who have also removed unwanted RNA aptamers by employing negative 
selection steps using GST bound to a matrix before selecting against a GST tagged 
target protein (Jeong et al., 2010; Kimoto et al., 1998).  
 
As an alternative to the transcription reporter assay in the first instance, further 
optimisation of the pVHL binding assay, could be used to assess the functionality of 
the RNA aptamer pool (section 3.3.5). RNA aptamers that prevented pVHL binding 
and hence inhibit HIF-1 ubiquitin mediated degradation could be achieved by 
incubating GHO bound to beads with reticulocyte lysate. Reticulocyte lysate contains 
PHDs which hydroxylate Pro564 of HIF-1α ODDD. Hydroxylated GHO could then be 
purified and either incubated with or without RNA aptamers that had already 
undergone a negative selection process with non-hydroxylated GHO bound to beads. 
This negative selection step would remove RNA aptamers with a higher affinity for 
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non-hydroxylated GHO. By incubating the hydroxylated GHO:RNA aptamer 
complexes in Hela cell lysate containing tagged and overexpressed pVHL, it would 
then be possible to determine whether RNA aptamers could inhibit pVHL binding. If 
the assay were successful, the predicted outcome would be pVHL bound to 
hydroxylated GHO in samples that were not treated with RNA aptamers and little to 
no pVHL presence in samples treated with RNA aptamers. In order to optimise this 
binding assay it would be necessary to introduce a tag to pVHL, possibly by His or 
Biotin labelling. This would result in a completely identifiable protein and remove 
the protein identification problems associated with the previous pVHL binding assay 
(figure 3.7). Chemical modification of the 2’OH group of ribose in RNA aptamers 
during the selection process would confer nuclease resistance and could help to 
achieve a successful outcome from this assay (section 3.5.1). Alternatively, RNA 
aptamers could be developed that inhibited the hydroxylating action of the PHDs. 
This could be achieved developing a similar type of binding assay. GHO bound to 
beads would be incubated either with or without RNA aptamers. The GHO: RNA 
aptamer/ GHO complexes would then be incubated with reticulocyte lysate, followed 
by Hela cell lysate containing tagged and overexpressed pVHL, it would then be 
possible to determine whether RNA aptamers could inhibit pVHL binding. If the 
assay were successful, the predicted outcome would be pVHL bound to GHO in 
samples that were not treated with RNA aptamers and little to no pVHL presence in 
samples treated with RNA aptamers. 
 
If functionality of the RNA aptamer pool using a pVHL binding assay could be 
achieved, cloning and sequencing of the aptamers would be the next logical step. 
Sequences can then be assessed for consensus sequence binding and predictive 
secondary structure assessment using a computer modelling program such as the 
MULFOLD program (Zuker, 2003). 
 
3.5.3 The future of RNA aptamer technology 
 
Experiments carried out since SELEX was first developed in the early 1990s have 
resulted in several methodological improvements to RNA aptamer synthesis. Most 
aptamers are purified via nitrocellulose filtration however, other methods have also 
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included gel affinity chromatography and immunoprecipitation (author). Other 
methods of SELEX have also been developed such as cell-SELEX. However, the 
majority of recent aptamers have been developed using automated or microarray 
based SELEX. Automated of microarray SELEX allow for the selection and 
characterisation of RNA aptamers to multiple targets within a few days rather than 
the weeks or months that were previously required (Zhou et al., 2010). 
 
Further improvements to the stability of RNA aptamers have also been essential due 
to the fact that unmodified therapeutic RNA aptamers, when delivered via the most 
common means i.e. intravenous, subcutaneous or intravitreous delivery, are 
metabolically unstable, subject to rapid renal filtration due to their small size and 
rapid biodistribution from plasma compartments into tissues. Several modifications 
have been developed which increase the structural stability of the RNA aptamer and 
also the half-life of the molecule against renal clearance. The most common of these 
modifications are to the ribose of the RNA and include 2’ Fluoro, 2’ O- Methyl, 
linked nucleic acids and spiegelmers (aptamers targeted to the mirror image of the 
target peptide). Aptamers can be conjugated to cholesterol or polyethylene glycol 
which reduces the level of renal filtration of the aptamer (Burnett and Rossi, 2012). 
 
Several RNA aptamers have now reached clinical trials including Pegatanib, an RNA 
aptamer targeted towards VEGF, the REG1 anticoagulation system, consisting of an 
aptamer – antidote pair to factor IXa and AS1411 and RNA apatamer targeted to 
nucleolin, a protein often overexpressed on the surface of cancer cells (Table 3.1). 
 
Table 3.1 Aptamer Therapeutics in Clinical Trials 
Aptamer 
Therapeutic 
Target Disease Current Status 
Pegaptanib 
(Macugen) 
VEGF 
Age related macular 
degeneration 
Approved 
ARC1905 
Complement 
component 5 
Neovascular age related 
macular degeneration 
Phase I 
E10030 PDGF 
Neovascular age related 
macular degeneration 
Awaiting phase 
III 
REG 1 (RB006 
and RB007 
apatamers) 
Factor IXa Coronary artery disease 
Awaiting phase 
III trials 
NU172 α - thrombin Coronary artery disease Phase II 
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Aptamer 
Therapeutic 
Target Disease Current Status 
ARC19499 
Tissue factor 
pathway inhibitor 
Hemophilia 
Uncertain status 
(Phase I/II) 
AS1411 nucleolin 
Renal cell carcinoma / 
non-small cell lung 
cancer 
Awaiting phase 
III trials 
NOX-A12 
Stroma cell-
derived factor-1 
Tumour 
Phase II 
recruitment 
ARC1779 
Activated von 
Willebrand Factor 
Von Willebrands Disease 
Awaiting phase 
III 
NOX-E36 
Monocyte 
chemoattractant 
protein 1 
Type II diabetes. Renal 
impairment/ neuropathy. 
Lupus nephritis 
Phase IIa 
Sundaram et al., 2013 and Burnett and Ross, 2012. 
 
Key: PDGF, platelet derived growth factor; VEGF, vascular endothelial growth factor;  
 
Pegaptanib sodium also known commercially as Macugen, is an anti-VEGF RNA 
aptamer which is used for the treatment of all types of neovasular age related 
macular degeneration. It is the first aptamer to be approved for clinical use (Ng et al., 
2006). Other RNA aptamers have also reached the clinical trial phase. Of particular 
importance for cancer therapy is AS1411, the first RNA aptamer to enter oncology 
clinical trials. AS1411 is an RNA aptamer that specifically targets nucleolin, a 
protein that is found on the surface of many cancer cells, including cancer cells 
associated with acute myeloid leukaemia and renal cell carcinoma. AS1411 is 
systemically administered and its internalisation results in a decrease in several 
cancer related mRNAs which results in reduced cell proliferation (Soundararajan et 
al, 2009 and Reyes-Reyes et al., 2010). 
 
The REG 1 anticoagulation system is also in clinical trials and represents an aptamer-
antidote pair to coagulation factor IXa (FIXa). RB006 is the active aptamer drug that 
binds FIXa and RB007 is the antidote which is an oligonucleotide controlling agent 
that is complementary to a portion of RB006 and when bound neutralises the anti-
FIXa activity of RB006. This drug is particularly useful in the treatment of 
thrombotic disease and represents a highly specific and controllable drug (Povsic et 
al., 2010). 
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Further developments in the RNA aptamer field have resulted in a fusion of 
technologies such as RNA aptamer delivery by siRNAs and RNA aptamer delivery 
by nanobiotechnology particles (reviewed by Guo et al., 2008). However, given that 
only one RNA aptamer has been approved for use in a clinical setting it seems this 
promising technology has still to fulfil its full potential. 
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Chapter 4: The impact of succinate dehydrogenase (SDH) 
inhibition on HIF 
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4.1 Introduction 
 
It has recently been discovered that germ-line and somatic mutations in 3 of the 4 
genes (SDHB, SDHC and SDHD) that encode mitochondrial complex II/succinate 
ubiquinone oxidoreductase (SQR) predispose affected individuals to head and neck 
paragangliomas (HNPs) and/or pheochromocytomas, tumours of the autonomic 
nervous system. The most common sites for these tumours are in the carotid body 
(CB) and adrenal medulla, respectively. HNPs and pheochromocytomas harbouring 
SDH mutations show a high degree of vascularity that is similar to the vasculature 
observed in sporadic carotid body (CB) tumours caused by chronic hypoxic exposure 
(reviewed by Maher and Eng, 2002) and pheochromocytomas harbouring VHL 
mutations (section 1.6.5), suggesting a link with the oxygen sensing pathway (Baysal 
et al., 2000).  
 
4.1.1 SQR structure and function. 
 
SQR straddles the inner mitochondrial membrane in a manner that allows complex 
participation in the citric acid/Kreb’s/tricarboxylic acid cycle (TCA) and the electron 
transport chain (ETC). The two largest subunits, SDH A (Fp, 70kDa) and SDH B (Ip, 
30kDa), form succinate dehydrogenase (SDH), the enzymatic portion of the 
complex. SDH A has a covalently bound FAD molecule while SDH B contains three 
distinct iron-sulphur centres. SDH C (15kDa) and D (12.5kDa), anchor SQR to the 
inner mitochondrial membrane, they share a heme b prosthetic group and the 
ubiquinone (UQ) binding site (figure 4.1).  
 
 144 
 
Mitochondrial 
matrix
Inner 
Mitochondrial 
membrane
Intermembrane
space
SDH A
Succinate 
binding 
site
FAD
SDH B
2Fe-2S
4Fe-4S
3Fe-4S
SDH C SDH D
Heme b
UQ
Figure 4.1 Succinate ubiquinone:oxidoreductase (SQR). 
 
SQR straddles the inner mitochondrial membrane and is comprised of four 
subunits SDH A-D. SDH A and B form the catalytic portion of the 
complex, succinate dehydrogenase (SDH). SDH A contains a covalently 
bound FAD moiety and SDH B contains three iron-sulphur centres. SDH C 
and D are the anchoring subunits and share a heme b group and the 
ubiquinone (UQ) binding site. 
 
Key: FAD, flavine adenine dinucleotide; FE-S, Iron-sulphur centres; SDH A-D, 
succinate dehydrogenase subunits A-D; SQR, succinate 
ubiquinone:oxidoreductase; UQ, ubiquinone 
 
Based on a figure by Ackrell, 2000. 
 
The TCA cycle oxidises an acetyl CoA group derived from glycolysis to CO2 via a 
series of reactions that occur in the mitochondrial matrix (figure 4.2). The seventh 
reaction in this series is the oxidation of succinate to fumarate which is catalysed by 
succinate dehydrogenase (SDH). The oxidation of succinate occurs after succinate 
has bound to the active site of SDH A, which is located between the covalently 
bound FAD molecule and the capping domain (Leger et al., 2001). After succinate 
has bound the capping domain is thought to move towards the binding site (reviewed 
by Ackrell, 2000). 
 145 
 
 
Figure 4.2 An overview of the tricarboxylic acid (TCA) cycle. 
 
The reactions of the tricarboxylic acid cycle are shown above. 
The reactions are catalysed by a series of enzymes, shown below 
as numbered in the diagram; - 
1.Citrate Synthase 
2.Aconitase 
3.Aconitase 
4.Isocitrate dehydrogenase 
5.a-ketoglutarate dehydrogenase 
6.Succinyl CoA synthetase 
7.Succinate dehydrogenase 
8.Fumarase 
9. Malate Dehydrogenase 
 
Key: CO2, Carbon Dioxide; FADH, flavin adenine dinucleotide; GTP, 
Guanine triphosphate; H2O, water; NADH, nicotinamide adenine dinucleotide 
 
Based on a figure by Raimundo et al., 2012. 
Citrate Cis-
aconitate
Isocitrate
-ketoglutarate
Succinate
Fumarate
Succinyl-CoA
Malate
Oxaloacetate
1
2
3
4
5
67
9
8
Acetyl CoA+ 
H2O
CO2 + 
NADH
CO2 + 
NADH
GTPFADH2
H2O
NADH
 
A hydrogen ion is then transferred from one methyl group of succinate to the N5 
position of FAD. Another hydrogen ion is then transferred from the second methyl 
group of succinate to a conserved arginine residue of the capping domain. Fumarate 
is thought to be released by movement of the capping domain away from the 
dicarboxylate binding site (Lancaster, 2003). The method by which FADH is reduced 
to FADH2 remains unclear. 
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The proposed mechanism of succinate oxidation is thought to be the reverse of 
fumarate reduction because SQRs and fumarate reductases (QFRs, quinol: fumarate 
oxidoreductases) are closely related. Evidence that supported the proposed 
mechanism was found in E. coli where SQRs and QFRs were found to be 
functionally able to replace each other (Lancaster, 2003). Comparison of the crystal 
structures for E. coli and W. succinogenes QFRs with the crystal structure of E. coli 
SQR showed a close similarity between the SDH A and SDH B subunits of E. coli 
SQR and the flavoprotein and iron sulphur proteins of E. coli and W. succinogenes 
QFRs (Yankovskaya et al., 2003). It is also known that the residues implicated in 
substrate binding and catalysis are conserved throughout the SQR and QFR 
superfamily suggesting the function of each complex could be reversible if 
necessary. 
 
The FAD molecule reduced during the oxidation of succinate to fumarate is 
covalently bound to the SDH A subunit of complex II, also known as 
succinate:ubiquinone oxidoreductase (SQR). Therefore, electrons from FADH2 must 
enter the mitochondrial respiratory chain (section 4.1.2) at this point. The pair of 
electrons are passed from FADH2 through three linearly aligned Fe-S clusters located 
in the SDH B subunit before being transferred to a bound ubiquinone at one of the 
two ubiquinone binding sites which are comprised of residues from both SDH C and 
SDH D, the membrane anchoring subunits of SQR (Yankovskaya et al., 2003). 
Electrons from the first bound ubiquinone are passed to a second bound ubiquinone 
which, when reduced to ubiquinol, is released into the membrane soluble ubiquinol 
pool (figure 4.4). Residues from SDH C and SDH D also form a cytochrome b 
containing a heme b group (reviewed by van den Heuval and Smeitink, 2001). The 
function of the heme b is not clearly understood as it does not appear to participate in 
any redox reactions associated with succinate oxidation however it is thought to play 
a structural role within SQR (Kim et al., 2012). The transfer of electrons through 
SQR is not linked with proton translocation and this is the only complex in the 
mitochondrial respiratory chain that does not act as a proton pump. 
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4.1.2 An overview of the mitochondrial respiratory chain. 
 
The mitochondrial respiratory chain is a series of four protein complexes that 
function in a specific order (figure 4.3). The passage of electrons through these four 
complexes releases energy that is stored as a proton gradient across the inner 
mitochondrial membrane. This proton gradient is used to drive the formation of ATP 
by the fifth complex found in the inner mitochondrial membrane, ATP synthase/ F1F0 
ATPase (van den Heuval and Smeitink, 2001). 
 
Electrons enter the mitochondrial respiratory chain when NADH or FADH2 produced 
in the TCA cycle are oxidised by Complexes I or II (see section 4.1.3), respectively. 
Complex I, also referred to as NADH:ubiquinone oxidoreductase / NADH:quinone 
oxidoreductase, is an L shaped complex consisting of a hydrophilic / promontory 
domain that protrudes into the mitochondrial matrix and a hydrophobic domain that 
is embedded in the inner mitochondrial membrane (Yano, 2002). The promontory 
domain is comprised of two subunits, a flavoprotein (Fp) subunit containing non-
covalently bound flavin mononucleotide (FMN) and two of the 8 or 9 Fe-S clusters, 
and an iron sulphur protein which contains the remaining Fe-S clusters. Once NADH 
has bound to the Fp subunit, it is reduced by FMN. The two electrons are then passed 
through the Fe-S clusters to bound ubiquinone whose binding site is located in the 
hydrophobic subunit of complex I. The transfer of two electrons from the terminal 
Fe-S cluster in the Ip subunit reduces ubiquinone to ubiquinol. It is at this point that 
electron transfer is coupled to the translocation of four protons across the inner 
mitochondrial membrane into the intermembrane space (Yano, 2002 and Hirst et al., 
2003). 
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Electron transfer from ubiquinol that has been reduced by complexes I and II is 
catalysed by the third complex in the mitochondrial respiratory chain, 
decylubiquinol:cytochrome c oxidase/ cytochrome bc1 complex. Cytochrome bc1 is a 
homodimeric complex where three out of the eleven subunits that comprise each 
monomer carry prosthetic groups. Cytochrome c1 contains heme c1, cytochrome b 
contains heme bH and bL and the Rieske protein contains an iron-sulphur cluster. The 
bc1 complex links the oxidation of a membrane bound ubiquinol and reduction of a 
water soluble cytochrome c with the translocation of protons across the inner 
mitochondrial membrane in a process known as the protonmotive Q cycle (van den 
Heuval and Smeitink, 2001). 
 
The Q cycle (figure 4.4) involves both ubiquinol oxidation and ubiquinone reduction. 
These reactions occur at two separate centres known as Qp (which is located near the 
electropositive side of the inner mitochondrial membrane) and QN (located near the 
electronegative side of the membrane). The oxidation of the first ubiquinol molecule 
at Qp releases two electrons. The first electron is recycled through cyt b to a 
ubiquinone molecule located at QN producing a semi-quinone anion while the second 
electron is passed through the iron sulphur cluster in the Rieske protein and cyt c1 to 
cyt c. The oxidation of the second ubiquinol results in the reduction of the semi-
quinone at QN by the first electron coupled with the uptake of two protons from the 
mitochondrial matrix. The second electron is channelled through the redox centres of 
the Rieske and cyt c1 proteins to a cyt c molecule. The oxidisation of each ubiquinol 
results in the pumping of two protons into the inter-membrane space (Hunte et al., 
2003). 
 
Electrons are transferred from the cytochrome bc1 complex via cytochrome c which 
acts as an electron shuttle, to the terminal complex in the mitochondrial respiratory 
chain, cytochrome c oxidase (COX). The mammalian COX complex is functional as 
a dimer, with each monomer being comprised of 13 subunits, the largest of which, 
subunits I-III, are encoded by the mitochondrial genome with the remaining 10 
subunits encoded by the nuclear genome (Richter and Ludwig, 2003). Subunits I and 
II contain the four redox centres of the COX complex. The CuA centre is located in 
subunit II and the heme a centre and the binuclear centre comprised of heme a3 and 
CuB are located in subunit I. Electrons enter the COX complex when cytochrome c, 
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bound to subunit II, transfers electrons to the CuA centre then to heme a and finally to 
the binuclear heme a3:CuB centre where dioxygen is reduced to water by the 
incoming four electrons together with four protons from the matrix. The reduction of 
dioxygen to two water molecules releases enough energy for the translocation of four 
protons across the inner mitochondrial membrane (Pecina et al., 2004; Richter and 
Ludwig, 2003). 
 
 
Figure 4.4 The Q Cycle 
 
A diagrammatic representation of the pathway of electron transfer through 
complex III is indicated above. The three sub-units containing redox centres are 
indicated, other sub-units have not been shown. Electron transfer is indicated by 
dashed arrows and direction of proton (H
+
) movement by dotted arrows. 
A) Ubiquinol (QH2) is oxidised at centre P (Qp) in a reaction that transfers one 
electron (e
-
) to the iron-sulphur cluster (2Fe-2S) located in the Rieske protein and 
the second electron to heme bL in the cytochrome b sub-unit resulting in the 
release of ubiquinone (Q). The electron from the Rieske protein is transferred to 
cytochrome c1 in the cytochrome c1 sub-unit and then to cytochrome c. The 
oxidisation of the Rieske protein is accompanied by the translocation of an H
+
 
across the inner mitochondrial membrane. The second electron is transferred to 
heme bH located in the cytochrome b sub-unit and then to a bound ubiquinone at 
centre N (QN) which is reduced to semiquinone (Q
.-
). B) A second QH2 is 
oxidised at QP electrons are transferred in the same manner as for A. Transfer of 
the electron from heme bH results in the reduction of Q
.-
 to QH2 accompanied by 
the uptake of 2H
+
 at QN. Based on a figure by Hunte et al., 2003. 
 
Key: e
-
, electron; FE-S, Iron – sulphur cluster; H, hydrogen; Q, ubiquinone; QH2, ubiquinol  
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The final step in oxidative phosphorylation is the synthesis of ATP from ADP and Pi, 
a process catalysed by complex V, more commonly known as ATP synthase or the 
F1F0 ATPase. The simplest F1F0 ATPases are found in prokaryotes e.g.. E. coli. They 
are bipartite proteins that are comprised of 8 subunits which form an F0 portion and 
an F1 portion linked by two stalks (figure 4.5).  
 
 
Figure 4.5 The E. coli F1F0 ATPase. 
 
A diagrammatic representation of the 8 sub-units that comprise the 
E. coli F1F0 ATPase. The F0 portion of the complex is embedded in 
the inner mitochondrial membrane and is responsible for proton 
translocation. The F1 portion of the complex acts as the ATPase . 
The F1 and F0 portions of the complex are linked via two stalks 
comprised of the δ and β subunits and the γ and ε subunits, 
respectively. Based on figures by Weber and Senior, 2003 and 
Capaldi and Aggeler, 2002. 
Inner mitochondrial 
membrane
Inter-membrane 
space
Mitochondrial matrix




C


a
2b
F1 (,,,,and  sub-units)
F0 (a, b and c sub-units)


 
The F0 portion of the complex is responsible for proton translocation. It is embedded 
in the inner mitochondrial membrane and consists of 1 a, 2 b and 10-12 c subunits. 
The F1 portion of the complex acts as the ATPase. It resides in the mitochondrial 
matrix and is comprised of 3 , 3 ,   and  subunits (Capaldi and Aggeler, 2002). 
The two stalks that link the F1 and F0 portions of the complex are comprised of the  
and β subunits and the  and  subunits, respectively (figure 4.5). The mammalian 
F1F0 ATPase is comprised of between 16-18 subunits the additional subunits do not, 
as yet, have an assigned role or location within the mitochondrial complex.  
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ATP is synthesised when the F0 portion of the ATPase translocates protons that were 
pumped into the inter-membrane space by complexes I, III and IV. The movement of 
these protons drives rotation of the rotor, which is comprised of the ,  and c 
subunits, leading to the synthesis of ATP by one of the three catalytic sites located in 
the 33 hexagon. The  and b subunits prevent the rotation of the 33 hexagon with 
the rotor. 
 
4.1.3 Hereditary paraganglioma (PGL). 
 
PGL is a rare autosomal dominant disease characterised by tumours of the 
paraganglionic system, a range of organs and cell clusters derived from neural crest 
cells (Baysal., 2003; Heutink et al., 1992). The most common locations for PGL 
associated tumours are in the adrenal medulla and the head and neck paraganglia. 
Two types of tumours are associated with PGL; pheochromocytomas which are 
catecholamine secreting tumours that can lead to hypertensive crises, and head and 
neck paragangliomas (HNPs), hormonally silent tumours clinically recognised 
because of the pressure effects exerted by them in the head and neck (Maher et al., 
2002; Baysal., 2003). 
 
Four loci have been identified that pre-dispose affected individuals to PGL. The 
responsible genes at the PGL1, PGL3 and PGL4 loci have been identified as SDHD, 
SDHC, and SDHB, respectively. These genes encode for three of the four proteins 
that comprise Succinate:Ubiquinone oxidoreductase (SQR, section 4.1.3). The first 
locus to be identified, PGL1, was genetically mapped in a five generation Dutch 
pedigree to chromosome band 11q23 (Heutink et al., 1992) and was later identified 
as SDHD, the gene that encodes SDH D (Baysal et al., 2000). The putative PGL2 
locus was mapped to 11q13 in a single large Dutch family suffering from 
paragangliomas,  and the gene responsible has been identified as SDHAF2, which 
encodes for SDH assembly factor 2 (SDHAF2), which is essential for SDH –
dependent respiration and SDH A flavination (reviewed by Maher and Eng, 2002; 
Hao et al., 2009). Following the identification of SDHD as the PGL1 locus other 
components of the SQR complex were analysed for mutations in individuals with 
paraganglioma and/or pheochromocytoma. This led to the discovery of PGL3 as the 
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SDHC locus in a single German family with PGL (Niemann and Muller, 2000) and 
PGL4 the SDHB locus in several families suffering from familial pheochromocytoma 
with or without HNPs (Astuti et al., 2001, Table 4.1). 
 
Table 4.1 Summary of PGL disease type and affected gene. 
PGL Type Locus Affected 
Gene 
Associated Tumour 
Types 
References 
PGL1 11q22-
23 
SDHD Paraganglioma; 
Pheochromocytoma 
Heutink et al., 1992; 
Baysal et al., 2000 
PGL2 11q13 SDHAF2 Paraganglioma Hao et al., 2009 
PGL3 1q21-
23 
SDHC Paraganglioma Niemann and Muller., 
2000 
PGL4 1p36 SDHB Paraganglioma; 
Pheochromocytoma 
Astuti et al., 2001 
Key: PGL, hereditary paraganglioma; SDHB-D, succinate dehydrogenaseB-D genes; SDHAF2, 
succinate dehydrogenase assembly factor 2 gene. 
 
4.1.4 Maternal Imprinting of PGL1. 
 
The PGL1 phenotype is only observed when transmitted through the father, whereas 
no phenotype is observed when transmitted maternally. This clinical observation was 
believed to show that PGL1 was maternally imprinted i.e. the maternally derived 
gene is transcriptionally inactivated by methylation of the promoter during female 
oogenesis. Reactivation of the gene can only be achieved during spermatogenesis 
when methylation of the promoter is removed (van der Mey et al., 1989). 
 
The precise mechanism of PGL1 imprinted inheritance has still to be determined 
because evidence of SDH D biallelic expression has been shown in lymphoblastoids 
and leukocytes from affected and imprinted carrier individuals (Baysal et al., 2000; 
Badenhop et al., 2001) and in unaffected adult brain, foetal brain and foetal kidney 
tissue (Baysal et al., 2000). Analysis of paraganglioma and pheochromocytoma 
tissue from affected PGL1 individuals showed monoallelic expression of the mutated 
paternal allele combined with a loss of heterozygosity (LOH) of the wild-type 
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maternal allele at the PGL1 loci (Baysal et al., 2000; Taschner et al., 2001; Gimenez-
Roqueplo et al., 2001). Retention of the mutated paternal allele and loss of the wild-
type maternal allele suggests SDH D acts as a classical tumour suppressor requiring 
two mutational occurrences for tumourigenesis to occur. However the transmittance 
of the disease through the paternal line only suggests SDH D acts as tumour 
suppressor gene subject to maternal imprinting. All other PGL loci are not subject to 
maternal imprinting. 
 
4.1.5 Mutational effects on the structure and function of Succinate Ubiquinone 
Oxidoreductase (SQR). 
 
Many mutations in the four genes that comprise SQR have now been identified, they 
lead to either severe encephalomyopathy in the case of SDH A mutations or tumour 
formation if subunits SDH B-D are affected. To date no mutations in SDH A have 
been identified that cause a pre-disposition in individuals to PGL, HNPs or 
apparently sporadic pheochromocytomas (ASPs, Table 4.2). 
 
Individuals carrying the homozygous arg554trp or the heterozygous ala524val 
mutation of SDH A all present with Leigh syndrome, a progressively 
neurodegenerative disease whose symptoms include neural lesions dystonia, ataxia, 
myopathy and breathing difficulties (Bourgeron et al., 1995; Parfait et al, 2000). The 
R554W and A524V mutations, located in the C-terminal domain of SDH A, are 
thought to be located near the catalytic site of SDH because they allow substrate 
binding but cause loss of activity of the SQR complex (reviewed by Ackrell, 2002). 
 
Individuals carrying the heterozygous R451C mutation have a non-covalently bound 
FAD moiety which prevents the oxidisation of succinate from occurring. Individuals 
survive because the second SDH A allele is unaffected (Ackrell, 2000).  
 
Analysis of SQR activity in pheochromocytoma tumour tissue harbouring the A43P, 
R46G, R46Q, 725 deleted c and IVS 4+1 ga (IVS- intervening sequence) 
mutations in SDH B, demonstrated a complete loss of function of the SQR complex 
(Gimenez-Roqueplo et al., 2002, 2003; Douwes-Dekker et al., 2003). Tumour tissue 
from individuals with the above mutations as well as tumour tissue from individuals 
 155 
with the R27X, H132P and 713-718 deleted tctc mutations in SDH B was found to 
have a loss of the wild-type allele at the SDH B locus (Gimenez-Roqueplo et al., 
2003; Neumann et al., 2002; Maier-Woelfle et al., 2004; Vanharanta et al., 2004, 
respectively). This demonstrated that SDH B acts as a classical tumour suppressor 
gene. 
 
Table 4.2 A Summary of SDH mutations 
SQR gene Nucleotide 
change  
Amino acid 
change 
Disease phenotype Reference 
SDH A 1a→c M1L Leigh syndrome Parfait et al., 2000 
SDH A 1351ct R451C Neurodegenerative 
disease, optic 
atrophy,ataxia and 
myopathy 
Reviewed by Rustin 
and Rotig, 2002 
SDH A 1571c→t A524V Leigh syndrome Parfait et al., 2000 
SDH A 1660c→t R554W Leigh syndrome Bourgeron et al., 1995 
     
SDH B 79c→t R27X ASP 
PGL4,RCC 
Neumann et al., 2002, 
Vanharanta et al., 
2004 
SDH B 86-87 ins cag ins Q after 
A29  
ASP Neumann et al., 2002 
SDH B 127g→c A43P ASP Gimenez-Roqueplo et 
al., 2003 
SDH B 136c→g R46G ASP Neumann et al., 2002, 
Gimenez-Roqueplo et 
al., 2003 
SDH B 137g→a R46Q ASP Gimenez-Roqueplo et 
al., 2002 
SDH B 174-175gc→tt Q59X HNPs Baysal et al., 2002 
SDH B 207-210 ins c Frameshift 
after M70 
PGL4 Baysal et al., 2002 
SDH B 260t→c L87S ASP Astuti et al., 2001a 
SDH B 268c→t R91X Hereditary 
pheochromocytoma 
and HNPs 
Astuti et al., 2001a 
SDH B 302g→a C101Y ASP Neumann et al., 2002 
SDH B 392c→g P131R PGL4 Baysal et al., 2002 
SDH B 395at H132P PGL4 Maier-Woelfe et al., 
2004 
SDH B 574t→c C192R ASP Neumann et al., 2002 
SDH B 587g→a C196Y ASP Neumann et al., 2002 
SDH B 590c→g P197R Hereditary 
pheochromocytoma 
Astuti et al., 2001a 
SDH B 591del c Frameshift 
after P197  
ASP Astuti et al., 2001a 
and Gimenez-
Roqueplo et al., 2003 
SDH B 620-621 del tg Frameshift 
after Y206 
ASP Gimenez-Roqueplo et 
al., 2003 
SDH B 688c→t R230C ASP Gimenez-Roqueplo et 
al., 2003 
SDH B 713-718 del tctc Frameshift 
after L240 
ASP 
 
PGL4 and RCC 
Neumann et al., 2002, 
Vanharanta et al., 
2004 
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SQR gene Nucleotide 
change  
Amino acid 
change 
Disease phenotype Reference 
SDH B 725 del c Frameshift 
after Y241 
ASP Astuti et al., 2001a 
SDH B 747c→a C249X ASP Neumann et al., 2002 
SDH B IVS 4+1 g→a Splice defect HNPs Douwes Dekker et al., 
2003 
     
SDH C 3g→a M1V 
abolishes start 
codon 
PGL3 Niemann and Muller, 
2000 
SDH D 1g→c M1I PGL1 Badenhop et al., 2001 
SDH D 14g→a W5X ASP Neumann et al., 2002 
SDH D 33c→a C11X ASP Neumann et al., 2002 
SDH D IVS1 +2 t→g Splice defect Paraganglioma and 
pheochromocytoma 
Gimm et al., 2000 
SDH D 34g→a G12S PGL1,ASP, 
Polymorphism 
Gimm et al., 2000, 
Taschner et al., 2001 
SDH D 36-37 del tg Frameshift 
after A13 
ASP Neumann et al., 2002 
SDH D 54 ins c Frameshift 
after A18 
PGL1 Taschner et al., 2001 
SDH D 64c→t R22X PGL1 Taschner et al., 2001 
SDH D 95c→t S32X PGL1 Milunsky et al., 2001 
SDH D 94-97 del ct Frameshift 
after S32 
Hereditary 
Pheochromocytoma 
Astuti et al., 2001b 
SDH D 106c→t Q36X PGL1 Baysal et al., 2000 
SDH D 112c→t R38X ASP Baysal et al., 2000, 
Gimm et al., 2000 
SDH D 120 ins c Frameshift 
after P41 
PGL1 Taschner et al., 2001 
SDH D 191-192 del tc Frameshift 
after L64 
PGL1 Badenhop et al., 2001 
SDH D  Frameshift 
after W66 
Hereditary 
pheochromocytoma 
Astuti et al., 2001b 
SDH D 208a→g R70G PGL1 Taschner et al., 2001 
SDH D 242c→t P81L ASP Baysal et al., 2000, 
Gimm et al., 2000 
SDH D 274g→t D92Y PGL1 Baysal et al., 2000 
SDH D  276-278 del cta del Y93 PGL1 Badenhop et al., 2001 
SDH D 284t→c L95P PGL1 Taschner et al., 2001 
SDH D 305a→t H102L PGL1 Baysal et al., 2000 
SDH D 325c→t Q109X PGL1 Baysal et al., 2002 
SDH D 336-337 ins t D113X PGL1 Milunsky et al., 2001 
SDH D 341a→g Y114C PGL1 Milunsky et al., 2001 
SDH D 361c→t Q121X ASP Neumann et al., 2002 
SDH D 381-383 del g Frameshift 
after L128 
PGL1 Baysal et al., 2002 
SDH D 416t→c L139P PGL1 Taschner et al., 2001 
SDH D 441-443 del c Frameshift 
after G148 
PGL1 Milunsky et al., 2001 
SDH D IVS3 -32 t→c  Splice defect PGL1 Taschner et al., 2001 
Nucleotide mutations and the corresponding amino acid change are indicated for each SDH gene 
along with the disease phenotype(s) the mutation has been associated with. 
Key: ASP, Apparently sporadic pheochromocytoma: HNPs, Head and neck paragangliomas; RCC, 
Renal cell carcinoma; PGL 1-4, Hereditary Paraganglioma Type 1-4 IVS, Intervening sequence 
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The only mutation to have been identified in SDH C to date abolishes the atg start 
codon causing the replacement of methionine 1 with valine. Tumour tissue from 
affected individuals was found to have loss of the unaffected SDH C allele while 
retaining the affected allele, demonstrating SDH C acts as a tumour suppressor 
(Niemann and Muller, 2000). Presumably, because both SDH C and SDH D are 
required for membrane association of SDH A and SDH B, tumours from individuals 
with the met1val mutation and loss of the wild type allele would only have SDH D 
present in the mitochondrial membrane (Ackrell, 2002). 
 
PGL1 tumours exhibiting LOH of the SDH D locus affecting the maternal allele have 
been found to harbour the mutations R22X, Q36X, R38X, P81L, D92Y, H102L and 
L139P (Gimenez-Roqueplo et al., 2001; Baysal et al., 2000; Taschner et al., 2001). 
These mutations cause a complete loss of function of the SQR complex (Gimenez-
Roqueplo et al., 2001; Douwes-Dekker et al., 2003). Preferential expression of the 
mutated paternal allele in tumour tissue from PGL1 individuals harbouring the M1I 
mutation has also been demonstrated (Badenhop et al., 2001). Pheochromocytoma 
tumour tissue that is not associated with PGL1 has also been found to exhibit LOH of 
the wild type-allele, the remaining mutated allele encodes for the P81L protein 
mutation (Gimm et al., 2000). Other mutations are predicted to produce truncated 
proteins or mutations that alter the structure of SDH D and these include R38X, 
P81L, Q109X and 381-383 deleted g (Baysal et al., 2002). 
 
4.1.6 Other TCA cycle associated tumour syndromes 
 
As well as germ-line mutations being identified in SDH A-D, they have also been 
identified in the fumarase gene (fumarate hydratase, FH) which encodes for 
fumarase, another enzyme of the TCA cycle. Fumarase (FH) catalyzes the 
conversion of fumarate to malate, which is the subsequent reaction after the catalysis 
of succinate to fumarate by SDH.  
 
Germ-line homozygous mutations of the FH gene cause fumarase deficiency, an 
autosomal recessive condition that is not associated with a tumour syndrome. This is 
similar to homozygous mutations in the SDH A gene which also cause a non-tumour 
 158 
associated condition. Heterozygous mutation of FH causes an autosomal dominant 
syndrome known as multiple cutaneous and uterine leiomyomatosis (MCUL). Male 
individuals with MCUL suffer from multiple leiomyomatas (benign smooth muscle 
tumours) of the skin while female sufferers present with skin and uterine 
leiomyomatas. MCUL is associated with an increased risk of type II papillary renal 
cell cancer and leiomyosarcoma and this form of the disease is called hereditary 
leiomyomatosis and renal cell cancer (HLRCC, Alam et al., 2003). In both MCUL 
and HLRCC the fumarase has been found to act as a classical tumour suppressor, as 
preferential loss of the wild-type allele and retention of the mutated allele is often 
seen in leiomyomata and renal cell carcinomas (Tomlinson et al., 2002). Loss of FH 
activity in cutaneous leiomyomatas relative to overlaying normal skin has also been 
demonstrated (Tomlinson et al., 2002).  
 
Renal cell cancer is also known to be a feature of VHL syndrome (section 1.6.5). The 
finding that mutation of another enzyme of the TCA cycle predisposes individuals to 
a form of cancer known to be related to VHL syndrome perhaps suggests an 
involvement of FH in oxygen sensing (Tomlinson et al., 2002). 
 
4.1.7 Approaches to inhibiting SDH 
 
Germ-line and sporadic mutations in, SDH B, SDH C and SDH D are known to pre-
dispose affected individuals to paraganglioma and/or pheochromocytoma (Astuti et 
al., 2001; Niemann and Muller, 2000 and Baysal et al., 2000, respectively). 
Pheochromocytoma also occurs in VHL syndrome, an autosomal dominant condition 
causing a pre-disposition of affected individuals to pheochromocytoma, renal cell 
carcinoma and central nervous system (CNS) hemangioblastomas (reviewed by 
Kondo and Kaelin Jr, 2001).  
 
One of the functions of pVHL, the protein product of VHL, is the regulation of 
hypoxia inducible factor-1 (HIF-1, Maxwell et al., 1999). HIF-1 dimerises with 
ARNT/HIF-1 to form hypoxia inducible factor 1 (HIF-1), a transcription factor that 
regulates a variety of genes that are involved angiogenesis, oxygen transport, glucose 
uptake, glycolysis and growth factor signalling. All of these processes are involved 
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in tumour cell survival and proliferation (reviewed by Bardos and Ashcroft, 2004; 
section 1.3.4). Inactivating mutations in VHL when combined with loss of expression 
or mutational inactivation of the remaining VHL allele prevent the regulation of HIF-
1, leading to a phenotype that resembles adaptation to hypoxia occurring under 
normoxic conditions (reviewed by Safran and Kaelin Jr, 2003).  
 
Vascularisation is a feature of the tumours involved in VHL disease because of the 
transcriptional activation by HIF-1 of genes encoding proteins involved in 
angiogenesis, oxygen transport, glucose transport, glycolysis and growth factor 
signalling. A high degree of vascularisation was observed in paraganglionic tumours 
harbouring germ-line SDH D mutations (Baysal et al., 2000). The similarities in 
tumour types and tumour pathology in individuals with VHL disease and in 
individuals with tumours caused by SDH B or SDH D mutations (SDH C mutations 
have yet to be identified in pheochromocytoma) suggested an involvement of the 
hypoxic response pathway. This led to the hypothesis that inactivation of SDH would 
lead to an up-regulation of HIF-1 subsequently followed by an increase in HIF-1 
transcriptional activation of target genes. 
 
4.1.7.1 The chemical inhibition of succinate dehydrogenase (SDH). 
 
Before embarking on expensive highly specific methods of disrupting succinate 
dehydrogenase (SDH) (e.g.. RNA interference) a less expensive model was sought 
after in the form of chemical inhibition.  
 
Preliminary experiments were performed with 3-nitropropionic acid/3-
nitropropionate (3-NPA) before testing whether malonate could produce the same 
effect. Both 3-NPA and malonate are analogues of succinate. The chemical structures 
of succinate, 3-NPA and malonate are shown in figure 4.7. 
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3-nitropropionic acid (3-NPA) is a toxin from the Indigofera endecaphylla plant. 3-
NPA is an isoelectric analogue of succinate that once bound to SDH A acts by 
progressively and irreversibly inactivating the enzyme and as such is defined as a 
suicide inhibitor (Alston et al., 1977). It is thought inactivation occurs by the slow 
oxidisation of 3-NPA into 3-nitroacrylate via the reduction of FAD to FADH2. An -
SH group located in the binding site of SDH A is thought to combine with the double 
bond in 3-nitroacrylate to form an irreversible covalent adduct (Coles et al., 1979).  
 
Malonate is a reversible competitive inhibitor of SDH (O’Donnell et al., 1995). Both 
3-NPA and malonate were employed to model the inactivation of SDH. 
Unfortunately this model has some limitations. Mutations associated with 
pheochromocytoma are usually found in SDH B or D not in SDH A which is the 
subunit targeted for inactivation by 3-NPA and malonate. Another limitation of this 
model is the specificity of action of both inhibitors as they may have other targets as 
well as SDH A. 
 
4.1.7.2 The inhibition of succinate dehydrogenase (SDH) by RNA interference 
(RNAi). 
 
An alternative approach to inhibiting SDH function is to use a specific targeted 
approach such as RNA interference (RNAi). RNAi is an evolutionary conserved 
pathway, first identified in plants, that was initially identified as a cellular defence 
mechanism against viral invasion and transposon expansion. However, RNAi also 
Figure 4.6 Structural similarities between succinate and 
inhibitors of succinate dehydrogenase. 
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has a more general role whereby specific genes in plants and mammals are regulated 
by post-transcriptional gene silencing. Following the discovery of RNA interference 
it has quickly become a valuable gene function analysis tool. In nature RNAi occurs 
when the host cell encounters a long piece of double stranded RNA (dsRNA). In 
Homo sapiens dsRNAs are processed by an RNase-III like enzyme called Dicer into 
small interfering RNA (siRNAs) duplexes of between 21 and 23 nucleotides. The 
duplexed siRNAs are subsequently incorporated into an RNA induced silencing 
complex (RISC) which unwinds the siRNA duplex. RISC complexes that incorporate 
the anti-sense strand of the unwound siRNA duplex guide the sequence specific 
cleavage of complementary or near complementary target mRNAs (reviewed by 
Meister and Tuschl, 2004).  
 
siRNAs have been commercially developed and utilised for target validation and 
gene function analysis e.g.. validation of Brk as a therapeutic target in breast cancer 
and more recently in determining the differing roles of HIF-1 and HIF2 in colon 
cancer (Harvey and Crompton 2003; Imamura et al., 2009). Several RNAi-based 
therapeutics have now reached clinical trials; these include RNAi-based therapeutics 
for the treatment of age related macular degeneration, hepatitis B and solid tumours 
(reviewed by Castanotto and Rossi, 2009) 
 
More SDH B mutations are associated with pheochromocytoma than SDH D or SDH 
C mutations (table 4.2). Therefore, inhibition of SDH B is a better model for 
studying the effect of tumour associated mutations. An antibody for SDH B was also 
commercially available thereby providing an important experimental tool for sample 
analysis. 
 
4.1.8 Hypothesis 
 
The aim of this work is to determine whether chemical inhibition of SDH by 3-NPA 
or malonate (chemical inhibitors of SDH A analogous to succinate) results in up-
regulation of HIF-1α. A further aim of this study is to determine whether inhibition 
of the SDH B subunit by RNA interference results in up-regulation of HIF-1α and 
subsequent up-regulation of HIF target genes.  
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4.2 Development of a chemical inhibition model to determine the 
effects of SDH mutation in pheochromocytoma. 
 
4.2.1 The optimisation of 3-NPA treatment of Hep G2 and T-47D cells. 
 
Previous studies performed using 3-NPA, have used varying concentrations to inhibit 
succinate dehydrogenase in cultured cells. These concentrations ranged from 4-8mM 
in PC12 cells and from 1-20mM in experiments designed to assess whether estradiol 
could attenuate the 3-NPA induced modulation of ATP production, mitochondrial 
membrane potential, reactive oxygen species (ROS) production and cell viability 
observed in SK-N-SH neuroblastoma cells (Mandavelli et al., 2005 and Wang et al., 
2001, respectively). Wang et al, (2001). Based on the experiments of Wang et al., the 
concentration of 3-NPA used in initial optimisation experiments designed to 
determine whether 3-NPA had any effect on HIF-1α protein levels was 12.5mM. 
 
At the time of performing these preliminary experiments it had been shown that p53 
could inhibit HIF-1 dependent transcription (Blagosklonny et al., 1998 ) by 
promoting Mdm2 mediated proteasomal degradation of HIF-1 (Ravi et al., 2000). 
Therefore it was of interest to see if any apparent effects on HIF-1 protein levels 
caused by cell incubation with 3-NPA were also dependent on the presence of wild-
type p53. With this aim in mind Hep G2 cells expressing wild-type p53 (Ho et al., 
1999) and T-47D cells, which express p53 containing a C-T mis-sense mutation in 
exon 6 resulting in a truncated protein, were used in preliminary experiments.  
 
Hep G2 and T-47D cells were treated 24 hours after seeding with 12.5mM 3-NPA or 
a carrier control (sterile H2O). Whole cell lysates prepared 3 and 6 hours after 
treatment were resolved by SDS-PAGE, western blotted and probed with an anti-
HIF-1 antibody (figure 4.7). Equal protein loading of the membranes was 
determined by Ponceau S staining (data not shown). 
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Figure 4.7 The effect of 3-NPA treatment on HIF-1 protein levels in 
Hep G2 and T-47D cells. 
 
Hep G2 and T-47D cells were incubated 24 hours after seeding with 
either a carrier control or 3-NPA to a final concentration of 12.5mM, as 
indicated. Whole cell lysates were prepared 3 and 6 hours after treatment. 
As a positive control to identify for HIF-1α protein, cells were incubated 
for 6 hours with either a carrier control (C) or DFO to a final 
concentration of 100M before whole cell lysates were prepared. Whole 
cell lysates were resolved by SDS-PAGE, western blotted and probed 
with an anti-HIF-1 antibody (Novus Biologicals). Equal protein loading 
of the membranes was determined by Ponceau S staining. The mobility 
of a standard protein is indicated (sections 2.1.1 - .2.16;). Figure 
represents n=1. 
 
Key: 3-NPA, 3-nitropropionic acid; C, carrier control; DFO, Desferrioxamine; HIF-1α, 
hypoxia inducible factor 1α; hrs, hours; kDa, kilodaltons. 
3 36 6
DFO Control 3-NPA
6 6
C
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T-47D
98kDa
HIF-1Hep G2
 
In Hep G2 cells, 3-NPA appeared to induce HIF-1 protein at the 6 hour time-point 
when compared to carrier control however the converse appeared to be the case at 
the 3 hour time-point, where more HIF-1 protein was detected in the carrier control 
sample than in the 3-NPA treated sample. 3-NPA did not induce any detectable HIF-
1 protein in T-47D cells at either time-point. A low level of HIF-1 protein can be 
detected in the control treated lysates of T-47D cells at both time-points. DFO, an 
iron chelator that induces HIF-1α protein levels in cells not subjected to hypoxia, was 
used to treat Hep G2 and T-47D lysates. These lysates were used as positive controls 
for the detection of HIF-1 protein. 
 
Due to the low level of HIF-1 protein induced by 3-NPA in Hep G2 cells and the 
absence of induction in T-47D cells, the incubation time of cells with 3-NPA was 
increased. Hep G2 and T-47D cells were treated 24 hours after seeding with either 
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12.5mM 3-NPA or carrier control. Whole cell lysates were prepared 16 and 24 hours 
after treatment, resolved by SDS-PAGE, western blotted and probed with an anti-
HIF-1 antibody (figure 4.8).  
 
 
Figure 4.8 The effect of 3-NPA treatment on HIF-1 protein levels in 
Hep G2 and T-47D cells. 
 
Hep G2 and T-47D Cells were incubated 24 hours after seeding with 
either carrier control (-) or 3-NPA to a final concentration of 12.5mM 
(+). Whole cell lysates were prepared 16 and 24 hours after treatment, 
were resolved by SDS-PAGE, western blotted and probed with an anti-
HIF-1 antibody (Novus Biologicals). Equal protein loading was 
determined by Ponceau S staining of the membrane. The mobility of a 
standard protein is indicated. (sections 2.1.1 – 2.1.6;). Figure represents 
one experiment (n=1). 
 
Key: 3-NPA, 3-nitropropionic acid; C, carrier control; DFO, Desferrioxamine; HIF-1α, 
hypoxia inducible factor 1α; hrs, hours; kDa, kilodaltons. 
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A low level of HIF-1 protein was detectable in T-47D samples treated with 3-NPA, 
however the corresponding control lanes contain more HIF-1 protein than is 
detectable in test lanes. In Hep G2 cells elevated levels of HIF-1 protein were 
detected in samples treated with 3-NPA when compared to control treated samples at 
both 16 and 24 hours. The multiple anti-HIF-1 bands detected in all samples could 
be due to post-translational modifications including the conjugation of a mono or 
poly-ubiquitin tail and/or phosphorylation. 
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To confirm the results observed in figure 4.8 the experiment was repeated (figure 
4.9). DFO treated Hep G2 and T-47D cells were used as a positive control for the 
detection of HIF-1 protein.  
 
 
Figure 4.9 The effect on HIF-1 protein levels in Hep G2 and T-47D 
cells incubated with 3-NPA. 
 
Hep G2 and T-47D cells were incubated 24 hours after seeding with either a 
carrier control (3-NPA -) or 3-NPA to a final concentration of 12.5mM (3-
NPA +), as indicated. Whole cell lysates prepared 16 and 24 hours after 
treatment. As a positive control for detection of HIF-1α protein, Hep G2 and 
T-47D whole cell lysates were prepared 6 hours after treatment with either 
carrier control (DFO -) or DFO (DFO +) to a final concentration of 100M 
as indicated. Whole cell lysates were resolved by SDS-PAGE, western 
blotted and probed with an anti-HIF-1 antibody (Novus Biologicals). Equal 
protein loading of the membranes was determined by Ponceau S stainings. 
The mobility of a standard protein is indicated (sections 2.1.1 – 2.1.6). Figure 
represents one experiment (n=1). 
 
Key: 3-NPA, 3-nitropropionic acid; DFO, Desferrioxamine; HIF-1α, hypoxia inducible 
factor 1α; hrs, hours; kDa, kilodaltons. 
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A higher level of HIF-1 protein was detected in Hep G2 cells treated with 3-NPA 
when compared to carrier control treated cells at 16 hours however, at 24 hours the 
converse appeared to be the case. Multiple bands representing anti-HIF-1 cross-
reactive species were observed in Hep G2 carrier control treated samples at 16 and 
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24 hours and in the 16hr 3-NPA treated sample. The mobility of detectable HIF-1 
protein in carrier control and 3-NPA treated samples was higher than in Hep G2 cells 
treated with DFO. However there was also some variability in HIF-1 protein 
mobility between samples treated with carrier control, which exhibited a higher 
mobility, and samples treated with 3-NPA which exhibited a lower mobility.  
 
Treatment of T-47D cells with 3-NPA appeared to cause a suppression of HIF-1 
protein levels at both 16 and 24 hours when compared to HIF-1 protein expressing 
carrier control samples. The same shift in HIF-1 protein mobility as was observed 
in Hep G2 cells could also be seen in T-47D cells. Carrier control treated samples 
contained a higher mobility HIF-1 protein than DFO treated sample. Multiple HIF-
1 reactive species could not be observed in T-47D cells. 
 
Figures 4.8 and 4.9 highlighted the variability of HIF-1 protein levels in control 
samples for both cell types. There was also a large variability in results between two 
experiments conducted in the same manner. The variability of HIF-1 protein 
expression in both cell types made the results difficult to interpret. 
 
4.2.2 The effect of low pH on cells incubated with 3-NPA.  
 
The optimisation experiments performed previously (section 4.2.1), involved the 
dissolution of 3-NPA in sterile H2O before addition to a final concentration of 
12.5mM to either Hep G2 or T-47D cells. This addition of 3-NPA caused the cells to 
be incubated in acidic conditions before lysis. Cells incubated with carrier control 
were not subjected to acidic conditions because the carrier control was sterile H2O 
which did not affect pH.  
 
To determine whether low pH was the cause of variable induction of HIF-1 in 3-
NPA treated cells, Hep G2 and T-47D cells were treated 24 hours after seeding with 
either 3-NPA pH 7.6 (buffered with NaOH) or a carrier control (sterile H2O 
containing the same amount of Na+ ions in the form of NaCl as used to buffer 3-
NPA). Whole cell lysates prepared 16 and 24 hours after treatment, were resolved by 
SDS-PAGE, western blotted and probed with an anti-HIF-1 antibody (figure 4.10). 
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DFO treated HepG2 or T-47D cells were used as positive controls for the detection 
of HIF-1. 
 
 
Figure 4.10 The effect of 3-NPA pH 7.6 on HIF-1 protein levels in Hep G2 and 
T-47 D cells. 
 
Hep G2 and T-47D cells were incubated 24 hours after seeding with either carrier 
control (sterile H2O containing the same amount of Na
+
 ions in the form of NaCl as 
used to buffer 3-NPA, -) or 3-NPA pH 7.6 (buffered with NaOH, +), to a final 
concentration of 12.5mM, as indicated. Whole cell lysates prepared 16 and 24 hours 
after treatment. As a positive control for the detection of HIF-1α protein Hep G2 and 
T-47D whole cell lysates were prepared six hours after treatment of cells with either 
or carrier control (-) or DFO to a final concentration of 100M (-) as indicated. 
Whole cell lysates were resolved by SDS-PAGE, western blotted and probed with an 
anti-HIF-1 antibody (Novus Biologicals). Equal protein loading of the membranes 
was determined by Ponceau S staining. The mobility of a standard protein is 
indicated (sections 2.1.1 – 2.1.6). Figure represents one experiment (n=1). 
 
Key: 3-NPA, 3-nitropropionic acid; DFO, Desferrioxamine; HIF-1α, hypoxia inducible factor 1α; 
hrs, hours; kDa, kilodaltons. 
98kDa
HIF-1
Hep G2
98kDa
HIF-1
T-47D
-- ++
DFO - +
3-NPA --
16hr 24hr
----
6hr
 
At 16 and 24 hours after 3-NPA treatment a low level of HIF-1 could be detected in 
treated Hep G2 cells however corresponding control samples contained a greater 
amount of HIF-1 protein (figure 4.10). T-47D samples at 16 hours contained a 
greater level of detectable HIF-1 protein in the control sample when compared to 
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the 3-NPA treated sample (figure 4.10). At 24 hours there was no discernable 
difference in HIF-1 protein levels between the control and 3-NPA treated samples 
in T-47D cells. 
 
The experiments performed to optimise the use of 3-NPA in both Hep G2 and T-47D 
cells showed a large degree of variability in the results obtained. Figures 4.8, 4.9 and 
4.10 showed a differing amount of HIF-1 protein present in Hep G2 control 
samples at 16 hours. At 24 hours the presence of detectable HIF-1 in control treated 
samples was variable. Figures 4.9 and 4.10 clearly indicated that HIF-1 protein 
could be detected in control treated samples at 24 hours yet in figure 4.8 HIF-1 
protein was not detected. In T-47D cells HIF-1 protein was detected in control 
treated samples at both time-points as shown in figures 4.8, 4.9 and 4.10. 
 
The effect of 3-NPA on HIF-1 protein levels was also variable. Figure 4.10 clearly 
showed 3-NPA caused an increase in HIF-1 protein levels at both time-points when 
compared to carrier control treated samples in Hep G2 cells. However, these results 
were not clearly reproduced in figures 4.9 and 4.10. The effect of 3-NPA treatment 
of T-47D cells was even more erratic. In figure 4.8, 3-NPA appeared to suppress the 
level of HIF-1 protein detected when compared to carrier control treated samples at 
both 16 and 24 hours. Figure 4.9 showed 3-NPA had no effect on HIF-1 protein 
levels and figure 4.10 showed 3-NPA treated samples contained less HIF-1 protein 
than carrier control treated samples at 16 hours but at 24 hours 3-NPA had no effect 
on HIF-1 protein levels when compared to carrier control treated samples. 
 
The results obtained seemed to indicate that low pH is not necessarily the cause of 
the variable HIF-1 protein levels observed in the preceding experiments. This can 
be shown more clearly if figures 4.9 and 4.10 are compared. Figure 4.9 showed a 
slight increase in HIF-1 protein levels at 16 hours, in response to 3-NPA, when 
compared to control in Hep G2 cells. At 24 hours the converse appeared to be the 
case. Figure 4.10 showed an apparent suppression of HIF-1 protein in 3-NPA 
treated cells when compared to controls at both time-points. T-47D cells treated with 
3-NPA showed a suppression in the level of HIF-1 protein when compared to 
controls at both time-points (figures 4.9 and 4.10).  
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4.2.3 The effect of cell confluence on HIF-1 protein levels. 
 
The variability in results observed in figures 4.8, 4.9 and 4.10 manifested themselves 
more often than not at the 24 hour time-point where there appeared to be more HIF-
1 protein present in control samples. This was not due to a difference in protein 
loading as determined by Ponceau S staining of the membranes prior to western 
blotting.  
 
During the course of the optimisation experiments it was observed that cells were 
becoming confluent after plating. Cultures of Hep G2 cells grown at a high density in 
an air-5% CO2 environment have been shown to utilise more O2 than can diffuse 
from the gas environment into the pericellular environment, indicating that confluent 
Hep G2 cells manifest a pseudo-hypoxic response (Metzen et al., 1995). High cell 
density has also been shown to induce nuclear HIF-1 protein expression and the 
activity of an HRE (hypoxia responsive element) reporter construct in LNCap 
(human prostate) cells cultured in normoxic conditions (Sheta et al., 2001). Figures 
4.9 and 4.10 showed HIF-1 protein expression in control treated Hep G2 cells 
cultured in normoxic conditions at 24 hours yet in figure 4.8 no detectable HIF-1 
protein was detected in the equivalent cell lysate. The variability in these results 
could be due to differences in cell density between experiments. Therefore, Hep G2 
cells were seeded at varying densities and cell confluence was judged by eye 48 
hours after seeding. A 200 000 cell starting population gave a good dispersal of cells 
in a monolayer across a well at the end of this time-period. The starting number of 
this cell population was approximately 50% less than used in previous experiments. 
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4.2.4 The effect of 3-NPA on HIF-1α protein levels. 
 
Previous studies performed using 3-NPA, have used varying concentrations to inhibit 
succinate dehydrogenase in cultured cells and tissues. These concentrations ranged 
from 10-100M in rat hippocampal slice cultures, 25-100M in rat striatal and 
corticostriatal slice cultures, 4-8mM in PC12 cells and from 1-20mM in SK-N-SH 
neuroblastoma cells (Wei et al., 2004, Storgaard et al., 2000, Mandavelli et al., 2005 
and Wang et al., 2001, respectively). To determine whether a different dose of 3-
NPA could produce an effect on HIF-1 protein levels Hep G2 cells were seeded 
200 000 cells/well. 24 hours after seeding cells were treated with concentrations of 3-
NPA ranging between 25mM and 12.2M 3-NPA pH 7.6 (buffered with NaOH) or 
carrier control (medium containing the same amount of Na+ ions in the form of NaCl 
as used to buffer 3-NPA). 24 hours after treatment whole cell lysates were prepared. 
Whole cell lysates were resolved by SDS-PAGE, western blotted and probed with 
anti HIF-1, anti-ARNT as a loading control additional to protein staining and anti-
p53 antibodies (figure 4.11). Both ARNT and p53 were chosen as loading controls; - 
ARNT because it has a similar protein structure to HIF-1α and therefore if any 
differences in protein level was observed in one protein and not the other it was 
likely that this was a specific result rather than a generalised one. ARNT has also 
been documented to be a constitutively expressed protein in all cells except ARNT 
null tumour cells (Griffiths et al., 2002). p53 is a protein that undergoes ubiquitin 
mediated degradation by the proteasome and it was for this reason that it was chosen 
as a control as it would be possible to establish whether any changes in HIF-1α 
protein levels were specific to HIF rather than due to generalised protein turnover. A 
more general protein such as actin was not considered as a control protein as it was 
felt ARNT and p53 protein levels were sufficient to determine whether anychanges 
in HIF-1α protein levels were specific to HIF-1α or due to a generalised effect as a 
result of the chemical treatment of Hep G2 cells. 
 
HIF-1 protein could not be detected in any samples and therefore no change in 
protein levels between 3-NPA treated samples and corresponding carrier control 
samples could be detected. ARNT protein detection was performed as a protein 
loading control in addition to Ponceau S staining of the membrane. ARNT was 
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thought to be a suitable control as it has been reported to be a constitutively 
expressed protein in all cells except ARNT null tumour cells (Griffiths et al., 2002). 
Therefore, it was somewhat surprising to discover that ARNT protein levels were 
reduced in 3-NPA treated samples when compared to corresponding carrier controls 
between 25mM and 0.78mM and at 12.2µM. Very little variation in ARNT protein 
levels was visible between 3-NPA treated samples and corresponding carrier controls 
at all other concentrations. 
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Figure 4.11 The effect of different doses of 3-NPA on protein levels. 
 
Hep G2 cells seeded at low density (200 000 cells per well) were treated 24 
hours after seeding with 3-NPA pH 7.6 (+, buffered with NaOH) to final 
concentrations ranging between 12.2μM and 25mM or a corresponding 
carrier control. Whole cell lysates prepared 24 hours after treatment were 
resolved by SDS-PAGE, western blotted and probed with anti HIF-1 
(Novus Biologicals), anti-ARNT (Novus Biologicals) and anti-p53 
antibodies, as indicated. Equal protein loading of membranes was 
determined by Ponceau S staining (data not shown). Mobilities of standard 
proteins are indicated (sections 2.1.1. – 2.1.6). Figure represents one 
experiment (n=1). 
 
Key: 3-NPA, 3-nitropropionic acid; ARNT, Aryl hydrocarbon nuclear translocater; DFO, 
Desferrioxamine; HIF-1α, hypoxia inducible factor 1α; kDa, kilodaltons; mM, millimolar; 
μM, micromolar 
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Due to the variability in ARNT protein levels between 3-NPA treated and carrier 
control treated samples another loading control had to be found. p53 was chosen as a 
loading control because of similarities shared with HIF-1. Both HIF-1 and p53 are 
 173 
predominantly localised in the nucleus of a cell and both proteins are subject to 
ubiquitin mediated proteasomal degradation. p53 protein levels were not affected by 
3-NPA treatment when compared to carrier control treated samples between 25mM 
and 0.78mM. At 12.5mM there appeared to be slightly more p53 protein in the 
carrier control treated sample when compared to the 3-NPA treated sample. This 
difference in protein levels was mirrored in the corresponding ARNT protein levels 
however the fold decrease of ARNT protein between carrier control and 12.5mM 3-
NPA treated samples appeared larger when compared to the fold decrease in p53 
protein levels. Any differences in ARNT protein levels between samples treated with 
concentrations of 3-NPA from 390M downwards, with the exception of 12.2µM, 
and the respective carrier controls were mirrored in the p53 protein levels suggesting 
these variations were dependent on protein content rather than caused by 3-NPA 
treatment. Ponceau S staining of the membranes also confirmed a slight difference in 
protein loading between the samples in question. 
 
The absence of any detectable HIF-1 protein in any of the cell lysates probed 
appeared to indicate that the variability in HIF-1 protein levels observed in previous 
experiments could be due to cell density. However, it is worth noting that less protein 
was loaded on the gel in this experiment than in previous experiments. Therefore, it 
is possible there was too little HIF-1α to be detected by Western blotting. 
 
The results shown in figure 4.11 indicate that the dose of 3-NPA that has the greatest 
knockdown effect on ARNT was 12.5mM. This was the dosage used in previous 
optimisation experiments and mM dosages had also been used by other researchers 
(Wang et al., 2001; Peng and Geddes, 1997). 
 
4.2.5 The effect of 3-NPA and malonate on HIF-1, ARNT, and SDH B protein 
levels. 
 
The change in ARNT protein levels discovered in the dose response experiment 
(section 4.2.4) was an extremely unexpected finding due to all published literature 
showing ARNT to be a constitutively expressed protein except in ARNT null cells 
(Griffiths et al., 2002). The results from the dose response experiment (section 4.2.4) 
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also appeared to confirm the hypothesis that changes in HIF-1 protein levels 
observed in previous may have been influenced by cell density, and thus subject to    
inter-experimental variability due to differences in oxygen diffusion through the 
media, an increase in growth factors in the incubation media or depletion of nutrients 
from the media. 
 
To confirm the observations from figure 4.11 cells were treated with 12.5mM 3-
NPA. Cells were also treated with another inhibitor of SDH, malonate, to determine 
whether the change in ARNT protein levels would be observed with a different 
inhibitor. Hep G2 and T-47D cells were seeded at low density (200 000 cells/well). 
24 hours after seeding cells were treated with either, 12.5mM 3-NPA pH7.6 
(buffered with NaOH), carrier control as previously described, sterile H2O, 12.5 mM 
malonate pH7.4 or carrier control for malonate (media). Whole cell lysates were 
prepared 24 hours after treatment. Lysates were resolved by SDS-PAGE, western 
blotted and probed with anti-HIF-1, anti-ARNT and anti-p53 antibodies as 
indicated (figure 4.12). 
 
HIF-1 protein was detected in 3-NPA and H2O treated Hep G2 cells. No HIF-1 
protein could be detected in T-47D cells treated with 3-NPA. None of the control 
treated samples in either cell type contained any detectable HIF-1 protein. Malonate 
did not appear to induce any up-regulation of HIF-1 protein in either cell type. 
Again, 3-NPA caused a decrease in ARNT protein levels in both Hep G2 and T-47D 
cell types. All other samples from both cell types contained detectable ARNT 
protein. In Hep G2 cells the detectable ARNT protein was seen as multiple bands but 
this was not observed in T-47D cells. These could be due to post-translational 
modifications or antibody recognition of related proteins such as ARNT 2 or ARNT 
3. Whole cell lysates were probed with an anti-p53 antibody to confirm protein 
loading. In cells incubated with media less p53 protein was detected in both cell 
types. The lower amount of protein present was reflected in the ARNT western blot. 
Slightly less p53 was observed in Hep G2 cells incubated with 3-NPA when 
compared to NaCl. This difference was also observed in the ARNT western blot but 
to a much greater extent. T-47D cells treated with 3-NPA had multiple p53 reactive 
bands which were of a lower molecular weight than in control samples. These 
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smaller p53 bands may be due to p53 protein that has not undergone post-
translational modification for example by ubiquitin. 
 
 
Figure 4.12 Treatment of low density Hep G2 and T-47D cells with 3-NPA 
and Malonate. 
 
Hep G2 and T-47D cells seeded at low density (200 000 cells/well) were 
treated 24 hours after seeding with either 3-NPA pH7.6 (buffered with NaOH,) 
to a final concentration of 12.5mM, carrier control (NaCl), sterile H2O, 
malonate pH7.4 to a final concentration of 12.5.mM or carrier control for 
malonate (media). Whole cell lysates prepared 24 hours after treatment were 
resolved by SDS-PAGE, western blotted and probed with anti-HIF-1 (Novus 
Biologicals), anti-ARNT (Novus Biologicals) and anti-p53 antibodies, as 
indicated. A blank lane was introduced between the two different cell lysates (-
).Equal protein loading of the membranes was determined by Ponceau S 
staining (data not shown). Mobilities of standard proteins are indicated 
(sections 2.1.1 – 2.1.6). Figure represents one experiment (n=1). 
 
Key: 3-NPA, 3-nitropropionic acid; ARNT, aryl hydrocarbon receptor nuclear translocator; 
H2O, water; HIF-1α, hypoxia inducible factor 1α; kDa, kilodaltons; NaCl, sodium chloride; 
NaOH, sodium hydroxide. 
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Following this experiment it was decided to concentrate research in Hep G2 cells 
because of the differences in HIF-1 and ARNT protein levels and also because of 
the wild-type p53 content. Pheochromocytoma tumours expressing mutated SDH B 
have so far, not been associated with any mutations in p53 therefore Hep G2 and not 
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T-47D cells may offer a better model for chemical SDH B inhibition due to their 
wild-type p53 status. 
 
To confirm the Hep G2 results observed in figure 4.12 the above experiment was 
repeated solely in Hep G2 cells. Whole cell lysates, prepared 24 hours after treatment 
were resolved by SDS-PAGE, western blotted and probed with anti HIF-1, anti 
ARNT and anti-p53 antibodies (figure 4.13). To confirm that the HIF-1 and ARNT 
results were not due to some form of protein modification at the site of antibody 
binding, alternative antibodies were employed that recognised distinct epitopes on 
the two proteins. Figures 4.7 -4 .12 utilised antibodies from Novus Biologicals that 
recognised HIF-1 amino acid residues 432-528 and ARNT amino acid residues 
496-789. The BD Biosciences antibodies used in figure 4.13 recognised HIF-1 
amino acid residues 610-727 and ARNT amino acid residues 461-574. DFO treated 
Hep G2 cell lysate was used as a positive control for HIF-1 identification (figure 
4.13).  
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Figure 4.13 The effect of 3-NPA and malonate treatment on low density 
Hep G2 cells. 
 
Hep G2 cells seeded at low density (200 000 cells/well) were treated 24 hours 
after seeding with either 3-NPA pH7.6 (buffered with NaOH,) to a final 
concentration of 12.5mM, carrier control (NaCl), sterile H2O, malonate pH7.4 
to a final concentration of 12.5.mM or carrier control for malonate (media). 
Whole cell lysates prepared 24 hours after treatment. As a positive control for 
HIF-1-α protein detection Hep G2 whole cell lysates were prepared six hours 
after treatment with either DFO (+) to a final concentration of 100M or 
carrier control (-) as indicated. Whole cell lysates were resolved by SDS-
PAGE, western blotted and probed with anti-HIF-1 (BD Biosciences), anti-
ARNT (BD Biosciences) and anti-p53 antibodies as indicated.. Protein loading 
of the membranes was determined by Ponceau S staining (data not shown). 
Mobilities of standard proteins are indicated (sections 2.1.1 – 2.1.6). Figure 
represents one experiment (n=1) 
 
Key: 3-NPA, 3-nitropropionic acid; ARNT, aryl hydrocarbon receptor nuclear translocator; 
DFO, desferrioxamine; H2O, water; HIF-1α, hypoxia inducible factor 1α; kDa, kilodaltons; 
NaCl, sodium chloride; NaOH, sodium hydroxide. 
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Cells treated with 3-NPA showed an increase in HIF-1 protein when compared to 
NaCl. Malonate did not induce any detectable HIF-1 protein. No HIF-1 protein 
was detected in either H2O or media treated samples. ARNT protein was detectable 
in all samples except cells treated with 3-NPA where no ARNT protein was detected 
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(fig. 4.13). Protein loading was confirmed by probing samples with an anti-p53 
antibody (figure 4.13). 
 
Independent experiments using antibodies with distinct epitopes confirmed the 
reduction of ARNT protein levels in cells treated with 3-NPA. No constitutive HIF-
1 expression was detected in multiple samples in repeated experiments on low 
density Hep G2 cultures except if treated with 3-NPA. This confirmed the possibility 
that high cell density was capable of inducing HIF-1 accumulation. 3-NPA 
treatment of Hep G2 cells induced a clear accumulation of HIF-1 protein, relative 
to p53 protein. Malonate treatment resulted in no appreciable difference in protein 
levels. 
 
4.2.6 Time course of the effect of 3-NPA treatment on HIF-1 and ARNT protein 
levels. 
 
The increase in HIF-1 protein and the decrease in ARNT protein observed in 
previous experiments could have been due to two distinct pathways. To determine 
whether the two phenomena were coincident, or one happened before the other and 
therefore might be causal of the other a time-course of 3-NPA treatment of Hep G2 
cells was performed. 24 hours after seeding at low density (200 000 cells/well) a 
whole cell lysate of untreated cells was prepared. Remaining cells were treated 24 
hours after seeding with either 12.5mM 3-NPA pH 7.6, DFO to a final concentration 
of 100M or respective carrier controls for each chemical. Whole cell lysates were 
prepared at 1, 3, 8 and 24 hours after treatment. Lysates were resolved by SDS-
PAGE, western blotted and probed with anti-HIF-1, anti ARNT and anti-p53 
antibodies (figure 4.14). A repeat of the above experiment was performed to confirm 
the results obtained (figure 4.15). 
 
No HIF-1 protein could be detected in any sample at 0 or 1 hours in either 
experiment (figures 4.14 and 4.15). At 3 hours no HIF-1 could be detected in any 
sample in figure 4.14. This observation was confirmed in figure 4.15 except for DFO 
treated cells. At 8 hours HIF-1 protein could only be detected in cells treated with 
DFO in figure 4.14 however, figure 4.15 showed elevated levels of HIF-1 protein in 
 179 
3-NPA and DFO treated cells when compared to the relevant controls. Both figures 
showed elevated levels of HIF-1 protein in 3-NPA and DFO treated cells when 
compared to relevant controls at 24 hours. ARNT protein could be detected in all 
samples at 0, 1 and 3 hours for both experiments. At 8 and 24 hours, in both 
experiments there was a noticeable reduction in ARNT protein in cells treated with 
3-NPA when compared to NaCl treated cells. The elevated HIF-1 and reduced 
ARNT protein levels were not due to a difference in protein loading between samples 
as indicated by the level of p53 protein present in each sample. Even protein loading 
was also confirmed by Ponceau S staining of the membranes. 
 
The chemical treatment of Hep G2 cells with an SDH inhibitor was intended to 
create a model for succinate dehydrogenase mutations in pheochromocytoma 
tumours. The published literature so far has only identified mutations in SDH B or 
SDH D that pre-dispose an individual to pheochromocytoma tumour development. It 
was therefore of interest to determine whether chemical inhibitors of SDH had any 
effect on SDH B protein levels. The effect on SDH D protein levels could not be 
investigated due to the lack of a commercially available antibody. Samples from 
figure 4.15 were additionally probed with an anti-SDH B antibody. No change in 
SDH B protein levels was observed in any sample at any time-point therefore SDH B 
seemed to be a suitable as a second loading control. 
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Figure 4.14 The effect of 3-NPA treatment of Hep G2 cells on HIF-1 
and ARNT protein levels at different time points. 
 
Hep G2 cells were seeded at low density (200 000 cells/well). 24 hours 
after seeding cells were either left untreated and lysed (0hr) or treated with 
12.5mM 3-NPA pH7.6 (buffered with NaOH, 3-NPA), 100M DFO 
(DFO) or their respective carrier controls (NaCl or media). Whole cell 
lysates for each treatment were prepared at the time points indicated above. 
Lysates were resolved by SDS-PAGE, western blotted and probed with anti 
HIF-1 (BD Biosciences), anti ARNT (BD Biosciences) and anti-p53 
antibodies. Membranes were Ponceau S stained to determine protein 
loading (data not shown). Mobilities of standard proteins are indicated 
(sections 2.1.1 -2.1.6). Figure represents one expermiment (n=1). 
 
Key: 3-NPA, 3-nitropropionic acid; ARNT, aryl hydrocarbon receptor nuclear 
translocator; DFO, desferrioxamine; H2O, water; HIF-1α, hypoxia inducible factor 1α; hrs, 
hours; kDa, kilodaltons; NaCl, sodium chloride; NaOH, sodium hydroxide. 
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Figure 4.15 Repeated time-course of the effect of 3-NPA treatment of 
Hep G2 cells on HIF-1 and ARNT protein levels  
 
Hep G2 cells were seeded at low density (200 000 cells/well). 24 hours 
after seeding cells were either left untreated and lysed (0hr) or treated with 
12.5mM 3-NPA pH7.6 (buffered with NaOH, 3-NPA), 100M DFO 
(DFO) or their respective carrier controls (NaCl or media). Whole cell 
lysates for each treatment were prepared at the time points indicated above. 
Lysates were resolved by SDS-PAGE, western blotted and probed with anti 
HIF-1 (BD Biosciences), anti ARNT (BD Biosciences) and anti-p53 
antibodies. Membranes were Ponceau S stained to determine protein 
loading (data not shown). Mobilities of standard proteins are indicated 
(sections 2.1.1 -2.1.6). Figure represents one experiment (n=1). 
 
Key: 3-NPA, 3-nitropropionic acid; ARNT, aryl hydrocarbon receptor nuclear 
translocator; DFO, desferrioxamine; H2O, water; HIF-1α, hypoxia inducible factor 1α; hrs, 
hours; kDa, kilodaltons; NaCl, sodium chloride; NaOH, sodium hydroxide; SDH B, 
succinate dehydrogenase B. 
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Figures 4.14 and 4.15 indicated that p53 protein levels remained relatively constant 
at each time-point irrespective of the imposed treatment conditions. SDH B protein 
levels also remained unchanged at each time-point irrespective of the treatment cells 
were subjected to. ARNT protein levels remained constant in all samples between 0 
and 3 hours however at 8 and 24 hours protein levels fell in cells subjected to 3-NPA 
treatment but remained constant in control and DFO treated samples (figures 4.14 
and 4.15). HIF-1 protein levels were more un-predictable, in figure 4.14, HIF-1 
protein could be detected in samples treated with DFO at 8 hours yet in figure 4.15, 
HIF-1 was clearly detected in DFO treated cells at 3 hours. HIF-1 was detected in 
samples treated with 3-NPA at 24 hours in figure 4.14 but at the earlier time-point of 
8 hours in figure 4.15. The detection of HIF-1 in samples treated with 3-NPA 
always happened at the time-point following HIF-1 detection in DFO treated cells 
(figure 4.14 and 4.15) suggesting that DFO acts more quickly than 3-NPA.  Figure 
4.15 showed the elevation of HIF-1 protein levels and the disappearance of ARNT 
protein levels occurring at the same time-point however this was not the case in 
figure 4.14. The discrepancy between the time-courses with regard to the time at 
which HIF-1 protein levels became elevated and ARNT protein levels reduced 
made interpretation of any putative relations between the respective pathways 
involved difficult to determine. 
 
4.2.7 The effect of 3-NPA treatment of Hep G2 cells on the transcriptional activity 
of an HRE driven transcription reporter gene. 
 
HIF-1, a heterodimer comprised of the subunits HIF-1 and ARNT, is known to 
drive the hypoxia responsive transcription of genes containing an HRE promoter, 
only when both subunits are present. To determine whether the increase in HIF-1 
protein levels and decrease in ARNT protein levels caused by the treatment of Hep 
G2 cells with 3-NPA could affect the transcription of hypoxia responsive genes, a 
transcription reporter assay was utilised. Hep G2 cells, seeded at low density (100 
000 cells/well), were transfected in triplicate 24 hours after seeding with either test 
plasmid, SV40 control plasmid or CMV control plasmid (pGL3prevPGK, 
pGL3control or pCMVluc, respectively, as described in sections 2.1.12 and 3.3.5). 
All wells were also co-transfected with a plasmid expressing Renilla luciferase (pRL-
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SV40), as an internal control to normalise transfection efficiencies. 48 hours after 
seeding cells were treated with 12.5mM 3-NPA pH 7.6, 3-NPA carrier control 
(NaCl), 100M DFO or DFO carrier control (media). Cells were lysed 72 hours after 
seeding/24 hours after chemical treatment. Cell lysates were assayed for firefly 
luciferase activity and corrected against Renilla luciferase activity (figure 4.16). 
 
Figure 4.16 shows the results from two independent experiments. The treatment of 
cells with DFO was used as a positive control for HRE dependent transcription of a 
luciferase reporter gene. In both experiments DFO treated cells (yellow) exhibited a 
strong HRE dependent expression of the luciferase reporter gene when compared to 
control treated cells (green). The experiment represented in the upper panel of figure 
4.16 showed a 42 fold-induction of HRE dependent luciferase expression in cells 
treated with DFO when compared to control treated cells. The second experiment 
(figure 4.16, lower panel) showed a 19 fold induction for the same treatments. Very 
little fold induction of HRE dependent luciferase expression was observed in the 
upper panel of figure 4.16 when 3-NPA treated cells (blue) were compared to NaCl 
treated cells (purple) however a 3 fold induction was seen in the lower panel.  
 
There was no significant difference in relative luciferase ratios between treatments in 
cells transfected with SV40 control in one experiment (figure 4.16, upper panel). The 
repeat experiment (lower panel) showed an increase in the relative luciferase ratio 
value for cells treated with 3-NPA when compared to NaCl and in cells treated with 
DFO when compared to media however the fold inductions of these increase were 
negligible.  
 
CMV promoter driven luciferase reporter gene transcription (CMV control) was 
elevated in DFO treated cells when compared to carrier control in both experiments 
although the fold induction was less than two in both cases. This mimicked the 
results observed in DFO cells transfected with the test plasmid. Cells treated with 3-
NPA demonstrated an almost 2 fold reduction of the transcription of the luciferase 
reporter gene under control of the CMV promoter when compared to carrier control 
in both experiments.  
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Figure 4.16 HIF responsive transcriptional reporter assays of 3-NPA 
treated Hep G2 cells. 
 
Hep G2 cells seeded at low density (100 000 cells/well) were transfected in 
triplicate 24 hours after seeding with test (HRE) , SV40 control or CMV control 
plasmids (sections 2.1.12 and 3.3.5). All wells were also co-transfected with a 
plasmid expressing Renilla luciferase (pRL-SV40). 24 hours after transfection 
cells were treated with 12.5mM 3-NPA pH 7.6 (buffered with NaOH, blue), 
carrier control for 3-NPA (NaCl, purple), 100M DFO (yellow) or DFO carrier 
control (media, green). Whole cell lysates were prepared 24 hours after 
chemical treatment (72 hours after seeding). Lysates were assayed for firefly 
luciferase activity and corrected against Renilla luciferase activity to normalise 
for transfection efficiencies using the Dual-luciferase reporter assay system 
(Promega, section 2.1.13). Results shown are from two independent 
experiments (n=2). Error bars are  S.D. 
 
Key: 3-NPA, 3-nitropropionic acid; CMV, cytomegalovirus; DFO, desferrioxamine; 
HIF, hypoxia inducible factor; HRE, hypoxia responsive element; NaCl, sodium 
chloride; NaOH, sodium hydroxide; S.D., Standard Deviation 
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ARNT and HIF-1 are subunits that comprise HIF-1 and both must be present for 
transcriptional activation. The depletion of ARNT protein levels by 3-NPA treatment 
of cells, as previously demonstrated (figures 4.10 - 4.15, inclusive), was expected to 
abrogate the transcriptional activation of a HRE dependent luciferase reporter gene. 
However, the three fold induction of an HRE dependent luciferase reporter gene in 
cells treated with 3-NPA when compared to NaCl contradicts this hypothesis (figure 
4.16, lower panel). One possibility for this contradiction is the observation in 3-NPA 
time-course studies that 3-NPA induced HIF-1α protein levels before ARNT protein 
levels were fully depleted (figures 4.14 and 4.15). Therefore, if 3-NPA induced HIF-
1α protein levels before ARNT protein levels were depleted in cells transfected with 
an HRE dependent luciferase reporter gene, then a low level of transcription would 
occur as shown in figure 4.16. 
 
4.2.8 The effect of 3-NPA on DFO treated Hep G2 cells. 
 
In order to further explore the outcome of ARNT depletion by 3-NPA, experiments 
were carried out to assess whether 3-NPA depletes ARNT in DFO-induced Hep G2 
cells. Hep G2 cells were seeded at low density (200 000 cells/well). 24 hours after 
seeding cells were left untreated or treated with; carrier controls for 3-NPA (NaCl) 
and DFO (media), 100M DFO and 3-NPA carrier control, 12.5mM 3-NPA pH 7.6 
and DFO carrier control or 12.5mM 3-NPA pH 7.6 and 100M DFO. Whole cell 
lysates were prepared 24 hours after treatment. Lysates were resolved by SDS-
PAGE, western blotted and probed with anti-HIF-1, anti-ARNT, anti-p53, anti 
SDH-B and anti-PTEN antibodies (figure 4.17).  
 
No detectable HIF-1 protein was present in untreated cells or cells treated with 
carrier controls only in either experiment. Cells treated with 3-NPA and media 
contained a small amount of detectable HIF-1 protein when compared to cells 
treated with DFO and NaCl or cells treated with 3-NPA and DFO. The largest 
amount of detectable HIF-1 was observed in cells treated with DFO and NaCl. The 
effect of 3-NPA on the induction of HIF-1 by DFO appeared to be one of 
suppression, because visibly less HIF-1 protein was detectable in cells treated with 
3-NPA and DFO than those treated with NaCl and DFO (figure 4.17). ARNT protein 
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was detectable in all cells except those treated with 3-NPA. Equal protein loading 
was confirmed by Ponceau S staining and as an additional control by probing 
western blots with anti-p53. Equal protein loading of the membranes was obtained in 
the second experiment (figure 4.17, right hand panel) however less protein was 
present in samples treated with 3-NPA and media in the first experiment (figure 4.17 
left hand panel). This reduction in protein was not observed in western blots probed 
with an anti-SDH B antibody as an additional loading control. In both experiments 
the levels of protein detected using an anti-SDH B antibody is lower in cells treated 
with chemicals i.e. 3-NPA and DFO when compared to untreated cells or cells 
treated with controls (media and NaCl). 
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Figure 4.17 The effect of 3-NPA on protein levels in DFO treated  
Hep G2 cells. 
 
Hep G2 cells seeded at low density (200 000 cells/well) were either left 
untreated 24 hours after seeding or were treated with carrier controls (NaCl 
and media), 12.5 mM 3-NPA pH7.6 and DFO carrier control (3-NPA and 
media), 100M DFO and 3-NPA carrier control (DFO and NaCl) or 12.5mM 
3-NPA pH7.6 and 100M DFO (3-NPA and DFO). Whole cell lysates were 
prepared 24 hours after treatment, resolved by SDS-PAGE, western blotted 
and probed with anti HIF-1 (BD Biosciences), anti-ARNT (BD 
Biosciences), anti-p53, anti-SDH B and anti-PTEN antibodies. Membranes 
were Ponceau S stained to determine protein loading. Mobilities of standard 
proteins are indicated. Each panel of western blots represents an independent 
experiment (n=2). 
 
Key: 3-NPA, 3-nitropropionic acid; ARNT, aryl hydrocarbon receptor nuclear translocator; 
DFO, desferrioxamine; HIF-1α, hypoxia inducible factor 1α; kDa, kilodaltons; NaCl, 
sodium chloride; NaOH, sodium hydroxide; PTEN, phosphatase and tensin homologue 
deleted on chromosome ten; SDH B, succinate dehydrogenase B. 
 
To determine whether the reduction in ARNT protein levels resulting from 3-NPA 
treatment was solely restricted to the nucleus whole cell lysates were resolved by 
SDS-PAGE, western blotted and probed with an anti-PTEN antibody (figure 4.17). 
The cellular localisation of PTEN is cell type dependent, for instance in epithelial 
cells such as those of skin, colon and breast the majority of PTEN is localised in the 
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cytoplasm. In contrast, neurons and fibroblasts have a high proportion of PTEN 
localised in the nucleus. No published literature was available about the cellular 
localisation of PTEN in hepatoma cells. However, PTEN is involved in the 
PI3K/AKT pathway which occurs at the plasma membrane. This involves at least a 
small proportion of PTEN protein being localised to the plasma membrane 
(Reviewed by Sulis and Parsons. 2003). PTEN protein was detected in control 
samples and in cells treated with DFO and NaCl but no protein was detected in cells 
treated with 3-NPA and media or with 3-NPA and DFO. This finding paralleled the 
results observed for ARNT protein levels. 
 
A transcription reporter assay was utilised to determine whether the apparent 
differences in HIF-1 and ARNT protein levels observed between control samples 
and samples treated with DFO and 3-NPA (figure 4.17) could result in a change in 
the transcriptional response of a firefly luciferase reporter gene under the control of 
an HRE containing promoter. Hep G2 cells were seeded at low density (100 000 
cells/well). 24 hours after seeding cells were transfected in triplicate with test 
plasmid, SV40 control plasmid or CMV control plasmid (pGL3prevPGK, 
pGL3control or pCMVluc, respectively, section 2.1.12). All wells were co-
transfected with a plasmid expressing Renilla luciferase (pRL-SV40), as an internal 
control to normalise transfection effieciencies. 48 hours after seeding (24 hours after 
transfection) cells were either left untreated or treated with NaCl (3-NPA carrier 
control) and media (DFO carrier control), 12.5mM 3-NPA pH 7.6 (buffered with 
NaOH) and media, 100M DFO and NaCl or 12.5mM 3-NPA pH 7.6 and 100M 
DFO. Whole cell lysates were prepared 24 hours after treatment (72 hours after 
seeding) and assayed for firefly luciferase activity before correction against Renilla 
luciferase activity (figure 4.18 which shows the results of two independent 
experiments).  
 
Hep G2 cells were treated with DFO and NaCl as a positive control for HRE 
responsive luciferase expression (yellow). In both experiments, Hep G2 cells treated 
with DFO and NaCl induced luciferase expression compared with carrier controls 
(blue). The experiment represented in the upper panel if figure 4.18 showed a 37 fold 
induction of HRE dependent luciferase expression in cells treated with DFO and 
NaCl when compared to control treated cells (media and NaCl). The second 
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experiment showed a 33 fold induction for the same treatments (figure 4.18, lower 
panel). However, cells treated with DFO and 3-NPA (green) exhibited a twofold 
reduction and a 19 fold reduction in the level of luciferase expression when 
compared with the DFO and NaCl treated cells, indicating 3-NPA was affecting the 
DFO response in Hep G2 cells treated with both chemicals (figure 4.18 upper and 
lower panels, respectively). In both experiments cells treated with DFO and NPA 
exhibited a higher level of expression of a HRE dependent luciferase reporter gene 
than when compared to 3-NPA and media (burgundy). 
 
Cells transfected with SV40 control did not exhibit any significant difference in 
luciferase reporter gene transcription between samples, in the first experiment (figure 
4.18, upper panel). The repeat experiment showed a reduction in the relative 
luciferase ratio value for cells treated with DFO and 3-NPA when compared to media 
and NaCl, media and NPA and NaCl and DFO. However, in all cases this fold 
reduction was less than two.  
 
The CMV control plasmid results exhibited the same luciferase expression pattern to 
those of the test plasmid samples (figure 4.18) except for the NaCl: DFO sample in 
the second experiment (figure 4.18, lower panel). The difference in results between 
the independent experiments with regard to cells treated with NaCl and DFO in the 
CMV control sample is difficult to account for.  
 
However, results from these experiments indicated that NPA appears to have the 
ability to reduce HRE dependent luciferase expression, which if HIF related, could 
indicate that SDH inhibition via depletion of ARNT inhibits HIF function. 
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Figure 4.18 The effect of 3-NPA on the DFO induced transcriptional 
response of a firefly luciferase reporter gene. 
 
Hep G2 cells seeded at low density (100 000 cells/well) were transfected 
in triplicate 24 hours after seeding with a test (HRE), SV40 control or 
CMV control plasmid. All wells were co-transfected with a plasmid 
expressing Renilla luciferase (pRL-SV40). 24 hours after transfection 
cells were treated with media and NaCl (carrier controls for DFO and 3-
NPA respectively, blue bars), 12.5mM 3-NPA pH7.6 and media (purple 
bars), 100M DFO and NaCl (yellow bars) or 12.5mM 3-NPA pH 7.6 
and 100M DFO (green bars). Whole cell lysates were prepared 24 hours 
after chemical treatment. Lysates were assayed for firefly luciferase 
activity and corrected against Renilla luciferase activity to normalise for 
transfection efficiencies using the Dual-luciferase reporter assay system 
(Promega, section 2.1.13). Results shown are from two independent 
experiments (n=2). Error bars are  S.D.  
 
Key: 3-NPA, 3-nitropropionic acid; CMV, cytomegalovirus; DFO, desferrioxamine; 
HIF, hypoxia inducible factor; HRE, hypoxia responsive element; NaCl, sodium 
chloride; NaOH, sodium hydroxide; S.D., Standard Deviation 
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4.2.9 The effect of 3-NPA treatment on membrane permeability. 
 
3-NPA treatment of Hep G2 cells caused a reduction in the detectable level of ARNT 
and PTEN. To determine whether the selective loss of these proteins was due to the 
cell membrane becoming compromised, cells were incubated with trypan blue, a dye 
used to distinguish the permeability of cell membranes. Non-permeable cell 
membranes result in non-stained cells and permeable membranes result in stained 
cells. Hep G2 cells were treated 24 hours after seeding at low density (200 000 
cells/well) with either 12.5mM 3-NPA pH7.6 or carrier control (NaCl). Adherent and 
non-adherent cells were stained in trypan blue and counted in triplicate at 0 hours 
(untreated cells) and 1, 3, 8 and 24 hours after treatment (figure 4.19). 
 
There was a progressive difference in total cell counts (i.e. adherent, non-adherent, 
non-permeable and permeable cell counts combined) between control (light blue) 
and 3-NPA (burgundy) treated cells after 3 hours. At 24 hours there was a greater 
than 2 fold difference in total cell count between carrier control treated cells and 3-
NPA treated cells. This difference was paralleled in adherent non-permeable cells 
where there was a greater than 2 fold difference between control and 3-NPA treated 
cells (figure 4.19, light yellow and light green bars, respectively). The proportion of 
adherent permeable cells was very low whatever the treatment.  Very little difference 
in cell number was observed between control treated adherent permeable cells 
(purple bars) and 3-NPA treated adherent permeable cells (salmon bars) at any time-
point (figure 4.19). The amount of non-adherent cells was less than 1% of the total 
cell count under all circumstances. There were no statistically significant differences 
between permeable adherent or non-adherent cell counts whatever the treatment.  
 
These results indicated that 3-NPA did not appear to have an effect on cell 
membrane permeability when compared to control treated cells. 3-NPA appeared to 
arrest Hep G2 proliferation when compared to control treated cells. This arrest of 
proliferation by 3-NPA coupled with depleted ARNT and PTEN protein levels may 
indicate a novel 3-NPA mode of action. 
 192 
 
-1
0
0
0
0
00
1
0
0
0
0
0
2
0
0
0
0
0
3
0
0
0
0
0
4
0
0
0
0
0
5
0
0
0
0
0
6
0
0
0
0
0
0
1
3
8
2
4
T
im
e 
(h
o
u
rs
)
Cell number
T
o
ta
l 
u
n
tr
ea
te
d
 c
el
ls
U
n
tr
ea
te
d
 a
d
h
er
en
t 
N
P
U
n
tr
ea
te
d
 a
d
h
er
en
t 
P
U
n
tr
ea
te
d
 n
o
n
-a
d
h
er
en
t
N
P
U
n
tr
ea
te
d
 n
o
n
-a
d
h
er
en
t
P T
o
ta
l 
ce
ll
s 
C
o
n
tr
o
l
T
o
ta
l 
ce
ll
s 
3
-N
P
A
C
o
n
tr
o
l 
ad
h
er
en
t 
N
P
3
-N
P
A
 a
d
h
er
en
t 
N
P
C
o
n
tr
o
l 
ad
h
er
en
t 
P
3
-N
P
A
 a
d
h
er
en
t 
P
C
o
n
tr
o
l 
n
o
n
-a
d
h
er
en
t 
N
P
 
3
-N
P
A
 n
o
n
-a
d
h
er
en
t 
N
P
C
o
n
tr
o
l 
n
o
n
-a
d
h
er
en
t 
P
3
-N
P
A
 n
o
n
-a
d
h
er
en
t 
P
F
ig
u
re
 4
.1
9
 T
h
e 
ef
fe
ct
 o
f 
3
-N
P
A
 o
n
 H
ep
G
2
 c
el
l 
m
e
m
b
ra
n
e 
p
e
r
m
ea
b
il
it
y
.
H
ep
G
2
 c
el
ls
 s
ee
d
ed
 a
t 
lo
w
 d
en
si
ty
 (
2
0
0
 0
0
0
 c
el
ls
/w
el
l)
 w
er
e 
tr
ea
te
d
 2
4
 h
o
u
rs
 a
ft
er
 s
ee
d
in
g
 w
it
h
 
ei
th
er
 
1
2
.5
m
M
 
3
-N
P
A
 
p
H
 
7
.6
 
(b
u
ff
er
ed
 
w
it
h
 
N
aO
H
) 
o
r 
ca
rr
ie
r 
co
n
tr
o
l 
(N
aC
l)
. 
In
 
tr
ip
li
ca
te
 
ad
h
er
en
t 
an
d
 n
o
n
-a
d
h
er
en
t 
ce
ll
s 
w
er
e 
in
cu
b
at
ed
 w
it
h
 t
ry
p
an
b
lu
e 
an
d
 c
o
u
n
te
d
 a
t 
0
 (
u
n
tr
ea
te
d
 c
el
ls
) 
1
, 
3
, 
8
 
an
d
 
2
4
 
h
o
u
r 
ti
m
e-
p
o
in
ts
 
fo
r 
co
n
tr
o
l 
an
d
 
3
-N
P
A
 
as
 
in
d
ic
at
ed
. 
U
n
st
ai
n
ed
 
ce
ll
s 
w
er
e 
co
n
si
d
er
ed
 n
o
n
-p
er
m
ea
b
le
 (
P
) 
an
d
 s
ta
in
ed
 c
el
ls
 c
o
n
si
d
er
ed
 p
er
m
ea
b
le
 (
P
).
 T
o
ta
l 
ce
ll
s 
(b
la
ck
, 
li
la
c 
an
d
 o
ra
n
g
e 
b
ar
s)
 e
n
co
m
p
as
s 
al
l 
ad
h
er
en
t 
an
d
 n
o
n
-a
d
h
er
en
t 
co
u
n
ts
 f
o
r 
ea
ch
 t
re
at
m
en
t.
 
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
2
.
3
.
4
.
1
.
-1
0
0
0
0
00
1
0
0
0
0
0
2
0
0
0
0
0
3
0
0
0
0
0
4
0
0
0
0
0
5
0
0
0
0
0
6
0
0
0
0
0
0
1
3
8
2
4
T
im
e 
(h
o
u
rs
)
T
o
ta
l 
u
n
tr
ea
te
d
 c
el
ls
U
n
tr
ea
te
d
 a
d
h
er
en
t 
N
P
U
n
tr
ea
te
d
 a
d
h
er
en
t 
P
U
n
tr
ea
te
d
 n
o
n
-a
d
h
er
en
t
N
P
U
n
tr
ea
te
d
 n
o
n
-a
d
h
er
en
t
P T
o
ta
l 
ce
ll
s 
C
o
n
tr
o
l
T
o
ta
l 
ce
ll
s 
3
-N
P
A
C
o
n
tr
o
l 
ad
h
er
en
t 
N
P
3
-N
P
A
 a
d
h
er
en
t 
N
P
C
o
n
tr
o
l 
ad
h
er
en
t 
P
3
-N
P
A
 a
d
h
er
en
t 
P
C
o
n
tr
o
l 
n
o
n
-a
d
h
er
en
t 
N
P
 
3
-N
P
A
 n
o
n
-a
d
h
er
en
t 
N
P
C
o
n
tr
o
l 
n
o
n
-a
d
h
er
en
t 
P
3
-N
P
A
 n
o
n
-a
d
h
er
en
t 
P
F
ig
u
re
 4
.1
9
 T
h
e 
ef
fe
ct
 o
f 
3
-N
P
A
 o
n
 H
ep
G
2
 c
el
l 
m
e
m
b
ra
n
e 
p
e
r
m
ea
b
il
it
y
.
H
ep
G
2
 c
el
ls
 s
ee
d
ed
 a
t 
lo
w
 d
en
si
ty
 (
2
0
0
 0
0
0
 c
el
ls
/w
el
l)
 w
er
e 
tr
ea
te
d
 2
4
 h
o
u
rs
 a
ft
er
 s
ee
d
in
g
 w
it
h
 
ei
th
er
 
1
2
.5
m
M
 
3
-N
P
A
 
p
H
 
7
.6
 
(b
u
ff
er
ed
 
w
it
h
 
N
aO
H
) 
o
r 
ca
rr
ie
r 
co
n
tr
o
l 
(N
aC
l)
. 
In
 
tr
ip
li
ca
te
 
ad
h
er
en
t 
an
d
 n
o
n
-a
d
h
er
en
t 
ce
ll
s 
w
er
e 
in
cu
b
at
ed
 w
it
h
 t
ry
p
an
b
lu
e 
an
d
 c
o
u
n
te
d
 a
t 
0
 (
u
n
tr
ea
te
d
 c
el
ls
) 
1
, 
3
, 
8
 
an
d
 
2
4
 
h
o
u
r 
ti
m
e-
p
o
in
ts
 
fo
r 
co
n
tr
o
l 
an
d
 
3
-N
P
A
 
as
 
in
d
ic
at
ed
. 
U
n
st
ai
n
ed
 
ce
ll
s 
w
er
e 
co
n
si
d
er
ed
 n
o
n
-p
er
m
ea
b
le
 (
P
) 
an
d
 s
ta
in
ed
 c
el
ls
 c
o
n
si
d
er
ed
 p
er
m
ea
b
le
 (
P
).
 T
o
ta
l 
ce
ll
s 
(b
la
ck
, 
li
la
c 
an
d
 o
ra
n
g
e 
b
ar
s)
 e
n
co
m
p
as
s 
al
l 
ad
h
er
en
t 
an
d
 n
o
n
-a
d
h
er
en
t 
co
u
n
ts
 f
o
r 
ea
ch
 t
re
at
m
en
t.
 
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
2
.
3
.
4
.
1
.
 193 
4.2.10 The effect of lactacystin, a proteasomal inhibitor, on the 3-NPA induced 
disappearance of detectable ARNT protein levels. 
 
The discovery that 3-NPA did not affect cell membrane permeability appeared to 
infer that the selective loss of ARNT and PTEN was occurring via some other 
process. Due to the involvement of proteasomal degradation in the HIF pathway, an 
experiment was performed to determine whether 3-NPA induced ARNT suppression 
was due to a similar process. Lactacystin, a proteasomal inhibitor was used at a 
concentration of 20M based on experiments performed by Salceda and Caro (1997). 
Hep G2 cells were treated 24 hours after seeding at low density (200 000 cells/well) 
with either 12.5mM 3-NPA pH 7.6 (buffered with NaOH) or carrier control (NaCl). 
Treated cells were co-incubated with either 20M lactacystin or lactacystin carrier 
control (SF media). Whole cell lysates were prepared 8 hours after incubation (the 
earliest time-point of ARNT disappearance observed). Whole cell lysates were 
resolved by SDS-PAGE, western blotted and probed with anti-HIF-1, anti-ARNT, 
anti-p53 and anti SDH B antibodies (figure 4.20).  
 
If lactacystin was successfully inhibiting proteasomal degradation, HIF-1 protein 
levels would have been expected to increase when cells were treated with lactacystin 
however, this did not occur in cells treated with NaCl and lactacystin. Hep G2 cells 
treated with 3-NPA and lactacystin showed elevated levels of detectable HIF-1 
protein compared to 3-NPA treated cells without lactacystin or NaCl treated cells 
with or without lactacystin (figure 4.20). 3-NPA has been shown to increase 
detectable HIF-1 protein levels in previous experiments, this was not the case in 
cells treated with 3-NPA without lactacystin. The increase in HIF-1 protein levels 
observed between cells treated with 3-NPA with or without lactacystin could solely 
be due to the action of lactacystin or, the combined effect of 3-NPA and lactacystin. 
 
 194 
  
Figure 4.20 The effect of the proteasomal inhibitor 
lacatcystin on 3-NPA induced ARNT disappearance. 
 
Hep G2 cells were treated 24 hours after seeding at low 
density (200 000 cells/well) with 12.5mM 3-NPA pH 7.6 
(buffered with NaOH) or carrier control (NaCl). Treated 
cells were co-incubated with either 20M lactacystin (+) 
or carrier control (-) as indicated. Whole cell lysates 
prepared after 8 hours were resolved by SDS-PAGE, 
western blotted and probed with anti-HIF-1 (BD 
Biosciences), anti-ARNT (BD Biosciences), anti-p53 and 
anti-SDH B antibodies, as indicated. Membranes were 
Ponceau S stained to confirm protein loading. Mobilities 
of standard proteins are indicated. Figure represents an 
independent experiment (n=1). 
 
Key: 3-NPA, 3-nitropropionic acid; ARNT, aryl hydrocarbon 
receptor nuclear translocator; HIF-1α, hypoxia inducible factor-1α 
kDa, kilodaltons; NaCl, sodium chloride; NaOH, sodium hydroxide; 
SDH B, succinate dehydrogenase B. 
250kDa
98kDa
HIF-1
Lactacystin ++ --
NaCl 3-NPA
30kDa
SDH B
50kDa
p53
98kDa ARNT
 
Whole cell lysates were also probed with an anti-p53 antibody to determine whether 
lactacystin was active under these conditions. p53 is targeted for ubiquitin mediated 
proteasomal degradation by the binding of Hdm2 (Giaccia and Kastan., 1998). The 
effect of a proteasomal inhibitor would be to prevent p53 degradation. In cells treated 
with NaCl without lactacystin higher molecular weight protein species, possibly 
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representing ubiquitin modified p53, could be observed above the 50kDa standard 
protein marker. In cells treated with NaCl and lactacystin these species were more 
prominent. p53 was detectable in cells treated with 3-NPA, however higher 
molecular weight p53 species were only detected in cells not treated with 3-NPA, 
which suggests that the action of 3-NPA was affecting p53 ubiquitination in some 
way (figure 4.20).  
 
No appreciable change in ARNT protein levels in response to lactacystin could be 
detected relative to SDHB and overall protein levels which were detected by 
Ponceau S staining (figure 4.20). Treatment of Hep G2 cells with 3-NPA caused the 
complete disappearance of detectable ARNT protein levels and lactacystin had no 
effect on this disappearance. This data suggested the selective loss of ARNT was not 
due to proteasomal degradation of the protein. 
 
4.2.11 The effect of 3-NPA treatment on ARNT, PTEN and SDH B protein levels 
in PC12 cells. 
 
The chemical inhibition model used to determine the effects of SDH mutation in 
pheochromocytoma was developed in Hep G2 cells (sections 4.2.2 – 4.2.10). The 
Hep G2 cell line is derived from a hepatoma, therefore results observed in previous 
experiments may be specific to this cell type. To determine whether the results 
observed in Hep G2 cells were representative, experiments were performed in PC12 
cells, a rat pheochromocytoma cell line. PC12 pheochromocytoma cells were not 
used in the development of the chemical inhibition model due to the lack of a 
commercially available HIF-1 antibody that could recognise rat protein.  
 
PC12 cells were either left untreated or treated with 12.5mM 3-NPA pH 7.6 
(buffered with NaOH), NaCl (carrier control for 3-NPA), 100M DFO or media 
(DFO carrier control) 24 hours after seeding (200 000 cells/well). 24 hours after 
treatment whole cell lysates were prepared and resolved by SDS-PAGE, western 
blotted and probed with anti-ARNT, anti-PTEN and anti-SDH B antibodies (figure 
4.21). 
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Figure 4.21 The effect of 3-NPA treatment on PC12 cells. 
 
PC12 cells were seeded at low density (200 000 cells/well). 24 hours after 
seeding cells were left untreated or were treated with 12.5mM 3-NPA pH 7.6 
(buffered with NaOH), NaCl (3-NPA carrier control), 100M DFO or media 
(DFO carrier control). Whole cell lysates prepared 24 hours after treatment 
were resolved by SDS-PAGE, western blotted and probed with anti-ARNT 
(BD Biosciences), anti-PTEN and anti-SDH B antibodies, as indicated. 
Membranes were Ponceau S stained to confirm protein loading. Mobilities of 
standard proteins are indicated. Left and right-hand panels represent two 
independent experiments (n=2; sections 2.1.1 -2.1.6). 
 
Key: 3-NPA, 3-nitropropionic acid; ARNT, aryl hydrocarbon receptor nuclear translocator; 
DFO, desferrioxamine; kDa, kilodaltons; NaCl, sodium chloride; NaOH, sodium hydroxide; 
PTEN, phosphatase and tensin homologue deleted on chromosome 10; SDH B, succinate 
dehydrogenase B. 
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Anti-HIF-1 and anti-p53 antibodies were not reactive with rat proteins and 
therefore were not used. 3-NPA treatment of PC12 cells resulted in a noticeable 
reduction of ARNT and PTEN protein levels in the first experiment (figure 4.21, left 
hand panel) but in the repeat experiment (right hand panel) no reduction was 
observed when compared to all other treatments. Equal protein loading of the 
membranes was confirmed by probing samples with an anti-SDH B antibody and by 
Ponceau S staining of the membranes (figure 4.21). 
 
The lack of consistency from PC12 experiments made the results difficult to 
interpret. The first experiment seemed to suggest that 3-NPA mediated ARNT and 
PTEN loss was not Hep G2 specific but this was contradicted by the second 
experiment, due to an unknown variable of cell culture. From previous experiments it 
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was known 3-NPA mediated ARNT loss was not Hep G2 specific as ARNT loss was 
also observed in T-47D cells (figure 4.12). 
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4.3 The effect of RNAi inhibition of SDH B on HIF-1α protein 
function 
 
4.3.1 siRNA design 
 
To determine whether the 3-NPA mediated up-regulation of HIF-1 and down-
regulation of ARNT reflects the regulatory effects in tumours, a specific means of 
targeting SDH was employed in the form of RNA interference. The best cell system 
in which to study a model of SDH B inhibition would have been a well characterised 
pheochromocytoma cell line. The only cell line available that fitted this criterion was 
the rat pheochromocytoma cell line, PC12. At the time of designing the SDH B 
targeting siRNAs no SDH B mRNA or cDNA sequences for rat were available and 
the only commercial SDH B and HIF-1α antibodies had no specificity for rat protein. 
Therefore RNA interference experiments were performed in Hep G2 cells. This also 
provided continuity between the chemical inhibition model of SDH, where the 
majority of experiments were performed in Hep G2 cells, and the more specific RNA 
interference model which targeted SDH B.  
 
An SDH B siRNA sequence was designed following the recommendations of 
Elbashir et al (2002) to target a 19 nucleotide sequence in human SDH B mRNA. 
This sequence corresponded to base pairs 362-384 of the human mRNA sequence 
(accession number gi22043306). The SDH B sense and anti-sense and control sense 
and anti-sense siRNAs were analysed using the Basic Local Alignment Search Tool 
(BLAST) at the National Center for Biotechnology Information (NCBI). The non-
redundant (nr) and human expressed sequence tags (EST) databases were searched 
using blastn for nucleotide sequences that were a similar or exact match to the 
control and SDH B siRNA sequences. The SDH B targeting siRNA was only 
homologous to Homo sapiens SDH B mRNA. There was no similarity to any other 
Homo sapiens mRNA. The control siRNA did not show 100% identity to any other 
human mRNA. 
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4.3.2. Oligofectamine mediated transfection of Hep G2 cells 
 
Hep G2 cells were utilised in all experiments in this section for continuity purposes 
(section 4.2.5, paragraph 4 explains the reasons behind the original decision to use 
Hep G2 cells). 
 
To determine whether Hep G2 cells could be transfected using Oligofectamine, cells 
were seeded at low density (100 000 cells/well). 24 hours after seeding, cells were 
transfected with oligofectamine only, FITC labelled DNA oligonucleotide (FITC-
DNA) or FITC-DNA and oligofectamine. Cells were photographed by light 
microscopy, in a random field of view, 24 hours after transfection (figure 4.22 panels 
A, C and E).The same field of view was subjected to fluorescence microscopy and 
images were constructed after 400 integrations (figure 4.22 panels B, D and F). No 
fluorescence could be detected in Hep G2 cells transfected with oligofectamine only 
or FITC-DNA only. Almost 100% of Hep G2 cells, transfected with oligofectamine 
and FITC-DNA retained fluorescence, showing the protocol for siRNA transfection 
already in existence was likely to be suitable for Hep G2 siRNA transfection. 
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A B 
C D 
E F 
Figure 4.22. Oligofectamine mediated transfection of Hep G2 cells with a 
FITC labelled DNA oligonucleotide. 
 
Hep G2 cells were seeded 100 000 cells/well. 24 hours after seeding cells 
were transfected with oligofectamine only (A and B), FITC labelled DNA 
oligonucleotide only (C and D) or FITC DNA oligonucleotide and 
oligofectamine (E and F). Cells were visualised 24 hours after transfection by 
light microscopy in a random field of view and photographed (A, C and E). 
This field of view was then subjected to fluorescence microscopy. Images 
were constructed after 400 integrations (B, D and F). Magnification 100. 
Figure represents one experiment. 
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To determine whether Hep G2 cells could be transfected with duplexed siRNA, Hep 
G2 cells were seeded at low density (100 000 cells/well). 24 hours after seeding cells 
were transfected with oligofectamine only, a Cy3 labelled siRNA duplex (Cy3-
siRNA) only or oligofectamine and Cy3-siRNA. 24 hours after transfection cells 
were visualised in a random field of view by light microscopy and photographed 
(figure 4.23 panels A, C and E). The same field of view was subjected to 
fluorescence microscopy and photographed after 200 integrations of the image at 
100X magnification (figure 4.23 panels B, D and F).No fluorescence could be 
detected in cells transfected with oligofectamine only (figure 4.23 panel B). 
Fluorescence was observed in Hep G2 cells transfected with Cy3-siRNA only and 
Hep G2 cells transfected with oligofectamine and Cy3 (figure 4.23 panels D and F, 
respectively). Cy3-siRNA appears to have a level of background fluorescence that is 
exhibited in Hep G2 cells transfected with Cy3-siRNA only (figure 4.23 D). This 
could be due to the Cy3-siRNA being internalised by Hep G2 cells without the 
presence of transfection reagent. It is also possible that the Cy3-siRNA was sticking 
to the cell membrane. However, the intensity of fluorescence, as observed by the 
naked eye, is more intense in Hep G2 cells transfected with Cy3-siRNA and 
oligofectamine (figure 4.23 F). 
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A B 
C D 
E F 
Figure 4.23 Oligofectamine mediated transfection of Hep G2 cells with a 
Cy3 labelled siRNA duplex.  
 
Hep G2 cells were seeded 100 000 cells/well. 24 hours after seeding cells 
were transfected with oligofectamine only (A and B), Cy3 labelled siRNA 
duplex only (C and D) or Cy3 labelled siRNA duplex and oligofectamine (E 
and F). 24 hours after transfection cells were visualised by light microscopy 
in a random field of view and photographed (A, C and E). This field of view 
was then subjected to fluorescence microscopy and images were compiled 
after 200 integrations (B, D and F). Magnification X100. Figure represents 
one experiment. 
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4.3.3 Optimisation of RNA interference targeted towards SDH B. 
 
To determine the amount of siRNA that would give the best knockdown of SDH B 
protein, several optimisation experiments were carried out in a similar manner. Hep 
G2 cells were seeded at low density (100 000 cells/well). 24 hours after seeding each 
well was transfected with either control or SDH B siRNA in the amounts indicated in 
figure 4.24. 24 hours after the first transfection cells were either re-transfected with 
the same concentrations of appropriate siRNA or lysed in 2X SDS-PAGE loading 
buffer. Cells were also lysed 24 and 48 hours after the second transfection. Whole 
cell lysates were resolved by SDS PAGE, western blotted and probed with an anti-
SDH B antibody (figure 4.24). 
 
The preliminary optimisation experiment showed all four amounts of SDH B siRNA 
reduced the detectable amount of SDH B protein 24 hours after the first transfection, 
and 24 and 48 hours after the second transfection when compared to the relevant 
control lanes (figure 4.24 panels A-C, respectively). Densitometry of these results 
indicated that in all cases SDH B protein levels were reduced in cells treated with 
SDH B targeting siRNA. The maximum percentage reduction in SDH B protein 
levels was 62.2% and this was achieved 24 hours after the second transfection in 
cells targeted with 120nmol SDH B siRNA when compared to control targeted cells. 
Cells targeted with 240nmol SDH B siRNA at the same time point showed a similar 
level of SDH B protein reduction – 61.8% when compared to cells targeted with  
control siRNA. At 48 hours after the second transfection cells targeted with 120nmol 
or 240nmol SDH B siRNA still exhibited the highest percentage knockdown of SDH 
B protein when compared to control targeted cells, 46.1% and 50.7%, respectively, 
but percentage knockdown achieved 48 hours after the second transfection of 
siRNAs was not to the same level as observed at 24 hours post second transfection. 
48 hours after the second transfection, samples from cells targeted with 120nmol, 
240nmol or 360nmol SDH B siRNA appeared to produce a similar suppression of 
SDH B protein when compared to relevant control samples (figure 4.24, panel C). 
Densitometry of these results indicated that the maximum level of reduction in SDH 
B protein was achieved at each time point by cells targeted with 120nmol or 
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240nmol of SDH B siRNA. The maximum knockdown of SDH B protein was 62.2% 
in cells targeted with 120nmol of occurred 24 hours after the second transfection of 
SDH B siRNA. A second experiment was carried out to confirm SDH B protein 
suppression in Hep G2 cells using 120nmol SDH B siRNA (figure 4.24 panel D). 
However, SDH B protein suppression in this experiment was not as pronounced as in 
the preliminary optimisation experiment (figure 4.24 panels A-C). Densitometry of 
the results showed the maximum knockdown of SDH B protein 24 hours after the 
second transfection was 26.3% and at 48 hours the maximum knockdown was 
59.5%. However, at 48 hours after the second transfection this level of knockdown 
was not consistent in both SDH B targeted samples. This could be due to the 
combined effects of transfection efficiency and the transient nature of RNA 
interference. Therefore, a final optimisation experiment was carried out to determine 
which of either 120nmol or 240nmol SDH B siRNA provided the largest suppression 
of SDH B protein. p53 was used a protein loading control for this experiment (figure 
4.24 panels E to J).This experiment clearly indicated that both amounts of SDH B 
targeting siRNA were capable of suppressing SDH B protein levels when compared 
to their respective controls. However, 48 hours after the second transfection, the level 
of SDH B protein suppression was more pronounced in samples treated with 
240nmol SDH B siRNA. Densitometry of the results showed 48 hours after the 
second transfection of SDH B siRNA that the percentage knockdown of SDH B 
protein was 44% for 120nmol and 46.9% for 240nmol. Based on these experiments 
240nmol SDH B siRNA was utilised in further experiments. 
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Figure 4.24 Optimisation of SDH B targeted RNA interference. 
 
Hep G2 cells seeded at low density (100 000 cells/well) were transfected 
consecutively, 24 hours (all panels) and 48 hours (B-E, Fand H-K) after 
seeding with control or SDH B siRNA in the amounts indicated (control –C, 
SDH B - S). Whole cell lysates were prepared 24 hours after the first 
transfection (A, E and F) and 24 hours (B, D, and G-J) and 48 hours after the 
second transfection (C, D, I and J) were resolved by SDS-PAGE, western 
blotted and probed with an anti-SDH B antibody or anti-p53 antibody as 
indicated. Mobilities of standard proteins are indicated. Detection of p53 was 
as a loading control but equal protein loading was also determined by 
Ponceau S staining of the membranes. Figure shows all data from three 
independent experiments (A-C (n=1); D (n=1) and E-J (n=1).  
 
Key: C, control siRNA targeted; kDa, kilodaltons; nmol, nanomoles; S, SDH B siRNA 
targeted; SDH B, succinate dehydrogenase; siRNA, small interfering siRNA. 
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4.3.4 The effect of siRNA targeted SDH B suppression on HIF-1, ARNT and p53. 
 
To determine the effect of SDH B suppression on HIF-1α, ARNT and p53 protein 
levels, Hep G2 cells were seeded at low density (100 000 cells/well). In consecutive 
transfections 24 and 48 hours after seeding, cells were transfected with either control 
or SDH B targeting siRNA. Whole cell lysates prepared 24 hours and 48 hours after 
the second transfection of siRNAs were resolved by SDS-PAGE, western blotted and 
probed with anti-SDH B, anti-p53, anti-ARNT and anti-HIF-1 antibodies. Equal 
protein loading of the membrane was determined by Ponceau staining (figure 4.25). 
 
Probing samples with an anti-SDH B antibody confirmed SDH B targeting siRNAs 
knocked down the level of SDH B protein 24 and 48 hours after the second 
transfection when compared with relevant controls (figure 4.25 as indicated). 
Ponceau staining of the membrane confirmed the decrease in SDH B protein levels 
24 and 48 hours after the second transfection were not due to un-equal protein 
loading or transfer. Probing with an anti-ARNT antibody (figure 4.25 as indicated) 
showed no change in ARNT protein levels between samples treated with control or 
SDH B targeting siRNA at either time-point. At both the 24 hour and 48 hour after 
second transfection time-points, HIF-1 protein could be detected in control samples 
although the level of HIF-1 detection was variable. No HIF-1 protein could be 
detected in corresponding SDH B targeted samples. DFO treated Hep G2 cells were 
used as a positive control for detection of HIF-1 protein levels. No change in p53 
protein levels could be detected between SDH B targeted or control targeted samples 
at either 24 or 48 hours after the second transfection. 
 
 207 
 
Figure 4.25 The effect of SDH B suppression on ARNT and HIF-1 protein 
levels. 
 
Hep G2 cells seeded at low density (100 000 cells/well) were transfected 
consecutively, 24 and 48 hours after seeding with 120nmol of either control (C) 
or SDH B (S) targeting siRNA. Whole cell lysates, prepared 24 and 48 hours 
after the second siRNA transfection were resolved by SDS-PAGE, western 
blotted and probed with anti-SDH B anti-p53, anti-ARNT (BD Biosciences) and 
anti-HIF-1 (BD Biosciences) antibodies as indicated. Mobilities of standard 
proteins are indicated. 
As a positive control for the identification for HIF-1α protein Hep G2 cells were 
treated with DFO to a final concentration of 100M. 6 hours after treatment 
whole cell lysates were prepared. Figure representative of two independent 
experiments (n=2; repeat data shown in figure 4.26). 
 
Key: ARNT, Aryl hydrocarbon nuclear translocator; C, Control; DFO, desferrioxamine; HIF-1α, 
hypoxia inducible factor 1α; kDa, kilodaltons; S, cells transfected with SDH B siRNA; SDH B, 
succinate dehydrogenase B. 
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Repetition of the experiment confirmed the results observed in figure 4.25 (figure 
4.26). Densitometry of these results indicated that SDH B protein was reduced by 
49.9% in SDH B targeted cells when compared to control targeted cells 24 hours 
after the second transfection. 48 hours after the second transfection SDH B protein 
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was reduced by 78.9% in cells targeted with SDH B siRNA when compared to cells 
targeted with control siRNA (figure 4.26). To determine that apparent SDH B 
knockdown was not due to a difference in protein loading, membranes were Ponceau 
stained. As in the previous experiment (figure 4.25) western blotting whole cell 
lysates and probing with either an anti-p53 antibody or an anti-ARNT antibody 
(figure 4.26 as indicated) showed no difference in protein levels between SDH B 
targeted or control targeted cells. HIF-1 protein can be clearly detected in control 
samples at 24 and 48 hours after the second transfection, however in SDH B targeted 
cells little or no HIF-1 protein could be detected (figure 4.26 as indicated).  
 
Figures 4.25 and 4.26 conclusively indicated the effectiveness of the SDH B 
targeting siRNA at knocking down SDH B protein levels. Probing samples with an 
anti-p53 antibody confirmed the observed SDH B protein knockdown was not due to 
unequal protein loading of the membranes. The knockdown of SDH B protein did 
not affect ARNT protein levels, in clear contrast to the result of 3-NPA treatment. 
The apparent decrease of HIF-1 protein levels in SDH B targeted samples also 
contrasted with the result of 3-NPA treatment.  
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Figure 4.26 A repeat experiment to determine the effect of 
SDH B suppression on ARNT and HIF-1 protein levels. 
 
Hep G2 cells seeded at low density (100 000 cells/well) were 
transfected consecutively, 24 and 48 hours after seeding with 
either control (C) or SDH B (S) targeting siRNA. Whole cell 
lysates, prepared 24 and 48 hours after the second siRNA 
transfection were resolved by SDS-PAGE, western blotted and 
probed with anti-SDH B anti-p53, anti-ARNT (BD 
Biosciences) and anti-HIF-1 (BD Biosciences) antibodies as 
indicated. Mobilities of standard proteins are indicated. Figure 
represents two indenpent experiments (n=2; repeat data shown 
in figure 4.25) 
 
Key: ARNT, Aryl hydrocarbon nuclear translocator; C, Control; HIF-1α, 
hypoxia inducible factor 1α; kDa, kilodaltons; S, cells transfected with SDH 
B siRNA; SDH B, succinate dehydrogenase B. 
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4.3.5 The effect of siRNA transfection on Hep G2 growth rate 
 
HIF-1 protein levels are affected by increasing cell density (Sheta et al., 2001). To 
determine whether the apparent down-regulation of HIF-1 protein levels in SDH B 
targeted cells was due to a difference in growth rate between control and SDH B. 
siRNA targeted cells, Hep G2 cells were seeded at low density and transfected as 
previously described. Three wells for each test condition were counted at 24, 48, 72 
and 96 hours after seeding. These time-points correspond to consecutive 
transfections 24 and 48 hours after seeding. 72 hours corresponds to 24 hours after 
the second transfection in western blot figures and 96 hours corresponds to 48 hours 
after the second transfection in western blot figures. The average cell number for 
each condition was plotted and standard deviation determined. Figure 4.27 shows 
two representative experiments. Both experiments indicated that there was no 
significant difference in growth rate between control siRNA and SDH B siRNA 
targeted Hep G2 cells. The results of both experiments were tested for statistical 
significance at the 96 hour time point using a two-tailed T-test. The p values were 
0.26 (figure 4.27, upper panel) and 0.15 (figure 4.27, lower panel). For any 
differences observed between samples to be generally deemed to be statistically 
significant p 0.05; therefore there was no significant difference between the 
proliferation in control or SDH B targeted cells. These results indicated that the 
effect of cell confluence on HIF-1 protein levels was not a contributing factor 
towards the differences in HIF-1 protein levels observed between control and SDH 
B targeted cells. 
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Figure 4.27 Cell proliferation curves of Hep G2 cells transfected 
with control or SDH B siRNAs. 
 
Hep G2 cells seeded at low density (100 000 cells/well) were 
transfected 24 and 48 hours after seeding with control (blue) or SDH B 
targeting siRNA (pink). Three wells for each test condition were 
counted at 24, 48, 72 and 96 hours after seeding. The average cell 
number for each condition was plotted and standard deviation 
determined. Data shown is for two independent experiments (n=2). 
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4.3.6 The effect of SDH B suppression on the transcriptional activity of an HRE 
driven transcription reporter gene. 
 
To determine whether the decrease in HIF-1 protein levels in cells targeted with 
SDH B siRNA could cause a difference in the transcription of hypoxia responsive 
genes, a transcription reporter assay was used. Hep G2 cells seeded at low density 
(100 000 cells/well) were transfected in triplicate 24 hours after seeding with either 
control or SDH B targeting siRNA. Cells were co-transfected with an SV40 control 
plasmid, a CMV control plasmid or a test plasmid (pGL3 control, pCMVluc or 
pGL3prevPGK, respectively). All wells were also co-transfected with a plasmid 
expressing Renilla luciferase (pRL-SV40), as an internal control to normalise 
transfection efficiencies (These plasmids have been described previously in sections 
2.1.12 and 3.4.5). 48 hours after seeding Hep G2 cells were transfected in triplicate 
with either control or SDH B targeting siRNA. 72 hours after seeding cells were 
lysed. Cell lysates were analysed for firefly luciferase activity and corrected against 
Renilla luciferase activity to normalise transfection efficiencies. Figure 4.28 shows 
the results from three independent experiments. In two of the three experiments, Hep 
G2 cells transfected with a control siRNA induced more HRE dependent 
transcription of the luciferase reporter gene (test [HRE]) than Hep G2 cells 
transfected with SDH B targeting siRNA (figures 4.28 inset charts, upper and central 
panels). These results when taken on their own correspond with the HIF-1α 
expression data observed in figure 4.26, namely that SDH B targeting siRNA reduces 
both HIF-1α protein expression and HRE dependent transcription of a luciferase 
reporter plasmid when compared with the respective controls. However, although the 
luciferase reporter assay results when taken on their own appear significant, this 
significance is lost when compared with the control plasmid results. In all three 
experiments SDH B targeting siRNA suppressed the level of luciferase expression in 
Hep G2 cells transfected with SV40 control and CMV control when compared with 
control siRNA samples. In all instances the level of luciferase expression is greater in 
cells transfected with siRNA and control plasmid when compared to cells transfected 
with siRNA and test (HRE) plasmid. The observation that the pattern of luciferase 
expression in cells transfected with control luciferase reporter genes exactly mimics 
that of the test luciferase reporter gene makes these results difficult to interpret. 
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Figure 4.28 Transcriptional reporter assay of siRNA transfected Hep G2 cells. 
 
Hep G2 cells seeded at low density (100 000 cells/well) were transfected in triplicate 24 
hours after seeding with 240nmol of either control or SDH B targeting siRNA. Hep G2 
Cells were co-transfected with 1μg of either pGL3prevPGK, pGL3control or pCMVluc. 
All wells were co-transfected with 0.02μg pRL-SV40. 48 hours after seeding cells were 
transfected with 240nmol of control (purple) or SDH B siRNA (blue). 72 hours after 
seeding whole cell lysates were prepared in passive lysis buffer. Lysates were assayed 
for firefly luciferase activity and corrected against Renilla luciferase activity to 
normalise transfection efficiencies. Inset panels (*) represent pGL3prevPGK results on a 
larger scale. Results shown are from three independent experiments (n=3). Error bars 
are  S.D. 
Key: CMV, cytomegalovirus: HRE, hypoxia responsive element; r0, SDH B, succinate dehydrogenase B. 
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4.3.7 The effect of SDH B suppression on GLUT-1 protein levels and HIF-1 
mRNA levels. 
 
Due to the difficulty in interpreting the data from figure 4.28 an alternative means of 
inferring the transcriptional activity of HIF was to investigate the protein level of a 
downstream target in the hypoxia pathway. GLUT-1 is a protein up-regulated when 
there is an increase in active HIF-1 due to the presence of an HRE near the promotor 
of the gene that encodes for GLUT-1. Hep G2 cells were seeded at low density (100 
000 cells/well). 24 hours after seeding cells were transfected with either control or 
SDH B targeting siRNA. Transfection was repeated 48 hours after seeding. Whole 
cell lysates prepared 24 hours and 48 hours after the second transfection of siRNA 
(72 and 96 hours after seeding) were resolved by SDS-PAGE, western blotted and 
probed with anti-SDH B, anti-p53, anti-HIF-1 and anti-GLUT-1 antibodies (figure 
4.29, as indicated).  
 
As observed in previous experiments SDH B targeting knocked down the level of 
SDH B protein 24 and 48 hours after the second transfection when compared to 
control targeted samples. Probing membranes with an anti-p53 antibody confirmed 
equal protein loading. HIF-1 protein was undetectable in cells targeted with SDH B 
siRNA when compared to control targeted samples at 48 hours after the second 
transfection. Probing samples with an anti-GLUT-1 antibody revealed no change in 
GLUT-1 protein levels between samples targeted with SDH B or control siRNAs 
with the exception of one sample targeted with SDH B siRNAs 48 hours after the 
second transfection. This apparent decrease in GLUT-1 protein was accompanied by 
a moderate increase in p53 protein levels that had not been observed in any previous 
experiments (figure 4.29, as indicated). All samples contained multiple anti-GLUT-1 
reactive bands indicating GLUT-1 protein may undergo some form of post-
transcriptional modification for example, phosphorylation.  
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Figure 4.29 The effect of SDH B suppression on GLUT-1 protein 
levels. 
 
Hep G2 cells seeded at low density (100 000 cells/well) were transfected 
24 and 48 hours after seeding with 120nmol of either control (C) or SDH B 
(S) targeting siRNA. Whole cell lysates prepared 24 and 48 hours after the 
second transfection were resolved by SDS-PAGE, western blotted and 
probed with anti- SDHB, anti-p53, anti-HIF-1 (BD Biosciences) and anti-
GLUT-1 antibodies, as indicated. The mobilities of standard proteins are 
indicated. Figure represents one experiment (n=1). 
 
Key: C, Control; GLUT-1;glucose transporter-1; HIF-1α, hypoxia inducible factor 1α; 
kDa, kilodaltons; nmol, nanomoles; S, cells transfected with SDH B siRNA; SDH B, 
succinate dehydrogenase B. 
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A repeat experiment was performed to determine whether the slight suppression in 
GLUT-1 protein levels in one SDH B targeted sample could be replicated (figure 
4.30). As observed in previous experiments SDH B targeting knocked down the level 
of SDH B protein 24 and 48 hours after the second transfection when compared to 
control targeted samples. Probing membranes with anti-p53 and and anti-ARNT 
antibodies confirmed equal protein loading. HIF-1 protein was undetectable in cells 
targeted with SDH B siRNA when compared to control targeted samples at both 24 
and 48 hours with the greatest level of HIF-1 suppression observed at 48 hours after 
the second transfection. Due to a lack of HIF-1α protein induction at 24 hours in the 
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first experiment (figure 4.29), HIF-1 levels were only suppressed in SDH B 
targeted samples 48 hours after the second transfection. Probing samples with an 
anti-GLUT-1 antibody revealed there was no apparent difference in GLUT-1 protein 
levels in SDH B targeted cells when compared to control targeted cells 24 hours after 
the second transfection (figure 4.30 as indicated). This concurred with the results 
observed in figure 4.29. GLUT-1 levels were elevated in control targeted cells when 
compared to SDH B targeted cells 48 hours after the second transfection, and also 
elevated compared with the control targeted cells 24 hours earlier (figure 4.30).  
 
This result was not in agreement with the result obtained in figure 4.29 where control 
levels were not elevated. The apparent delay before GLUT-1 protein levels became 
elevated 48 hours after the second transfection could have been due to a requirement 
for a certain threshold level of HIF-1 protein, HIF-1α protein modification or simply 
the time taken for HIF-1 nuclear translocation. If a threshold level of HIF-1 protein 
were required for induction of GLUT-1 expression, this may explain the absence of 
elevated GLUT-1 levels in figure 4.29.  
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Figure 4.30 A repeat experiment to determine the effect of SDH 
B suppression on GLUT-1 protein levels.  
 
Hep G2 cells seeded at low density (100 000 cells/well) were 
transfected 24 and 48 hours after seeding with 120nmol of either 
control (C) or SDH B (S) targeting siRNA. Whole cell lysates 
prepared 24 and 48 hours after the second transfection were 
resolved by SDS-PAGE, western blotted and probed with anti- 
SDHB, anti-p53, anti-HIF-1 (BD Biosciences) and anti-GLUT-1 
antibodies, as indicated. The mobilities of standard proteins are 
indicated. Figure represents one experiment (n=1). 
 
Key: C, Control; GLUT-1;glucose transporter-1; HIF-1α, hypoxia inducible 
factor 1α; kDa, kilodaltons; nmol, nanomoles; S, cells transfected with SDH B 
siRNA; SDH B, succinate dehydrogenase B. 
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To determine whether the suppression of HIF-1 protein levels by SDH B targeting 
siRNA was due to a reduction in HIF-1 mRNA levels an RT-PCR was performed 
on parallel samples to those analysed in figure 4.30. Total RNA was extracted 24 and 
48 hours after the second transfection, DNase digested and subjected to reverse 
transcription with or without reverse transcriptase. The resulting cDNA was 
amplified by PCR using exon/intron spanning primers specific for HIF-1 mRNA 
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and -actin mRNA that yielded 462 bp and 486bp PCR products, respectively. H2O 
was amplified as a control for contamination (figure 4.31). 
 
 
500bp
400bp
462bp HIF-1
RT-PCR 
product
400bp
500bp
600bp 486bp -actin
RT-PCR 
product
Reverse 
Transcriptase
--------+ + + + + + + + H 2
O
C S
Targeting 
siRNA C S CC SS CC SS C C S S
Hours post 
second 
transfection
24 2448 48
Figure 4.31 The effect of SDH B suppression on HIF-1 and -actin 
mRNA levels. 
 
Hep G2 cells seeded at low density (100 000) cells per well were transfected 
24 and 48 hours after seeding with 120nmol of either control or SDH B 
targeting siRNA. Cells were lysed 24 and 48 hours after the second siRNA 
transfection. Cell lysates were DNase digested and RNA was purified using a 
Qiagen RNeasy kit, as indicated. 1μg of total RNA was transcribed with (+) or 
without (-) reverse transcriptase and subjected to PCR with HIF-1 or -actin 
primers as indicated. A negative control PCR reaction was undertaken for each 
primer set (H2O). PCR products were resolved by agarose gel electrophoresis 
and visualised under ultra violet light. Molecular weight markers are indicated. 
Figure represents one experiment (n=1). 
 
Key: bp, base pairs; C, control siRNA; H2O, water;  HIF-1α, Hypoxia inducible factor-1α; RT-
PCR, reverse transcriptase- polymerase chain reaction; S, SDHB siRNA; SDH B, succinate 
dehydrogenase B. 
 
HIF-1 product and -actin product were detected in both control and SDH B 
targeted cells employing RNA subjected to reverse transcription with reverse 
transcriptase. RNA extracted from a control targeted sample 24 hours after the 
second transfection did not amplify with HIF-1 primers. No detectable HIF-1 
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product was observed in samples reversed transcribed without reverse transcriptase 
or in the H2O control lane. In reverse transcriptase negative samples amplified with 
-actin primers a product was visualised in all lanes except a control targeted sample 
lane 24 hours after the second transfection and an SDH B targeted sample lane 48 
hours after the second transfection. These bands were not caused by contamination 
because no detectable DNA was observed in the H2O control lane. The -actin 
product visible in reverse transcriptase negative lanes could be caused by a 
pseudogene. Incomplete DNAse digestion of the DNA encoding the pseudogene 
could allow amplification, revealing the product bands observed in the reverse 
transcriptase negative -actin lanes. Alternatively, total RNA in reverse transcriptase 
negative samples could be reverse transcribed by Taq and then amplified. Reverse 
transcription by Taq has been reported and reverse transcriptase independent RT-
PCR of a subset of RNA sequences has been observed previously (Grabko et al., 
1996; M R Crompton pers. commun). The variation observed in HIF-1 mRNA 
levels between control and SDH B samples 48 hours after the second transfection 
was also observed in -actin mRNA indicating the quality of the RNA was the 
probable cause of the variability. These results confirm that SDH B targeting siRNAs 
do not have an off target effect resulting in HIF-1α mRNA degradation. The 
variability in the data was probably due to the small number of cells employed in this 
experiment. More quantitative analysis of any changes in mRNA levels would 
require an alternative approach, for instance employing quantitative PCR assays or 
more cells per assay (for example by the establishment of cell lines with constitutive 
siRNA expression). 
 
4.3.8 The effect of SDH B suppression on SDH A. 
 
Mutations that prevent the translation of SDH B or mutations that are predicted to 
alter the folding of SDH B are predicted to destabilise the SDH complex 
(Yankovskaya et al., 2003). Not only would these mutations abrogate the catalytic 
activity of SQR but they would also prevent the binding of SDH A, because SDH A 
itself does not bind to the anchoring subunits SDH C and D. If SDH B binding was 
essential for SDH A protein stability, then suppression of SDH B could perhaps 
result in the degradation of SDH A. To test this hypothesis whole cell lysates 
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prepared in 4.3.7 (figure 4.30) were resolved by SDS-PAGE, western blotted and 
probed with anti SDH A and anti-ARNT antibodies (figure 4.32, as indicated). To 
enable the loading control to be on the same blot as SDH A, ARNT was used instead 
of p53. Figure 4.29 indicates there is no difference in ARNT protein levels between 
control and SDH B targeted samples. The same figure also shows no difference in 
protein loading between p53 and ARNT. These observations justify the use of ARNT 
as a loading control. 
 
 
Figure 4.32 The effect of SDH B suppression on SDH A. 
 
Hep G2 cells were seeded at low density (100 000) cells/well. 24 and 48 hours 
after seeding cells were transfected with 240nmol control (C) or SDH B (S) 
targeting siRNA. Whole cell lysates prepared 24 and 48 hours after the final 
transfection were resolved by SDS-PAGE, western blotted and probed with 
anti-SDH A and anti-ARNT (BD Biosciences) antibodies, as indicated. 
Mobilities of standard proteins are indicated. Data represents on experiment 
(n=1). 
 
Key: ARNT, Aryl hydrocarbon nuclear translocator; C, Control; kDa, kilodaltons; S, cells 
transfected with SDH B siRNA; SDH A, succinate dehydrogenase A; SDH B, succinate 
dehydrogenase B. 
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There was no appreciable difference in SDH A protein levels between control 
targeted and SDH B targeted samples at 24 or 48 hours after the second transfection. 
Probing samples with an anti-ARNT antibody confirmed equal protein loading of the 
membrane. These results indicated that SDH A protein was not degraded in samples 
that had knocked down SDH B protein levels. The nature of RNA interference is to 
produce a knockdown phenotype rather than a knockout phenotype. In these 
experiments complete suppression of SDH B was never achieved, therefore, it is 
possible that the remaining SDH B protein binds the SDH A protein present in 
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mitochondria and therefore no change in SDH A protein levels is observed. It is also 
possible that suppression of SDH B results in unbound SDH A that is not subject to 
targeted degradation in its un-complexed form. This would also explain why no 
changes in SDH A protein levels were observed between control and SDH B targeted 
samples. 
 
4.4 Discussion 
 
The hypothesis outlined in section 4.1.6 stated that the inhibition of SDH would 
result in an up-regulation of HIF-1 protein levels followed by an increase in HIF-1 
transcriptional activation of target genes. The aim was to determine whether 
pharamacological inhibition in the form of 3-NPA would support the hypothesis and 
then to verify the findings using a more targeted approach in the form of RNA 
interference. Results obtained using 3-NPA mediated inhibition supported the 
hypothesis (figures 4.12 - 4.15). However, siRNA mediated inhibition of SDH B 
contradicted the 3-NPA data (figures 4.25 – 4.26 and 4.29 – 4.30).  
 
4.4.1 Differences and similarities between pharmacological inhibition and siRNA 
mediated knockdown. 
 
One possible explanation for the differing results observed between cells treated with 
3-NPA (pharmacological inhibition) and those subjected to RNA interference 
mediated silencing of SDH B is the method by which inhibition or knockdown is 
achieved. Although the aim of both strategies is the same – to perturb the function of 
a target protein, the methodology is not. Pharmacological inhibition abrogates the 
function of the target protein but the protein itself is still present. This means that the 
target protein although lacking in activity can potentially still bind to binding 
partners or be incorporated into complexes. If the target proteins incorporation into a 
protein complex is also important for its biological activity, this could still take place 
if only the protein enzymic activity has been perturbed. In contrast, RNA 
interference mediated knockdown targets the mRNA of the protein of interest 
resulting in knockdown of mRNA and hence protein level. If enzymic activity and 
incorporation into a protein complex are important for protein function both will be 
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abrogated by RNA interference mediated knockdown compared to just enzymic 
activity by a pharmacological inhibitor (Weiss et al., 2007). 
 
Both inhibition and knockdown can result in off target effects. 3-NPA for example is 
a relatively simple molecule (figure 4.6) and it is possible that the function of other 
proteins could be inhibited by 3-NPA treatment of Hep G2 cells. Microarray analysis 
of RNA interference first identified that siRNAs were capable of silencing 
unintended targets as well as the original target (Jackson et al., 2003). siRNAs can 
also result in up-regulation of Type I interferons and cytokines, proteins which can 
lead to inflammation in vivo (Samuel-Abraham and Leonard., 2010). It is possible, 
given the outdated methodology of siRNA design used in these studies that siRNA 
mediated interference of SDH B could have resulted in unintended off target effects 
(discussed in section4.4.5). Taking into account the disparity in results between 3-
NPA inhibition of SDH and siRNA mediated suppression of SDH B and the 
differences between the two methods of inhibition/knockdown, the results obtained 
are discussed separately. 
 
4.4.2 3-NPA suppresses ARNT and PTEN protein levels 
 
3-NPA mediated the suppression of ARNT and PTEN protein levels in Hep G2 and 
PC12 cells, indicating this was not a cell type specific response (figures 4.17 and 
4.21 left hand panel, respectively). ARNT and PTEN protein levels were also 
suppressed by 3-NPA in the presence of DFO. Treatment of Hep G2 cells with 3-
NPA and lactacystin, a proteasomal inhibitor, confirmed the suppression of ARNT 
protein levels was not due to ubiquitin mediated proteasomal degradation, suggesting 
ARNT protein levels were being suppressed by another, as yet unknown, mechanism 
(figure 4.20). The suppression of ARNT and PTEN proteins at 24 hours was not due 
to 3-NPA induced permeability of the Hep G2 cell membrane. This was determined 
by a trypan blue exclusion experiment (figure 4.19). The trypan blue exclusion 
experiment showed a marked difference in growth rate between control and 3-NPA 
treated Hep G2 cells. Extending the time course of the trypan blue exclusion 
experiment would be required to determine if cell growth appeared to be arrested by 
3-NPA and if this were the case to determine whether 3-NPA caused cell death in 
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Hep G2 cells. However, at the time-point of 3-NPA treatment at which marked 
selective suppressions of the levels of PTEN and ARNT were observed, there was no 
selective loss of plasma membrane integrity of the cells assayed, and protein loss 
could not simply be accounted for as being due to cell permeabilisation. Further 
experimentation to determine whether the suppression of ARNT and PTEN was 
regulated at the protein or mRNA level, could be determined by quantitative RT-
PCR. 
 
One possible explanation for 3-NPA mediated suppression of PTEN and ARNT 
protein levels is microRNA repression. MicroRNAs (miRNAs) are a class of 
endogenous non-coding RNAs approximately 18-25 nucleotides in length. They are 
capable of negatively regulating gene expression by binding to the 3’ un-translated 
region (3’UTR) of target messenger RNAs which causes either translational 
repression or degradation (Bartel, 2004).   
 
Recently, two different miRNAs have been identified that repress ARNT and PTEN, 
they are miRNA 107 and miRNA 21, respectively. miRNA 107 is p53 regulated and 
when the pre-cursor to miRNA-107 is overexpressed, is able to inhibit ARNT 
expression in the human colon cancer cell line HCT116 (Yamakuchi et al., 2010). 
miRNA 21 represses PTEN in non-small cell lung cancer tumour tissue (Zhang et al.,  
2010). The discovery that miRNAs can repress ARNT and PTEN leads to the 
hypothesis that 3-NPA treatment of Hep G2 cells promotes the increase of one or 
more miRNAs which either repress ARNT and PTEN mRNA levels or inhibit ARNT 
and PTEN mRNA translation, thus leading to a reduction in ARNT and PTEN 
protein levels. 3-NPA has been shown to cause apoptosis and autophagy in rat 
striatum (Zhang et al., 2009). Therefore, it could also be hypothesised that 
suppression of PTEN and ARNT in 3-NPA treated Hep G2 cells is essential for 
reducing cell viability and be a pre-cursor to apoptosis. Extension of the trypan blue 
exclusion experiment could confirm whether cell viability was compromised at a 
later time-point and western blotting protein samples for a pro-apoptotic marker 
protein such as caspase 3 could indicate an apoptotic response to 3-NPA in Hep G2 
cells. However, in order to prove the involvement of miRNAs a microarray approach 
would be required. 
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4.4.3 The effect of 3-NPA on HIF-1 protein levels in Hep G2 cells. 
 
Following optimisation of the 3-NPA treatment protocol (sections 4.2.1 - 4.2.5), 
subsequent experiments showed 3-NPA treatment of Hep G2 cells resulted in the 
induction of HIF-1 protein levels when compared to control treated samples 
(figures 4.13 - 4.15). 3-NPA suppressed the HIF-1 protein response to DFO in Hep 
G2 cells when compared to cells treated with DFO and carrier control. However, the 
protein levels of HIF-1 in cells treated with 3-NPA and DFO were higher than in 
cells treated with 3-NPA and carrier control (figure 4.17). The effect of 3-NPA on 
HIF-1α protein levels in PC12 cells could not be assessed due to the lack of an anti-
HIF-1α antibody that would recognise the rat protein. The induction of HIF-1 
protein in Hep G2 cells could have been caused by reactive oxygen species (ROS), 
particularly hydrogen peroxide, H2O2. 3-NPA has been shown to induce ROS 
production in HM06 human microglia cells (Ryu et al., 2003) and induce the 
production of H2O2 in PC12 cells (Mandavilli et al., 2005). These results indicated 
that 3-NPA mediated ROS production was not cell type specific and it was predicted 
that ROS/H2O2 production was occurring in Hep G2 cells. H2O2 has been shown to 
elevate HIF-1 protein levels in normoxic Hep 3B and HEK 293 cells (Chandel et 
al., 2000). If H2O2 was being produced in Hep G2 cells after 3-NPA treatment, this 
may have been the cause of the elevated HIF-1 protein levels observed in figures 
4.13 – 4.15 and figure 4.17. This hypothesis could be tested by pre-treating cells with 
catalase, a scavenger of H2O2, before treating cells with 3-NPA. Similar experiments 
have been performed by Zhou et al., who treated PC-3 cells with catalase before 
treating with insulin in order to determine whether insulin mediated up-regulation of 
H2O2 resulted in increased VEGF and HIF-1 expression (Zhou et al., 2007). 
 
One hypothesis that links both PTEN suppression and HIF-1α up-regulation is that 3-
NPA induces the production of H2O2. As described in 4.4.1, 3-NPA has been shown 
to induce H2O2 in PC12 cells (Mandavilli et al., 2005) and H2O2 has been shown to 
inactivate purified PTEN in vitro (Lee et al., 2002). The loss of, or suppression of 
PTEN protein levels (as shown in figure 4.17 and 4.21) would be predicted to cause 
the constitutive activation of the phosphatidylinositol 3-kinase (PI3K) signalling 
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pathways mediated by Tec family tyrosine kinases, AKT/PKB and Rac/Rho GTPases 
(figure 4.33). 
 
The mammalian target of rapamycin (mTOR) is a downstream target of Akt/PKB, 
which has been implicated in the upregulation of HIF-1 protein levels in normoxia 
and hypoxia (Hudson et al., 2002). Suppression of PTEN protein levels in Hep G2 
cells due to the increase in H2O2 would be predicted to constitutively activate the 
Akt/PKB pathway resulting in the mTOR mediated up-regulation of HIF-1 protein 
levels. This combined with the hypothesised H2O2 up-regulation of HIF-1 protein 
levels (section 4.4.1) could explain the 3-NPA mediated increase in HIF-1 protein 
levels observed in figures 4.13 – 4.15 and figure 4.17. One way of testing this 
hypothesis would be to probe samples with a phospho-Akt antibody. Activated Akt is 
phosphorylated, therefore if 3-NPA samples contained more phosphorylated Akt 
Figure 4.33 PI (3, 4, 5) P3 dependent pathways constitutively activated 
through the loss of PTEN. 
 
Loss of PTEN prevents the dephosphorylation of the second messenger 
phosphatidylinositol - (3, 4, 5) – trisphosphate, PI  (3, 4, 5) P3, back to 
phosphatidylinositol – (4, 5) diphosphate, PI (4, 5) P2. This causes the 
constitutive, PI3K (phosphatidylinositol 3 kinase) dependent activation of Tec 
family kinases, Akt/PKB (protein kinase B) and Rac/Rho family GTPases, 
which are involved in the regulation of the pathways indicated in the figure 
(Fruman D., 2004, Takesono et al., 2002, Welch et al., 2003 and Cantrell D., 
2001). 
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than control samples, this could support the hypothesis described above (Vara et al., 
2004). 
 
4.4.4 The effect of 3-NPA on transcription. 
 
The discovery that 3-NPA suppressed the levels of ARNT protein in Hep G2 cells 
resulted in the expectation that Hep G2 cells treated with 3-NPA would not exhibit a 
transcriptional response from an HRE driven luciferase reporter construct. However, 
figure 4.16 showed that 3-NPA induced a small transcriptional response of an HRE 
dependent luciferase reporter construct when compared to carrier control samples, 
this was particularly apparent in the second independent experiment (figure 4.16 
lower panel). The low level of response was probably caused by incomplete 3-NPA 
mediated ARNT disappearance, which is illustrated in figures 4.14 and 4.15. 3-NPA 
suppressed the DFO response of an HRE driven luciferase reporter gene when 
compared to DFO. However, DFO and 3-NPA induced a higher level of expression 
when compared to 3-NPA alone (figure 4.18). In the 3-NPA time course 
experiments, DFO induced HIF-1 protein before 3-NPA which could explain why 
DFO and 3-NPA induced a higher level of expression of an HRE driven reporter 
gene than 3-NPA alone (figures 4.14 and 4.15). However, although the above results 
can be explained in terms of the HRE data alone, it is by no means conclusive 
because, as seen in previous luciferase assays (figure 3.17), the controls for these 
assays were variable. The most pronounced variability was seen in the CMV control 
data (figures 4.16 and 4.18). One explanation for this variability is the effect of cell 
passage number on protein expression, cell signalling and growth rate as described in 
section 3.5.1. 
 
Another possible explanation could be that the cell culture, transfection or chemical 
treatment conditions that Hep G2 cells were subjected to in this experiment, resulted 
in the CMV driven transcription of luciferase as a result of a stress response. For 
example, in FR cells (rat skin cells), Hep G2 cells and human prostate cancer cell 
lines, exposure to chemotherapeutic stimuli resulted in an increase in CMV promoter 
driven transcription of exogenous gene expression (Kinoshita et al., 2008 and 
Svensson et al., 2007). In the FR cells this upregulation was accompanied by 
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increased mRNA levels of c-fos and c-jun (Kinoshita et al., 2008). These genes 
encode for proteins that are members of the Fos and Jun family of proteins which are 
important in regulation of the cell cycle and stress responses. Fos and Jun proteins 
dimerise to form the inducible transcription factor activator protein -1 (AP-1) and 
there is an AP-1 binding site in the CMV enhancer (Sambucetti et al., 1989). The 
CMV enhancer also has an ATF (activating transcription factor) binding site and 
ATF is a known downstream target of the p38 MAPK pathway which when activated 
is thought to have up-regulated CMV promoter activity in human prostate cells  
(Sambucetti et al., 1989 and Svensson et al., 2007). Consistent with these findings 
Bruening et al., had previously shown that p38 MAPK pathway inhibitors were able 
to block arsenite induced CMV promoter driven transcription (Bruening et al., 1998). 
It is therefore feasible that one or both of these pathways could have been up-
regulated in Hep G2 cells transfected with CMV control and each treatment 
condition potentiated a different level of CMV promoter driven response; DFO being 
the most potent initiator and 3-NPA the least. This may be explained by the findings 
that RNA extracted from the liver of rats treated with 3-NPA contained increased 
levels of c-fos mRNA when compared to control samples. However junb mRNA 
levels were reduced when compared to control samples (Przybyla-Zawislak et al., 
2005). If the induction of CMV promoter driven transcription observed in Hep G2 
cells treated with DFO or carrier controls were due to AP1 mediated transcription, it 
could be hypothesised that reduced levels of Jun proteins as a result of the 3-NPA 
mediated decrease in junb mRNA levels, may result in the low level of CMV control 
luciferase expression in 3-NPA samples when compared to carrier control and DFO 
samples (figure 4.16 and figure 4.18). Both p38 MAPK and JNK (c-Jun N-terminal 
Kinase) are known inducers of Fos and Jun proteins, therefore the use of a p38 
MAPK or JNK inhibitor in the transcription reporter assay could determine whether 
transcription of CMV control could be due to AP1 or ATF binding. 
 
It is also possible that a trans effect between the promotors of the reporter plasmids 
used in the luciferase reporter assay may have affected the expression levels 
observed in figure 4.16 (Farr and Roman. 1992). It is possible that a trans effect can 
be observed due to incorrect ratios between co-transfected plasmids or the effect can 
be cell type specific (Promega Technical Bulletin – pRL Renilla luciferase reporter 
vectors). One way to assess whether a trans effect is responsible for the variability if 
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results observed in figure 4.16 would be to carry out a luciferase reporter assay in an 
alternative cell type of low passage number. If no variability in the controls were 
observed in an alternative cell type this would indicate the results seen in figure 4.16 
were cell type specific.  
 
4.4.4 The effects of siRNA mediated SDH B suppression. 
 
Initially it was predicted that loss of SDH B expression would cause an increase in 
HIF-1 protein levels (section 4.1.6). However, inhibition of SDH B protein levels 
using RNA interference reproducibly suppressed HIF-1 protein levels, a finding 
that opposed our initial predictions (figures 4.25 and 4.26 and 4.29 and 4.30). Hep 
G2 cells appeared to have a basal level of GLUT-1 protein expression (the protein 
product of a a HIF-1 target gene) when cultured under the conditions used in these 
experiments. In SDH B targeted cells where HIF-1 protein levels were suppressed, 
GLUT-1 protein levels also showed a substantial reduction (figure 4.30). However 
this reduction only occurred when GLUT-1 levels were substantially elevated and 
was not reproducible suggesting that there was a threshold level of HIF-1 
suppression required for down regulation of GLUT-1 (figure 4.29). The suppression 
of HIF-1 protein level was not due to an off target effect of the SDH B targeting 
RNAi as HIF-1 mRNA levels were not substantially altered by SDHB targeting 
RNAi (figure 4.31). 
 
Confirmation of HIF-1 protein suppression mediated by SDHB targeting RNAi was 
sought by using an HRE driven transcription reporter assay. However, once again 
there were intra and inter experimental variability in the SV40 and CMV controls 
which prevented any meaningful discussion of the Test (HRE) results achieved. As 
previously described, this variability may have been due to cell passage number or 
expression of the SV40 and CMV driven luciferase reporter genes in a cell type 
dependent manner, possibly due to transcription factor binding to consensus 
sequences present in the promoter region of CMV (section 3.5.1 and 4.4.3).  
 
The level of cell density/confluency in cultured cells has been reported to affect HIF-
1 stabilisation in 293T, RCC, PC3 and LNCaP cells (Paltoglou and Roberts, 2005; 
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Sheta et al., 2001). However, SDH B targeting in Hep G2 cells had no effect on cell 
proliferation when compared to control targeted Hep G2 cells (figure 4.27). 
Therefore the suppression of HIF-1 and GLUT-1 protein levels mediated by SDH B 
targeting could not be attributed to differential cell densities. Hep G2 cells have been 
reported to be hypoxic in confluent cultures (Metzen et al., 1995), however all RNAi 
targeted cells were harvested when sub-confluent. Therefore, the detection of HIF-1 
protein in control targeted Hep G2 cells is probably not due to pericellular hypoxia 
induced by high cell density but due to non-oxygen dependent pathways that can up-
regulate HIF-1 protein levels in normoxic conditions. Two signalling pathways that 
have been identified in the non-oxygen dependent regulation of HIF-1 are those 
involving PI-3-kinases, and mitogen-activated protein kinases (MAP kinases, 
reviewed by Bardos and Ashcroft, 2004 and Semenza G., 2002). Although it is 
difficult to ascertain the exact nature by which one of these pathways may be 
affecting HIF-1 in Hep G2 cells, treating Hep G2 cells, cultured in the same 
conditions as for SDHB targeting RNAi experiments, with PI3K or MAPK 
inhibitors, such as LY294002 or PD 98059, respectively may indicate which pathway 
is involved. 
 
The presence of HIF-1 in control targeted Hep G2 cells could also be explained by 
the presence of glucose in the culture media. Hep G2 cells can produce lactose in a 
glucose dependent manner. This would generate glycolytic ATP and therefore reduce 
the dependency of Hep G2 cells on the TCA cycle and electron transport for ATP 
production (Weber et al., 2002). The ability of Hep G2 cells to produce lactose in 
this manner is probably due to a phenomenon known as the Warburg effect, where 
cancer and cultured cells display high levels of aerobic glycolysis. The end products 
of glycolysis, lactate and pyruvate, have been shown to activate HIF-1 in normoxia 
(Lu et al., 2002). SDH B mutations mainly predispose individuals to extra-adrenal 
pheochromocytomas and most tumours associated with SDH B mutations have a 
high malignant potential. It is thought that the ability of these tumours to proliferate 
is manifested via the Warburg effect although this has not yet been conclusively 
proven (reviewed by Kantorovich et al., 2010). In support of this are the findings that 
a Chinese hamster cell line harbouring a mutation in one of the SDH membrane 
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anchoring sub units grows normally in cell culture when glucose is provided 
(Oostveen et al., 1995). 
 
In contrast to the results in this study where SDH B inhibition resulted in HIF-1 
suppression (figures 4.25 and 4.26 and 4.29 and 4.30), other researchers have shown 
that mutation of SDH B and SDH D results in increased HIF activity (Gimenez-
Roqueplo et al., 2001; Selak et al., 2005; Lee et al., 2005; Pollard et al., 2005; Guzy 
et al., 2008). Of particular interest are the results of Selak et al., who carried out 
experiments using RNA interference to knockdown SDHD. They identified that 
knockdown of SDHD mRNA levels resulted in the increased activity of an HRE 
dependent luciferase reporter gene and increased HIF-1α protein levels. SDHD 
knockdown by RNA interference also resulted in the accumulation of VEGF mRNA 
and VEGF target gene of HIF-1.  
 
SDHD knockdown by RNA interference results in an accumulation of succinate and 
loss of SDH B in is also known to result in an accumulation of succinate (Selak et 
al., 2005; Pollard et al., 2005). This accumulation inhibits PHD activity, resulting in 
increased HIF stabilisation and increased transcription of HIF target genes, thus 
providing a direct link between SDH B-D mutation and tumourigenesis (Selak et al., 
2005; Lee et al., 2005; Pollard et al., 2005; Koivunen et al., 2007). 
 
One possibility as to why HIF-1 protein levels do not accumulate when SDH B 
protein levels are suppressed, is that succinate oxidation may still occur, possibly due 
to the limited levels of suppression observed (figures 4.25 and 4.26 and 4.29 and 
4.30). In support of this theory is the finding that suppression of SDH B did not 
affect SDH A protein levels in Hep G2 cells, a finding that has also been observed in 
tumours harbouring either SDH B or SDH D mutations (Douwes Dekker et al., 
2003).  
 
Continued succinate oxidation does not explain the reduction in HIF-1 protein 
levels as a result of SDH B RNAi targeting. One possibility for this suppression 
could be a disruption to the homeostasis of the TCA cycle. Limited succinate 
oxidation would be predicted to not only result in a build up of succinate but also 
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other TCA cycle intermediates that occur prior to succinate, such as -ketoglutarate. 
A fall in TCA cycle intermediates may also occur after succinate oxidation, for 
example fumarate levels. The levels of both -ketoglutarate and fumarate can 
directly affect the activity of the PHDs. -ketoglutarate (2-oxoglutarate) is a 
substrate of the PHDs that is required as well as molecular oxygen for their ability to 
hydroxylate HIF- subunits (Epstein et al., 2001). Conversely, fumarate inhibits the 
activity of the PHDs and is a more potent inhibitor than succinate (Pollard et al., 
2005). Therefore, it could be hypothesised that SDH B suppression results in 
increased -ketoglutarate levels and decreased fumarate levels, as a result of this, 
PHD activity increases and HIF-1 protein levels fall. In support of this hypothesis is 
the finding that derivatives of -ketoglutarate can alleviate pseudohypoxia in 
succinate dehydrogenase deficient cells (MacKenzie et al., 2007). Fumarate 
inhibition can also be alleviated by elevated -ketoglutarate (2 oxoglutarate) levels 
(Isaacs et al., 2005). It is also interesting to note that -ketoglutarate levels are 
‘topped’ up by glutaminolysis, the process by which glutamine, a component added 
to cell culture media, is converted first to glutamate and then -ketoglutarate (Mates 
et al., 2009). This presents the possibility that glutaminolysis may also be a 
contributory factor to increased PHD activity. One way of assessing this hypothesis 
in vitro would be to treat Hep G2 cells targeted with control or SDH B RNAi with -
ketoglutarate or fumarate and assess the effect on HIF-1 protein levels.  
 
The complexity in determining the effect of SDH B-D mutations on HIF can be 
further increased by the findings that mutations in SDH B-D can be accompanied by 
increased levels of ROS in some circumstances but not in others, suggesting there 
may be two pathways responsible for the regulation of HIF protein levels. For 
instance, Selak et al. did not detect any ROS in cells where SDH D expression was 
suppressed. Similarly, Pollard et al. did not detect any ROS in paraganglioma tissue 
harbouring SDH B mutations. However, in contrast to these findings elevated levels 
of ROS were found in C. elegans carrying a mis-sense mutation in SDHC (Senoo-
Matsuda et al., 2001). The corresponding mutation in mammals also resulted in 
elevated ROS levels (Ishii et al., 2005). Stably suppressed SDH B has also been 
shown to cause elevated ROS levels, leading to the activation of hypoxia inducible 
factor (Guzy et al., 2008).  
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In addition to SDH mutations identifying SDH B-D as tumour suppressor genes, 
mutations in the genes encoding for fumarate hydratase (FH) and isocitrate 
dehydrogenase 1 (IDH1) have identified them as tumour suppressors. Interestingly 
deficiencies in each of these metabolic enzymes present with distinct tumour types 
but a similar mode of tumourigenesis. For instance, biallelic FH mutations result in 
the inherited cancer syndrome hereditary leiomyomatosis and renal cell cancer 
(HLRCC, Tomlinson et al., 2002). HLRCC kidney tumours show increased levels of 
HIF-1 when compared to normal kidney tissue, which results in increased 
expression of HIF target genes (Pollard et al., 2005). The exact mechanism by which 
pseudohypoxic drive (the aberrant stabilisation of HIF under normoxic conditions) 
occurs as a result of FH mutation is not completely clear. However, it is possible that 
tumourigenesis due to FH mutation occurs in a similar manner as proposed for SDH 
mutation i.e. loss of fumarate hydratase activity results in increased fumarate levels 
which inhibit PHD activity, resulting in up-regulation of HIF-1 and subsequently 
HIF target genes. However, experiments performed in an HLRCC derived cell line 
showed HIF stabilisation occurred as a result of increased ROS levels, thus adding 
another level of complexity to the manner in which FH mutations result in up-
regulation of the HIF pathway (Sudarshan et al., 2009). Mutations in the gene 
encoding for IDH1 are mainly found in gliomas although one IDH1 mutation has 
been identified in a sporadic paraganglioma (Zhao et al., 2009; Kang et al., 2009 and 
Gaal et al., 2010). Inactivation of isocitrate dehydrogenase in human glioblastoma 
cells resulted in decreased levels of -ketoglutarate, leading to decreased PHD 
activity and an increase in HIF-1 activity, thus resulting in tumourigenesis as a 
result of HIF pathway activation (Zhao et al., 2009). Therefore it is clear that the 
mode of tumourigenesis for the majority of SDH, FH, and IDH1 mutations involves 
loss of function of the proteins these genes encode for, resulting in up-regulation of 
the HIF pathway which is a known contributor to tumourigenesis. The fact that the 
abnormal de-regulation of HIF in so many forms of cancers including tumour cells 
harbouring TCA cycle mutations indicates the importance of HIFs role in 
tumourigenesis.  
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The finding that SDH B targeting results in the suppression of HIF-1 protein levels 
is difficult to fit into a model of how SDHB acts as a tumour suppressor gene. This is 
because HIF-1 accumulation caused by loss of pVHL has been proposed as an 
important mechanism for tumourigenesis and several other signalling pathways 
implicated in oncogenesis result in the up-regulation of HIF-1 (reviewed in 
Semenza G., 2002 and Bardos and Ashcroft. 2004). However, it should be noted that 
VHL mutations that result in type 2C VHL disease only pre-dispose carrier 
individuals to pheochromocytoma. These tumours retain the ability to regulate HIF-
1 protein levels (Hoffman et al., 2001 and Clifford et al., 2001). This would 
suggest that the de-regulation of other pVHL functions is responsible for the 
development of pheochromocytoma in pre-disposed individuals and that the 
accumulation of HIF-1 may not be required in all cases of pheochromocytoma 
development. Therefore, pheochromocytoma tumours harbouring SDHB mutations 
may develop due to the de-regulation of other, as yet, unknown pathways and not, as 
hypothesised in this study, by accumulation of HIF-1. It is also interesting to note 
that suppression of another TCA cycle enzyme also results in reduction of HIF-1 
protein levels. IDH2 is an NADP+ dependent mitochondrial isocitrate 
dehydrogenase, which catalyses the conversion of isocitrate to α-ketoglutarate. The 
conversion of isocitrate to α-ketoglutarate yields NADPH, a reducing agent that is 
used in processes that protect cells from oxidative damage. Knockdown of IDH2 
sensitises tumour cells to apoptosis in response to treatment with several anti-cancer 
drugs e.g. doxorubicin and it was hypothesised that this knockdown could also 
impact on HIF-1α protein levels. Suppression of IDH2 in PC3 cells via RNAi 
targeting resulted in suppressed HIF-1 protein levels (Kim et al., 2010). This 
suggests that loss of, or suppression of some TCA cycle enzymes may not lead to 
tumourigenesis. However, the results observed in PC3 cells could have been a cell 
type specific response. This is also true of the results observed as a result of SDH B 
suppression in Hep G2 cells (figures 4.25, 4.26, 4.29 and 4.30); particularly as Hep 
G2 and PC3 cells are not representative of the cell types that harbour SDH mutations. 
IDH2 suppression in PC3 cells resulted in HIF-1 protein suppression which was 
accompanied by a decrease in HIF-1 mRNA. This appeared to be mediated via the 
PI3K/ Akt pathway and was not a result of an off target effect of the RNAi. These 
results are in marked contrast to those obtained from SDH B suppression, where 
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there was no apparent knockdown of HIF-1 mRNA (figure 4.31). However, in 
contrast to the results described, experiments carried out by Selak et al., in HEK 293 
cells, a non-representative cell type of pheochromocytoma or paraganglioma, appear 
to have produced a mechanistic model of what happens as a result of SDH mutation 
i.e. upregulation of HIF as a result of SDH D suppression. These observations 
highlight the complexity that exists in determining the mode of action of 
tumourigenesis from mutations in TCA cycle enzymes.  
 
4.4.5 siRNA methods. 
 
The approaches used to design the siRNAs used in this study were based on the 
thought that siRNA targeting was specific and non-immunostimulatory (Elbashir et 
al., 2001). However, in practice unmodified siRNAs such as the ones used in this 
study have some limitations. Unmodified siRNAs are susceptible to nuclease attack, 
have been shown to have off target effects as a result of interference in natural 
miRNA pathways and are potent triggers of the innate immune response (Gavrilov 
and Saltzman, 2012) 
 
Off target effects of unmodified siRNAs were shown in expression profiling studies 
carried out by Jackson et al., (2003), using siRNAs designed to the standard selection 
rules of Elbashir et al., (2001). Sequence analysis of several off target transcripts 
revealed there was only partial complementarity between the siRNA and the off 
target transcript (Jackson et al., 2003). Further research revealed that guide strand 
(the strand of siRNA incorporated into RISC) off targeting effects were the result of 
complementarity between the seed region of siRNA (positions 1-8 of the 5’ end of 
the strand) and the 3’ untranslated region (3’ UTR) of mRNA (Jackson et al.,  2006). 
MicroRNAs (miRNAs) are endogenous and regulate gene expression via incomplete 
hybridisation of their seed region with 3’UTRs. This results in gene suppression by 
translational inhibition and deadenylation. 3’UTR sequences can be shared by 
mRNAs, therefore a single miRNA can regulate hundreds of gene siRNAs and 
miRNAs share the same silencing machinery and therefore it is thought siRNA off 
target silencing occurs as a result of the siRNA entering the miRNA pathway and 
causing miRNA-like effects thus downregulating off-target genes (Kanasty et al., 
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2012). Other causes of off target effects can also be caused by as little as 11 
nucleotides of continuous sequence of homology in coding regions (Jackson et al., 
2006) or passenger strand incorporation into RISC. The strand selection process of 
RISC is dependent on several factors including duplex thermodynamics where the 
least tightly bound 5’ end of the duplex is normally incorporated into the complex 
(Khvorova et al., 2003; Schwarz et al., 2003), a 5’ phosphate required for RISC 
binding and the sequence located at the 5’ end of the guide strand as it appears 
argonaute-2 prefers A and U nucleotides over G and C (Deleavey and Damha., 
2012).To avoid miRNA like off target effects siRNA design algorithms have been 
developed that attempt to select sequences with minimum seed complementarity to 
3’UTR regions (Naito et al., 2009).  
 
Chemical modifications can also be introduced to limit miRNA like off target effects, 
increase stability and prolong the half-life of the siRNA. The most common 
modifications in siRNAs are the 2’ modifications to the ribose ring and these include 
2’-O-Methyl, 2’ – fluoro and 2’ –O- deoxymethymethoxyethl modifications. Linked 
nucleic acids (LNAs) which introduce a methylene bridge between the 2’ oxygen and 
4’carbon of the ribose ring are a further modification that can be introduced to the 2’ 
site of the ribose ring (Shukla et al., 2012). Backbone modifications of siRNAs can 
provide further resistance to nuclease attack and these include modifying backbone 
with phosphothioate or boranophosphate. Both of these modifications can enhance 
nuclease resistance of the siRNA (Gavrilov and Saltzman, 2012). Nuclease 
degradation of the SDH B siRNA used in this study may have affected its potency 
and could account for the differences in knockdown that are shown in western blots. 
It is also possible that a true signature of SDH B gene silencing was not observed in 
this study due to off target gene silencing by the SDH B siRNA. Alternatively, the 
control siRNA could equally have been responsible for an off target effect and the 
levels of HIF-1α observed in control treated samples (figure 4.30) was actually up-
regulation due to a target effect of the siRNA. 
 
Studies carried out by Reynolds et al., (2004) and Ui-Tei et al., (2008) have 
identified positional preferences an A or U is preferred at position 1 of the antisense 
strand, G or C is preferred at position 19, an A or U is favoured at position 10 (the 
cleavage site of argonaute-2) and A-U richness in positions 1-7 is favourable. These 
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positional preferences result in highly functional siRNAs and are also important for 
guide strand entry into RISC (Ui-Tei et al., 2008). In both control and SDH B 
siRNAs an A or U is present at position 1 of the anti-sense strand, AU richness was 
also present in positions 1-7. However, an A or U was not present at position 10 of 
the siRNA and this could have affected the action of argonaute-2. Only the control 
siRNA had a G or C at position 19, thus indicating the SDH B siRNA used in this 
study may not be highly functional.  
 
Original experiments using siRNAs suggested they were non-immunostimulatory 
(Elbashir et al., 2001). However, it was subsequently shown that siRNAs can 
provoke the innate immune system via Toll like receptors (TLRs). TLRs are nucleic 
acid responsive with TLRs 7 and 8 thought to mediate the dominant immune 
response in vivo. Activation of TLR7/8 results in upregulation of type I interferons 
and cytokines (Samuel-Abraham and Leonard, 2010). HIF-1α can be upregulated by 
TLR7/8 ligands and therefore it is possible that up-regulation of HIF-1α seen in 
control targeted samples could be sue to provocation of an immune response by 
siRNA transfection (Nicholas and Sumbayev, 2009).  
 
Further developments in RNA interference have resulted in the generation of vectors 
containing RNA polymerase II or III promotors. The RNAi trigger can be expressed 
as an miRNA of short hairpin RNA (shRNA). These are then cleaved into small 
siRNAs by Dicer before entry into RISC. Development of these vectors allows for 
stable long-term knockdown of the target transcript (Paddison et al., 2002). 
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5. Discussion 
 
Hypoxia, the result of low levels of oxygen concentration in tissue, causes cells to 
activate several adaptive responses to match O2 supply with metabolic, bioenergetic 
and redox demands. These events are co-ordinated by several processes including the 
unfolded protein response and mTOR signalling (Wouters and Koritzinsky, 2008). 
However, transcription regulation in hypoxia by hypoxia inducible factors is 
recognised as one of the key processes in a cell’s adaptation to low oxygen levels.  
 
HIF function has been identified as a major contributory factor in several major 
diseases including pulmonary hypertension, ischaemia, angiogenesis and 
tumourigenesis. HIF has also been identified as having a specific involvement in 
asthma, inflammatory bowel disease, coeliac disease and haematological 
malignancies such as leukaemia (Hirota et al., 2009 and Konopleva et al., 2009). 
Therefore, the development of therapeutic strategies capable of modulating HIF 
function is an attractive prospect. Current research strategies involve the 
development of targeted small molecules that result in HIF-1 up-regulation for 
ischaemic disease therapy or the inhibition of HIF-1 activity for cancer-therapy 
(figure 5.1, Li et al., 2005; Hewitson and Schofield, 2004; Semenza, 2003; 
Belozerov and Van Meir, 2005). 
 
The involvement of HIF signalling in disease outlines the importance of developing 
therapeutics to HIF, whether to inhibit or regulate its activity. Currently, very few 
therapeutics that specifically target HIF are used clinically. However, many novel 
anti-cancer drugs which specifically target other regulatory pathways also have anti-
angiogenic effects largely due to their ability to inhibit HIF-1. For example, the 
anthracyclines e.g. doxorubicin and daunorubicin decrease HIF-1 DNA binding, 
EGFR inhibitors, microtubule inhibitors, mTOR inhibitors and topoisomerase 
inhibitors decrease HIF-1a synthesis, proteasome and histone deacetylases decrease 
HIF-1a transactivation and finally histone deacetylases and HSP90 inhibitors 
increase HIF-1a degradation (Semenza, 2010). In the case of HSP90 inhibitors, this 
is due to an oxygen and PHD independent ubiquitin mediated degradation (Liu et al., 
2007). 
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The development of RNA aptamers as novel therapeutics provides another avenue of 
exploration for HIF inhibitors/up-regulators. Pegaptanib sodium also known 
commercially as Macugen, is an anti-VEGF RNA aptamer which is used for the 
treatment of all types of neovasular age related macular degeneration. It is the first 
aptamer to be approved for clinical use (Ng et al., 2006). Other RNA aptamers have 
also reached the clinical trial phase. Of particular importance for cancer therapy is 
AS1411, the first RNA aptamer to enter oncology clinical trials. AS1411 is an RNA 
aptamer that specifically targets nucleolin, a protein that is found on the surface of 
many cancer cells, including cancer cells associated with acute myeloid leukaemia 
and renal cell carcinoma. AS1411 is systemically administered and its internalisation 
 
Figure 5.1 Potential therapeutic target sites in the HIF pathway. 
 
An overview of the potential points of therapeutic intervention in the HIF 
pathway either to increase (+) or decrease (-) the levels of HIF-1. 
 
Key: ARNT, aryl hydrocabonreceptor nuclear translocator; FIH, factor inhibiting HIF; HIF-1α, 
hypoxia inducible factor; HRE, hypoxia response element; HSP90, heat shock protein 90;  1-α 
mTOR, mammalian target of rapamycin; N, asparagine; P, proline; PHDs, prolyl hydorxylases; 
PI3K, phosphatidylinositol 3-kinase; pVHL, von-Hippel Lindau protein; OH, hydroxyl; TOPO I, 
topoisomerase I. 
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results in a decrease in several cancer related mRNAs which results in reduced cell 
proliferation (Soundararajan et al, 2009 and Reyes-Reyes et al., 2010). 
 
The REG 1 anticoagulation system is also in clinical trials and represents an aptamer-
antidote pair to coagulation factor IXa (FIXa). RB006 is the active aptamer drug that 
binds FIXa and RB007 is the antidote which is an oligonucleotide controlling agent 
that is complementary to a portion of RB006 and when bound neutralises the anti-
FIXa activity of RB006. This drug is particularly useful in the treatment of 
thrombotic disease and represents a highly specific and controllable drug (Povsic et 
al., 2010). 
 
The level of HIF involvement in disease and the advantages of RNA aptamers such 
as high target specificity, high target affinity, in vitro development and low 
immunogenicity led to the development of RNA aptamers targeted to the HIF 
oxygen dependent degradation domain. The hoped for outcome was blockage of 
ubiquitin mediated degradation resulting in increased HIF-1α protein levels and a 
subsequent increase in HIF signalling. It was hoped that these results would be useful 
in potentially developing a therapeutic agent for the use in HIF related diseases, for 
example in ischaemic disease. Although no conclusive results could be drawn from 
this study, it is possible that the RNA aptamer developed against the HIF-ODDD 
suppressed HIF function (figure 3.17). A more robust test assay would be required to 
assess this (section 3.5). However, aptamers developed towards HIF that decrease 
HIF signalling would potentially be useful in the treatment of cancer. HIF exerts its 
affects on cancer progression by activating target genes involved in angiogenesis, 
cell survival, chemotherapy and radiation resistance, genetic instability, 
immortalisation, immune evasion, invasion and metastasis, proliferation, metabolism 
and pH regulation (reviewed by Semenza, 2010). Development of a specific anti-HIF 
RNA aptamer would be useful as this could prevent tumour angiogenesis and 
metastasis. 
 
Further developments in the RNA aptamer field have resulted in a fusion of 
technologies such as RNA aptamer delivery by siRNAs and RNA aptamer delivery 
by nanobiotechnology particles. RNA aptamer hybrids have also been developed and 
this would be a useful area for further study in the case of a HIF-1α RNA aptamer 
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(reviewed by Guo et al., 2008). This is because HIF-1α is a cytoplasmic and nuclear 
protein, therefore any RNA aptamer targeting HIF-1α would need to be delivered to 
the cell type of interest and internalised before it could act. Therefore, development 
of a cell type specific RNA aptamer and hybridisation with a HIF-1α aptamer could 
provide a delivery mechanism. 
 
The involvement of HIF in intratumour hypoxia is well documented however, 
alterations resulting in oncogene gain of function or tumour suppressor loss of 
function (as is the case for SDH B), often lead to increased HIF-1 activity, 
suggesting increased HIF-1 activity represents a common pathway in cancer 
pathogenesis. One of the most studied cancer syndromes known to exhibit de-
regulation of the HIF pathway is von Hippel Lindau disease (section 1.6.5). Sufferers 
of VHL disease suffer from central nervous system and retinal hemagioblastomas, 
clear cell renal carcinomas and pheochromocytomas (Kim and Kaelin Jr., 2004). 
Similarities in the tumour type and tumour vasculature between VHL disease and 
paraganglionic tumours harbouring SDH D mutations suggested HIF involvement in 
tumour formation that was not solely due to the role of HIF in tumourigenesis with 
regards to tumour hypoxia. Germline mutations in SDH B also resulted in 
paraganglioma and pheochromocytoma. Therefore, the effect of SDH B inhibition on 
HIF-1 was investigated. 3-NPA, an inhibitor of complex II of the mitochondrial 
respiratory chain, was used to treat of Hep G2 cells in a proof of principle 
experiment that determined 3-NPA inhibition of complex II resulted in increased 
levels of HIF-1α protein (section 4.2.6). However, a more targeted approach to 
suppress SDH B in the form of RNA interference targeted to SDHB mRNA resulted 
in suppression of HIF-1α protein levels (figures 4.25 and 4.26). This was in marked 
contrast to research carried out by other groups and could possibly be due to the cell 
type experiments were carried out in or because the level of SDH B suppression was 
not great enough to induce HIF-1α protein levels (Gimenez-Roqueplo et al., 2001; 
Selak et al., 2005; Lee et al., 2005; Pollard et al., 2005 and Guzy et al., 2008). 
Mutations in SDHAF2 (the gene encoding for succinate dehydrogenase assembly 
factor 2), SDH B, SDH C, SDH D, FH, IDH1 and IDH2 have all been shown to cause 
up-regulation of HIF-1α protein levels resulting in the up-regulation of HIF regulated 
target genes (Kantorovich et al, 2010; Pollard et al.,  2007 and Gaal et al, 2009). This 
suggests that the results achieved in this study were not indicative of the tumour 
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mechanism for SDH B mutation. Until recently, no genetic link between SDH A and 
paraganglioma/pheochromocytoma syndromes had been identified. However, a 
germline mutation in SDH A has been identified in a patient suffering from an 
abdominal catecholamine secreting paraganglioma. This mutation resulted in a 
pseudo-hypoxic response which is also observed in other tumours caused by 
mutation of TCA cycle intermediates. Loss of heterozygocity at the SDH A loci in 
the tumour tissue identifies SDH A as a tumour suppressor gene (Burnichon et al., 
2010). 
 
Several facets in the regulation of HIF have recently been described. These 
mechanisms could provide further therapeutic targets for HIF regulation. Under 
hypoxic conditions stimulated sphingosine kinase 1 (SphK1) converts sphingosine to 
sphingosine 1-phosphate resulting in the up-regulation of HIF-1α via an Akt/GSK3β 
pathway (Ader et al., 2009). microRNAs have also been identified that can regulate 
HIF-1 both under hypoxic conditions (where the microRNA is referred to as a 
hypoxamir) and independently of hypoxia. For example, the hypoxamir miR20b 
suppresses HIF-1α expression in MCF-7 breast cancer cells whereas the hypoxamir 
miR424 targets CUL2 in the pVHL ubiquitin ligase complex resulting in impaired 
prolyl hydroxylation of HIF-1α and a subsequent stabilisation of HIF-1α protein 
levels. Independently of hypoxia c-MYC induces the miR17-92 cluster which 
suppresses expression of HIF-1α in lung cancer cells whereas miR31 targets FIH 
resulting in the stabilisation of HIF-1α (Loscalzo, 2010 and Loboda et al., 2010).  
 
The involvement of HIF in so many types of cancer e.g 
pheochromocytoma/paraganglioma syndromes, lymphoma and leukaemia, and also 
in several different diseases such as ischaemia, highlights the importance of 
developing therapeutics specifically targeted towards HIF, whether as HIF inhibitors 
or as HIF up-regulators. As our knowledge of the mechanisms which regulate HIF 
and the roles the HIF family of proteins are involved in grow so does the opportunity 
for development of novel HIF specific therapeutics. 
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